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Chapter 1 . 
GENERAL INTRODUCTION. 
1.1. INTRODUCTION. 
The complex structure of higher organisms, with organs and 
tissues that perform highly specialised functions, requires an 
effective mechanism for the inter- and extracellular targeting 
of compounds. The organism has to accurately direct all kinds 
of regulatory substances, biosynthetic building blocks, and 
energy containing compounds towards their specific sites of 
action or utilization. In the last decades, a large number of 
carrier proteins have been identified, that are involved in the 
transfer of a variety of molecules to specific sites within the 
body. Carrier proteins have also been found within the cell, 
involved in the trafficking of compounds towards intracellular 
compartments and in the transcellular transport. 
Many transport proteins have been found in the blood. The 
binding proteins for peptide hormones as somatotropin and somato­
medins are involved in the regulation of distribution and metabo­
lic clearance rate of these factors η,Ζ]. Blood also contains a 
number of proteins that transfer steroids and related compounds: 
sex hormone-binding globulin (SHBG), corticosteroid-binding pro­
tein (CBG) and progesterone-binding globulin (PBG) [3]. Like with 
the peptide hormones, these proteins markedly influence the 
metabolism of their ligands [3,4]. Furthermore, binding proteins 
have been identified for vitamins A and D, plasma retinol-binding 
protein [4] and vitamin D-binding protein [4,5]. The plasma retinol-
binding protein circulates in a complex with transthyretin, a 
thyroid hormone-binding protein [4]. 
Serum albumin is considered to be a more general carrier 
protein, with affinity for many lipophilic substances u.&.n. It 
plays a major role in the transport of free fatty acids through 
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the cardiovascular system. Apolipoproteins form structural and 
functional components of chylomicrons and various types of lipo­
proteins, which are involved in transport of triacylglycerols, 
phospholipids, cholesterol and cholesterolesters [виз. Plasma 
lipid-transfer proteins play a role in the exchange of lipids 
between lipoproteins сігз. 
The cytoplasm forms a barrier between the plasma membrane 
and intracellular organelles, in which lipophilic molecules are 
metabolized or have specific functions. To facilitate the intra­
cellular and also the transcellular passage, the cytosol contains 
several specific carrier proteins, with affinities for distinct 
classes of hydrophobic ligands. Cellular retinol-binding proteins 
[5,133, and ot-tocopherol-binding protein інз are involved in intra­
cellular transport of vitamins A and E, respectively. The cyto­
plasm also contains specific binding proteins for steroids [isi, 
glycolipids іібз, and bile acids итз. Two sterol-carrier proteins 
(SCP, and SCP2) have been described, that participate in diffe­
rent steps of cholesterol synthesis and its transfer and utili­
zation within the cell [18,19]. The latter of the two is identical 
to a protein named nonspecific-lipid transfer protein (ns-LTP) 
that is capable of phospholipid exchange between membranes 
[18,193. Several other types of cytosolic phospholipid transfer 
proteins have been isolated that may catalyze the flow of phos­
pholipids between membranes [20-223. In fetal and newborn plasma, 
alpha-fetoprotein is an important carrier for unsaturated fatty 
acids, and in some species also for estrogens [23,243. 
Fatty acid-binding proteins (FABPs) form a group of cyto­
solic proteins that are believed to be involved in the intra­
cellular transport of fatty acids, and acyl-CoA and-carnitine 
esters [25·2β]. Since their discovery at the end of the 1960's, 
much knowledge has been obtained regarding this group of low-
molecular-mass cytosolic proteins. The investigations described 
in this thesis aimed at the structure of these proteins, their 
characteristics, and their functions in various tissues of rat, 
man, and pig. 
1.2. OUTLINE OF THIS THESIS. 
This thesis starts with an overview of the current knowledge 
on FABPs (Chapter 2). It also includes the data that have been 
gathered during the investigations that are described in the 
following chapters. 
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Chapter 3 gives a detailed description of the materials and 
practical procedures that have been applied. 
The purification and characterization of FABPs from heart 
of man, pig and rat is described in Chapter 4. The characteris-
tics of these proteins are compared to those of FABPs from other 
tissues. They clearly demonstrate the existence of distinct types 
of this protein, related to different tissues. 
Chapter 5 deals with the influence of various physiological 
conditions, postnatal development, and Clofibrate treatment on 
the cytosolic fatty acid-binding capacity of rat tissues, deter-
mined by a radiochemical binding assay. In Chapters 6 and 7 the 
cytosolic FABP content of tissues from rat, man, and pig is 
assessed by an enzyme-linked immunosorbent assay, using specific 
antibodies against distinct FABP types. The fatty acid-binding 
capacity is compared with these data (Chapter 6). 
A summary of the results of the investigations described 
in Chapters 4-7 is given in Chapter 8. 

Chapter 2. 
INTRACELLULAR FATTY ACID-BINDING PROTEINS* 
An overview. 
2.1. EXTRACELLULAR TRANSPORT OF FATTY ACIDS. 
Fatty acids are distributed by the bloodstream to peripheral 
tissues where these molecules are utilized for energy production, 
in biosynthetic pathways, or are (temporarily) stored. Transport 
of fatty acids in plasma occurs in the form of triacylglycerols 
in chylomicrons and very-low-density lipoproteins, or non-
covalently bound to serum albumin. On their route from the capil­
lary to the intracellular organelles fatty acids have to pass a 
series of aqueous spaces and membrane barriers (Fig. 2.1) . Endo­
thelial cells of the capillary wall may transfer monomeric fatty 
acids from the blood to the interstitial space, but also albumin-
fatty acid complexes are able to pass the endothelial walls [29]. 
Specific albumin-binding proteins have been identified in the 
capillary endothelium c30j, that may be instruments in a carrier-
mediated uptake and transcytosis of albumin and its ligands. As 
in the bloodstream, albumin probably also functions in fatty acid 
transport through the interstitial fluid and the delivery of 
fatty acids directly to the cell сзіі. By keeping the extracellu­
lar free fatty acid concentration low, albumin may prevent cyto­
toxic effects of fatty acids. 
Scow and coworkers [32,33] proposed another model, based on 
electron microscopy. In this view, fatty acids are transported 
from the capillaries to the sites of utilization by lateral move­
ment in membranes, that form a continuum across the capillary 
endothelium and within cells. 
This chapter was adapted from Paulussen and Veerkamp [28]. 
Fig. 2.1. Extra- and intracellular transport of fatty acids. 
Abbreviations: FA, fatty acid; VLDL, very-low-density lipoproteins; chylos, chylo­
microns; LPL, lipoprotein lipase; ECF, extracellular fluid; y , albunin receptor; 
β& , plasma membrane fatty acid-binding protein. 
2 . 2 . CELLULAR FATTY ACID UPTAKE. 
Total c e l l u l a r f a t t y ac id uptake i s dependent on the r a t e 
of f a t t y a c i d metabolism, and on t h e e x t r a - and i n t r a c e l l u l a r 
f a t t y a c i d c o n c e n t r a t i o n s . The e x t r a c e l l u l a r f ree f a t t y ac id 
c o n c e n t r a t i o n i s determined by the t o t a l f a t t y ac id concentrat ion 
and t h e albumin-fatty ac id r a t i o №,35]. In cu l tured and i s o l a t e d 
hear t c e l l s , uptake apparently i s r e l a t e d t o the t o t a l f a t t y ac id 
c o n c e n t r a t i o n аб.ъп, but in Ehrl ich a s c i t e s c e l l s [38], perfused 
r a t l i v e r an, ra t hepatocytes tun, and in cu l tured human l e u -
kaemic myeloid c e l l s MI i t depends on t h e f ree f a t t y ac id con­
c e n t r a t i o n . 
The d i f f e r e n t models t h a t have been p o s t u l a t e d for c e l l u l a r 
f a t t y a c i d uptake are summarized in Fig. 2 . 2 . In the p a s s i v e 
d i f f u s i o n model (Fig. 2.2-A), f a t t y a c i d s from the aqueous phase 
e n t e r t h e outer l e a f l e t of the plasma membrane, and spontaneously 
f l i p - f l o p t o the inner-hal f кгі. At p h y s i o l o g i c a l pH the f l i p -
f l o p r a t e may be rather high, s i n c e approximately 50% of the 
f a t t y a c i d s in membranes are unionized [43]. The maximal r a t e of 
f a t t y a c i d uptake w i l l be determined by the r a t e of d i s s o c i a t i o n 
of f a t t y a c i d s from albumin, or the t ransport of f a t t y a c i d s 
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from the capillary to the plasma membrane. The serum-tissue 
concentration gradient that was found in heart of rat, dog and 
man [44,45] supports a role for uptake by diffusion, but pure 
passive diffusion cannot explain the sex differences in fatty 
acid uptake in perfused rat liver MÍ . 
Plasma membranes derived from male liver showed a lower 
affinity for fatty acids as palmitic and oleic acid versus plasma 
membranes from female liver, but the rates of uptake in perfused 
male and female liver were identical when the concentrations of 
fatty acids in the plasma membranes of male and female liver were 
the same кл. This indicates important differences in the inter­
actions between fatty acids and livers from male and female rats, 
besides different affinities of the plasma membranes for fatty 
acids. 
Kinetic studies of single-pass hepatic uptake of fatty acids 
[48] suggested that uptake is mediated primarily by interaction of 
the albumin-ligand complex with a component on the hepatocyte 
surface, rather than by the small fraction of unbound fatty acid 
(Fig. 2.2-B). In more recent studies, catalysis of the dissociat­
ion of oleic acid from albumin by an albumin receptor could not 
be established. Dissociation from albumin could be the rate-
limiting step in ligand transport. Thus, uptake apparently 
becomes dependent on the bound ligand [49]. The pH and the acyl 
chain-length are important factors in the regulation of fatty 
acid transfer from albumin to membranes [4ï,50,5i]. According to Noy 
et al. [52], uptake in the perfused liver is not limited by kine-
tic factors, but is determined by the equilibrium distribution 
of fatty acids between albumin and the plasma membrane. A change 
of the molar fatty acid/albumin ratio therefore has a marked 
influence on fatty acid uptake. The intrahepatic pool sizes for 
palmitic acid predicted on basis of this model correspond well 
with the measured values at palmitate/albumin ratios of two and 
four [И]. Recent studies with perfused rat liver indicate that a 
portion of oleic acid uptake occurs by an electrogenic, sodium-
coupled transport mechanism [54]. 
The saturation of uptake of fatty acids alone is not suffi­
cient evidence for a specific transport system [52,53], and studies 
on the presence of an albumin receptor in plasma membranes of 
liver and adipocytes are not equivocal tss-sn. Influx kinetics 
indicated a membrane-associated fatty acid transport system in 
adipocytes [58-60], hepatocytes [6i-63], cardiomyocytes [64,65], and 
jejunal mucosa cells [66], and also the inhibition of fatty acid 
uptake by phloretin and by trypsin suggested the involvement of 
a carrier protein (Fig. 2.2-C,D,E). Uptake in rat hepatocytes [62] 
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and basolateral liver plasma membrane vesicles ип was potential-
sensitive, sodium-coupled, and could be inhibited by ouabain and 
metabolic inhibitors, in contrast to uptake in adipocytes [58-60] 
and cardiac myocytes [64,65]. Heat- and trypsin-sensitivity of 
oleic acid-binding to plasma membranes of liver [68,69], jejunum 
[70], and heart [«] indicated the involvement of a membrane-
associated protein. A basic 40 kDa protein was isolated from 
plasma membranes of rat liver [69] and adipocytes [60,70], and from 
rat jejunal microvillous membranes [71]. These plasma membrane 
fatty acid-binding proteins are immunologically related, since 
all react with an antibody raised against the protein from liver 
[60,70,71]. They differ from the cytosolic FABPs with respect to 
molecular mass, isoelectric point and 
structural and immunochemical proper­
ties [69-71]. The antibody against the 
plasma membrane fatty acid-binding 
protein from liver can inhibit fatty 
acid uptake in hepatocytes [62,63], adi­
pocytes [60], cardiac myocytes [65], and 
jejunal mucosa cells [66] and fatty acid 
binding to plasma membranes of liver 
[69] and jejunum [71]. 
F A
 FA 
Jiie I 
(WBP) J 
extracellular 
intracellular 
Fig. 2.2. Models for the cellular uptake of fatty acids. 
A Passive diffusion of fatty acids through the plasma membrane. 
В Membrane-associated alboni η receptor, that facilitates the dissociation of the albmin-fatty acid 
conplex. Uptake by passive diffusion. 
С Extrinsic membrane fatty acid-binding protein. Uptake by facilitated diffusion. 
D Intrinsic membrane fatty acid translocator. Additional alternatives: 
1. extracellular albunin-binding site. 
2. intracellular FABP-binding site. 
E Intrinsic membrane fatty acid translocator, with extracellular albumin-binding site, and intracellular 
fABP receptor function. 
a 
An antibody against the protein from heart inhibits oleic acid 
binding to heart plasma membranes and its influx in cardiomyo-
cytes с«]. The evidence presented for the existence of closely 
related, if not identical, plasma membrane fatty acid-binding 
proteins in various tissues sustains the idea that fatty acid 
uptake does not occur by diffusion only, but that it also is a 
facilitated process. The differences between hepatocytes and 
adipocytes and cardiomyocytes in the sensitivity of fatty acid 
uptake to membrane potential, sodium, and energy deprivation may 
relate to variations in other components, or to the micro-
environment of the transport system. 
The possible roles for the plasma membrane fatty acid-
binding protein are depicted in panels C-Ε of Fig. 2.2. It could 
influence the albumin-fatty acid binding, and/or function as an 
acceptor for extracellular fatty acids. After (flip-flop) passage 
of the membrane the fatty acids are bound by cytosolic FABP (Fig. 
2.2-C). Alternatively, the fatty acid may be transferred to the 
inner surface of the membrane by the membrane fatty acid-binding 
protein itself (or by another membrane-linked protein) by a con­
formational change (Fig. 2.2-D). In the last model (Fig. 2.2-Е), 
the membrane fatty acid-binding protein functions both as albumin 
receptor and as fatty acid translocator. 
No information is available until now on the primary and 
secondary structures of the plasma membrane fatty acid-binding 
proteins. Their high isoelectric point of 9.0 suggests an elec­
trostatic interaction with a fatty acid anion. The extractability 
of the plasma membrane fatty acid-binding protein from membranes 
by sonication at a high salt concentration t/oj, and the inhi­
bition of fatty acid uptake by antibodies against this protein, 
suggest that it is a peripheral, rather than an integral membrane 
protein. Apparently, it is a common fatty acid acceptor in 
various tissues. Spontaneous transbilayer movement of the fatty 
acids may occur, or an additional, possibly tissue-specific, 
transfer process may subsequently take place after binding of the 
fatty acid. Such a complex system may be comparable to that from 
Escherichia coli [72]. 
2.3. INTRACELLULAR TRANSPORT OF FATTY ACIDS. 
Cellular fatty acid uptake differs largely among various 
tissues. These differences are related to the type of fatty acid 
metabolism of these tissues. The intracellular systems utilize 
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fatty acids for oxidation, synthesis of triacylglycerols, phos­
pholipids, cholesterol, sphingolipids, and eicosanoids, with 
special preferences for certain fatty acids. In various tissues 
also de-novo fatty acid synthesis takes place. Therefore, intra­
cellular transport and trafficking of fatty acids are important 
processes. Fatty acids can be transferred through the intra­
cellular water phase as monomers, but the cytosolic fatty acid-
binding proteins (FABPs) may have an important function in the 
targeting of these molecules. They may also play a modulatory 
role in cellular metabolism. Structural and functional aspects 
of these proteins will be surveyed in the next paragraphs. 
FABPs form a class of proteins with a molecular mass of 
14-15 kDa, that are abundantly present in the cytosol of tissues 
that are involved in the uptake or utilization of fatty acids. 
Their name was derived from their high affinity for long-chain 
fatty acids. The FABPs are members of a large group of low-
molecular mass, soluble proteins, that are involved in the 
binding of various hydrophobic substances. These proteins were 
first discovered when Levi and coworkers fractionated the cytosol 
(105,000 χ g supernatant) of liver in their search for proteins 
that account for the binding of bromosulfophthalein and bilirubin 
[73]. They found two major fractions involved in binding of these 
ligands, that were designated Y and Z. In the Y class, Mr 30-50 
Table 2.1. 
The occurrence of fatty acid-blndinj proteins. 
Species Rat Han Pig Cattle House Rabbit Guinea Chicken 
Tissue pig 
Liver • • • • • • • • 
Heart + + • • + + + 
Intestine • + • + + 
Stomach + 
Kidney + • + 
Adrenal • 
Brain • + 
ling • • 
Adipose tissue + + + + * 
Skeletal muscle + + • • • + 
Малгіагу gland • • 
Placenta • + + 
Testes • 
Ovary • 
Aorta + 
Semn -
Erythrocyte 
Retina • 
Only the tissues investigated for the presence of FABP are given. 
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kDa, organic anions are mainly bound by a group of glutathione 
S-transferases. The Ζ class contains a number of proteins with 
molecular masses between 10 and 20 kDa, that each bind a diffe­
rent class of hydrophobic ligands. Among these are the sterol-
carrier proteins, phospholipid-transfer proteins, retinoid-bind-
ing proteins and FABPs. The study of Levi et al. с/З] initiated an 
extensive research of the proteins involved in binding of organic 
anions. 
FABPs were first recognized in the early 1970's ітз-га, when 
cytosolic proteins were incubated with tUC]oleic acid and then 
chromatographed over a gel filtration column. The radioactive 
label was recovered in two fractions, one with a Mr of approxi­
mately 68 kDa, containing albumin, and a second fraction of about 
14-15 kDa (often described as 12 kDa in the early reports). This 
fraction was called fatty acid-binding protein (FABP). Soon this 
FABP-fraction was demonstrated in a large number of tissues of 
various species (Table 2.1). It does not appear to be present in 
bloodserum or erythrocytes. Recently a protein with a molecular 
mass of 9955 was isolated from bovine liver [77,78], that binds 
medium-chain acyl-CoA esters. In the last few years several 
review papers have been published on FABPs in general [27,2B,79,80], 
or focusing on hepatic and intestinal C25,8i], or cardiac FABPs [26) 
and the role of FABP in muscular fatty acid metabolism [82]. 
2.4. QUANTITATION AND ISOLATION OF FABPs. 
For the quantitative determination of cytosolic FABP content 
a variety of methods has been deployed. These methods, summarized 
in Table 2.2, will be discussed in more detail in Chapter 5. 
Table 2.2. 
Assay methods for quantitation of fatty acid-binding proteins. 
Coelution on gel filtration chromatography 
Electrophoretic comigration 
Equilibnun dialysis 
Affinity chromatography on oleoyl-ammohexylammo-Sepharose 
Radiochemical binding assay (charcoal. Lipide«; 1000) 
Binding of fluorescent fatty acid analogues 
Transfer of labelled fatty acids from liposomes 
Iimunochemical assay with specific antibodies 
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FABPs have been isolated from cytosols of a number of 
tissues of several species. Most isolation procedures are a com­
bination of gel filtration and ion-exchange chromatography [e.g. 83-
86]. Sometimes other techniques, such as affinity chromatography 
сел, preparative isoelectric focusing [76,88-94], heat treatment [95-
98] or ammoniumsulphate precipitation [95-97,99,100] are incorporated. 
Differences in protocols for the isolation of FABPs from distinct 
sources especially concern the buffers used in the ion-exchange 
steps. They reflect the structural differences of the FABP types 
isolated from various tissues. 
2.5. STRUCTURAL FEATURES OF FABPs. 
Amino acid composition and primary structure. 
A comparison of amino acid composition, amino acid sequence, 
and nucleotide sequence of cloned cDNA or mRNA, of FABPs from 
different tissues clearly reveals the existence of distinct FABP 
types. The data reported for the amino acid composition of heart 
and liver FABPs of cattle, man, pig and rat are summarized in 
Table 2.3. 
General amino acid composition of heart and liver FABPs from cattle, man, 
pig and rat, and intestinal FABPs from man and rat. 
Ammo acid composition (residues per mol FABP) 
Amino acid 
Asx 
Thr 
Ser 
Glx 
Pro 
Gly 
Ale 
Cys 
Val 
Het 
I l e 
Leu 
Туг 
Phe 
Тгр 
HIS 
Lys 
Ara 
Liver 
11-13 
10-12 
6-7 
16-20 
1-4 
11-13 
2-6 
1-3 
9-12 
1-7 
6-12 
3-10 
1-3 
6-9 
0 
1-2 
13-17 
2-3 
Heart 
14-17 
17-19 
6-9 
12-17 
1-2 
9-12 
5-7 
(pig 
(pig 
(pig 
0 (see ' 
8-15 
2-3 
3-7 
9-14 
2-3 
5-6 
1-4 
2-4 
10-18 
3-5 
7) 
6) 
11) 
t e x t ) 
Intestine 
19-21 
10 
1-5 
15-18 
0 
10-14 
6-7 
0 
9-11 
1-3 
7 
10 
3-4 
8-9 
1-2 
1-2 
14-16 
6-7 
Data are derived from Refs. 83,84,86,87,90,95-97,101,103,105-110,138,259. 
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Table 2.3, together with values for intestinal FABPs of man and 
rat. Except for some discrepancies [95-98,ion all studies agree on 
the presence of cysteine only in hepatic FABPs, while tryptophan 
is present in all FABPs, except the liver type. Intestinal FABPs 
contain no proline, and their serine content is lower than that 
of the other types. Threonine and leucine content of heart FABP 
are higher. The arginine and the asparagine/aspartic acid con­
tents are higher in heart than in liver FABPs, but even markedly 
more elevated in the intestinal type. The number of isoleucine 
and glutamine/glutamic acid residues are higher in liver FABPs. 
Recently the amino acid composition of a kidney specific FABP 
type from rat was described imi. This FABP contains both cysteine 
and tryptophan residues. 
At least two isoforms can be distinguished in liver FABPs 
of man, pig and rat that behave differently on DEAE-cellulose 
anion-exchange chromatography [25,76,83,90,93]. No significant diffe­
rences could be detected in the amino acid composition of the 
isoforms [74,83,90,93], but they were shown to contain different endo-
genously bound fatty acids [25,90]. Bovine heart and liver FABPs 
Table ZA. 
Structure of FABPs from various tissues. 
Origin 
RAT 
I i ver 
intestine 
heart 
kidney 
m. quadriceps 
HAN 
liver 
heart 
intestine 
m.psoas 
CATTLE 
liver 
heart 
PIG 
liver 
heart 
Mr 
(0a) 
14,272 
и,ш 
15,062 
H,776 
H,992 
15,500 
16,000 
14,178 
15,500 
15,500 
14,768 
15,100 
15,000 
11,800 
15,300 
14,673 
14,500 
15.000 
Amino 
acids 
(nr) 
127 
127 
132 
133 
134 
n.d. 
n.d. 
127 
n.d. 
n.d. 
132 
132 
n.d. 
n.d. 
n.d. 
132 
n.d. 
n.d. 
IEP 
n.d. 
5.5 
n.d. 
n.d. 
5.0 
5.3 
5.2 
5.8 
5.3 
5.2 
5.2 
n.d. 
5.2 
7.0 
4.9 
4.9 
5.8 
4.9 
N-term nus 
blocked 
blocked 
blocked 
n.d. 
blocked 
n.d. 
n.d. 
blocked 
blocked 
n.d. 
blocked 
n.d. 
n.d. 
n.d. 
blocked 
blocked 
n.d. 
n.d. 
Cys Trp 
(residues/mc 
1 
1 
0 
0 
0 
2 
0 
1 
2 
0 
0 
0 
0 
2 
3 
1 
1 
0 
0 
0 
1 
1 
2 
1 
η 
0 
2 
1 
2 
1 
n.d. 
0 
2 
2 
0 
5 
Pro 
ilecul 
2 
2 
0 
1 
1 
1 
.d. 
1 
2 
3 
1 
0 
1 
1 
1 
2 
1 
4 
Ref 
>) 
99 
103 
101 
123 
110 
102 
* 
105 
97 
84 
109 
107 
260 
95 
96 
108 
83 
84 
* J.H. Veerkamp et al., unpublished results; n.d., not determined. 
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could be separated into two isoforms with distinct isoelectric 
points by CM-cellulose cation-exchange chromatography [96] and 
isoelectric focusing [95], respectively. Only the bovine liver 
FABP isoforms differ in amino acid composition [95]. 
A number of characteristics of FABPs from different tissues 
is given in Table 2.4. The amino-terminal amino acid is acetyla-
ted [іоі.іоз]. This was thought to be an indication of their cyto­
plasmic destination мозі, but apparently, acetylation is related 
to the residues adjacent to the amino-terminal amino acid [io4]. 
Molecular masses of liver FABPs show values of just over 
14 kDa, in contrast to 15 kDa for all other types. Isoelectric 
points of the hepatic FABPs are generally higher than those of 
the other FABP types. 
The amino acid sequence of the FABPs appears to be highly 
conserved throughout the evolution моя . Corresponding FABP types 
from different species show a remarkably high degree of sequence 
homology (Table 2.5). The human and rat liver FABPs have an 82% 
sequence identity [106]. A similar 82% sequence identity was found 
for human and rat intestinal FABPs [107]. Bovine, human and rat 
heart FABPs also show a very high degree of homology [ioa,i09]. Rat 
intestinal FABP has only 31 and 26% homology with heart and liver 
FABP, respectively [ioi,iiO]. The amino acid sequences of heart 
FABPs also have a large degree of homology with the murine adipo­
cyte P2 (p422) protein [in], the human ni2] and bovine [ііз] myelin 
P2 proteins, with bovine mammary-derived growth inhibitor (MDGI) 
til*], and with the cellular retinoid-binding proteins [115,116]. 
No sequence homology of rat liver and intestinal FABPs tii7] 
could be established with serum albumin ηιβ], nonspecific lipid-
transfer protein (sterol-carrier protein2) [ii9], phosphatidyl-
choline-transfer protein nzo], and the apolipoproteins apo A-I and 
apo A-IV [106,10л. Statistical analyses of mRNA and protein 
Table 2.5. 
Amino acid sequence homology of FABPs and other hpid-binding proteins. 
Rat heart FABP 
Hunan heart FABP 
Bovine heart FABP 
Murine adipocyte P, (p422) 
Hunan myelin P, 
Rat intestinal FABP 
Bovine MOGI 
100 
90 
89 
67 
61 
31 
84 
Rat h ver FABP 
Human liver FABP 
Rat intestinal FABP 
Rat heart FABP 
Hunan myelin P, 
Murine adipocyte Pj (p422) 
100 
82 
26 
38 
27 
23 
14 
sequence data ηοβ] showed that distinct FABP types must have 
diverged some 650 million years ago, long before today's species 
diverged from their common ancestor. Divergence of FABPs and 
other, closely related, proteins as murine adipocyte P2 (p422) 
and the myelin P2 protein must have taken place several hundred 
million years earlier, before the invertebrate-vertebrate diver­
gence [105] . 
Secondary structures. 
Circular dichroism measurements and computer-aided predict­
ions of secondary structures according to Chou and Fasman nzu 
reveal a relatively high content of α-helical structures in all 
FABPs (Table 2.6). Furthermore, a high percentage of /?-structures 
is predicted. The α-helices and ^ -structures form an alternating 
pattern of hydrophobic and hydrophilic domains tw.io«, that pro­
bably yield a protein with a hydrophilic surface for solubiliza­
tion in the aqueous cytoplasm, and a distinct hydrophobic domain 
for ligand binding. The predicted secondary structure of human 
liver FABP cío« suggests that this protein may orient at a lipid-
water interface, a property that may play an important role in 
the binding of fatty acids from membranes nosj. 
Table 2.6. 
Structural details of FABPs from various tissues 
Origin 
HEART 
rat 
man 
cattle 
РІ9 
LIVER 
rat 
man 
cattle 
INTESTINE 
rat 
α-helix 
22 
32 
25 
15 
19 
19 
14 
29 
38 
30 
12 
33 
Ä-structures 
β-sheet 
51 
49 
48 
30 
27 
45 
14 
β 
45 
44 
45 
39 
37 
-turn 
В 
27 
β 
22 
В 
15 
20 
Random 
coil 
33 
24 
30 
26 
5 
25 
47 
19 
27 
33 
27 
33 
Method 
CD 
CF 
CO 
CO 
CF 
CD 
CD 
CF 
CF 
CF 
CD 
CF 
Ref. 
86 
109 
109 
96 
108 
192 
261 
90 
103 
105 
139 
101 
Values are given in X, and were obtained with the Chou-Fasman method (CF) (Ref 121) or 
circular dichroism measurement (CD). 
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Investigation of the amino acid sequence of rat and human 
liver FABPs presented evidence for the presence of tandemly 
arranged repeats, that contain a relatively high degree of a-
helix structure [Μ,ΙΟΑΙ. The existence of two regions of high homo­
logy, that contain tandem repeats, has also been shown in rat 
intestinal [117], and rat tuoi and human cío« cardiac FABPs. No 
significant relationships could be demonstrated among these 
sequences of the different FABP types. These repeats appear to 
be the most highly conserved amino acid sequences of the entire 
protein, together with the amino-terminal part of the molecule 
[109]. Despite the high degree of amino acid sequence homology 
between human and rat heart FABPs, the internally repeating 
sequences of human heart FABP did not match with the repeats of 
its rat counterpart [109]. The occurrence of two small, highly 
homologous oligopeptides, each consisting of tandemly repeated 
sequences, in the two halves of rat and human liver FABP mole-
cules led to the assumption that two separate intragenic dupli-
cations occurred in the evolution of these proteins [90,i06,iin. 
However, this hypothesis appears unlikely on basis of a structu-
ral analysis of rat liver FABP, that showed that the segments 
containing the highly homologous polypeptides are not located 
symmetrically in each half of the FABP molecule [122]. 
cDNA sequences and FABP genes. 
Complementary DNA sequences have been established for rat 
liver and intestinal FABPs on basis of intestinal mRNAs [іоі,іоз,і07], 
for murine adipocyte P2 (p422) protein [ini, and human liver FABP 
[105,122]. Recently the structures of cDNA of rat [123,124] and bovine 
[108] heart FABPs were also described. All cDNAs contain 3' and 5' 
non-coding regions, of which the first show more homology between 
the same FABP types of different species than the latter мое, 1221. 
The coding sequences of cDNA of rat liver and intestinal 
FABPs have been inserted in an appropriate expression vector [125, 
126], and could be efficiently expressed in E.coli. The liver FABP 
from E.coli [125] however, does not have a blocked amino-terminus, 
in contrast to that in liver cytosol [9o,io3]. A frameshift mutat­
ion, introduced in vitro in the coding region of liver FABP cDNA, 
resulted in the production of a less stable FABP, with a lower 
fatty acid-binding affinity H25]. 
The nucleotide sequences of the genes encoding rat liver 
FABP [122] and human intestinal FABP [1071 have been completely esta­
blished. These genes contain 3790 and 3382 nucleotides, respecti­
vely, and consist of 4 exons and 3 introns. The rat intestinal 
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FABP gene was partially defined пол. Also the genes for murine 
adipocyte P2 (p422) protein [i27] and cellular retinol-binding 
protein II [128] were characterized. The genes encoding these 
proteins have a similar organization of 4 exons and 3 introns. 
Comparably positioned introns may vary considerably in size, but 
the introns in each of the genes are identically positioned 
relative to their exons по/.ігв]. 
The polypeptide sequences encoded by each exon of rat liver 
FABP were compared with rat intestinal FABP, rat cellular reti­
nol-binding protein (CRBP) , bovine cellular retinoic acid-binding 
protein, human myelin P2 protein, and murine adipocyte P2 protein 
(p422) [122]. The first exon of liver FABP was significantly rela­
ted to that of all the other members of this multigene protein 
family. Only the rat intestinal FABP sequence showed similarity 
with the sequence encoded by the third exon of liver FABP [122]. 
The amino-terminal sequence of these proteins (exon I) may define 
a structural and functional domain that is involved with the 
common property of these proteins, namely the binding of hydro­
phobic ligands [106,122]. Exons III and IV may be related to the 
differences in ligand specificities of the members of the protein 
family and/or to differences in the enzymes or cellular membranes 
with which they interact. 
Tertiary structure. 
A highly comparable secondary structure model has been 
proposed for all proteins of the above described multigene fami­
ly, together with specific variations for each separate protein 
[129]. Generally, the secondary structure predictions show a high 
level of /3-structures, that can assemble into a β-barrel tertiary 
structure. A thorough investigation of the tertiary structure by 
X-ray diffraction at 2.5 A resolution has been reported for the 
intestinal FABP type from rat изо], using the crystallized protein 
derived from E.coli [ізп . The protein is build up of 10 ^ -strands 
that are arranged in anti-parallel direction. These /J-strands 
form a "shell-like" structure or /3-barrel, with two α-helices on 
top in a parallel arrangement. The outer surface of the protein 
predominantly contains hydrophilic side-chains, whereas most 
non-polar residues are located at the inner side of the "shell", 
thus creating a hydrophobic cavity where one fatty acid molecule 
can be bound. 
The internal repeat sequences are located in areas of the 
FABPs with predicted /3-structures and decreasing hydrophobicity 
[it»], yielding a protein with alternating hydrophobic and hydro-
17 
philic regions. Offner et al. non predicted a secondary struc­
ture for human heart FABP consisting of 6 regions of ^ -structure, 
separated by reverse turns or α-helices. Although slightly diffe­
rent from the 10 ß-strands of intestinal FABP изі], this secon­
dary structure for heart FABP can allow the protein to be folded 
into a ^-barrel tertiary structure. Based on the high degree of 
sequence homology and the predicted comparable secondary struc­
ture [129], it is likely that other members of the multigene family 
of FABPs have a comparable tertiary structure. 
A corresponding conformation of a /}-barrel composed of eight 
anti-parallel ^-strands has been reported for another group of 
proteins that carry hydrophobic ligands, as serum retinol-binding 
protein ci32], bilin-binding proteins [ізз,із4], and /}-lactoglobulin 
C135]. These proteins show only 25-30% sequence homology and have 
neither an evolutionary nor a structural relationship to the FABP 
family 1128]. Appropriate modification of the primary structure 
of the residues that build up the central cavity of the proteins 
may lead to their different ligand specificities изб]. 
2.6. THE LIGAND-BINDING SITE OF FABP. 
Most information concerning the ligand-binding site of FABPs 
has been derived from comparative studies of amino acid sequences 
and secondary structure predictions. The remarkably high degree 
of sequence homology of the amino-terminal segments of FABPs and 
the closely related cellular retinoid binding proteins, adipocyte 
P2 (p422) and myelin P2 proteins, indicates an involvement of 
this part of the protein in the binding of hydrophobic ligands 
1106,109,110,117,122]. Other sequences within the proteins may be 
involved in the specificity of the ligand-binding, either sepa­
rate or in concert with the amino-terminal domain иоб]. Domains 
with amphipathic α-helical structure have been suggested to be 
involved in the binding of FABPs to hydrophobic ligands, since 
this was observed for albumin из/] and the apolipoproteins apo-
A-I and apo A-IV моб.Ш]. However, sequences homologous with the 
latter proteins and such amphipathic structures were not found 
ІП FABPS [106,110,117] . 
The hydropathy of FABPs is of great importance for their 
interaction with ligands. Relative hydropathy plots are clearly 
different for liver, intestinal, and heart FABPs [no], but hydro­
pathy has been highly conserved during evolution. Out of the 23 
amino acids that are non-identical in human and rat liver FABP, 
18 
74% maintain the same relative hydropathy tio6]. 
Binding of long-chain fatty acids to FABP is non-covalent 
[90], and involves both hydrophobic and ionic interactions [139,HOJ. 
The fatty acid-binding site of liver and heart FABPs is diffe­
rent, as can be deduced from their interaction with fluorescent 
fatty acid analogues ію.ко.ніі. The ionic interactions may be 
ascribed to arginine in liver, intestinal and heart FABPs. Modi­
fication of arginine residues of human [83] and bovine [139] liver 
FABP, and of pig heart FABP [83) strongly reduced binding of long-
chain fatty acids. The remaining binding activity was entirely 
due to hydrophobic interactions [139]. Detailed X-ray diffraction 
analysis of rat intestinal FABP confirmed the interaction of an 
arginine residue at position 127 of the protein with the ionized 
carboxyl-moiety of the fatty acid изо]. The bound fatty acid is 
located in the interior of the protein, and has a bent confor­
mation with several gauche bonds. The arginine involved is the 
only basic amino acid that extends into the hydrophobic core of 
the FABP-molecule. More support for the involvement of this amino 
acid in the ligand binding came from comparison of the amino acid 
sequence of other FABPs and closely related proteins. All, except 
CRBP, have an arginine residue at the same position [139]. The 
absence of this arginine in a mutant FABP produced in E.coli 
[125], results in a reduction of fatty acid-binding, comparable to 
chemical modifications of this amino acid [83,139]. Arginine resi­
dues are also involved in ionic interactions with the polar head-
group in the binding of phospholipids by the phosphatidylcholine-
transfer protein ti«). 
1IC-NMR spectroscopy studies of the structure-function 
relationships of rat liver and intestinal FABPs revealed some 
major discrepancies between the interactions of these two FABP 
types with [carboxyl-13C] fatty acids [нз,Н4]. Whereas both proteins 
bind oleic acid to a maximum of 1 mol/mol, palmitic acid may be 
bound up to 2-3 mol/mol by liver FABP. The intestinal type only 
binds one mol of palmitic acid per mol protein. The maximal pal­
mitic acid binding by the liver type is dependent on the (tempe­
rature-dependent) physical state of the unbound fatty acids, and 
the pH. Furthermore, differences were found in the type of inter­
action of the fatty acids with these two FABP types. As with the 
high affinity binding of fatty acids to albumin η«], fatty acid 
binding to intestinal FABP involves ionic interactions. The 13C-
NMR data и«] support the involvement of Arg-127 in this inter­
action, as was proposed from X-ray diffraction analysis изо]. 
Although they appear to be fully ionized at neutral pH, the 
anionic carboxyl groups of the fatty acid are not involved in 
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electrostatic ion-pair interactions with cationic residues of 
hepatic FABP. Binding affinities (for the first mol fatty acid) 
were comparable for both FABPs И26,К4]. 1H-NMR studies of ligand 
interaction with bovine liver FABP gave strong indications for 
the occurrence of conformational changes upon fatty acid binding 
[139]. Involvement of histidine and lysine residues was excluded 
by 1H-NMR and acetylation studies on bovine liver FABP [139] and 
13C-NMR studies of rat intestinal and liver FABPs aw. 
The presence of cysteine only in hepatic FABP (and, as was 
recently reported, in the kidney type мог)) , and the ligand speci­
ficity of this protein that clearly differs from that of the 
other types, could be an indication of an involvement of this 
amino acid in the interaction of the protein with (some of) its 
ligands. Fatty acid binding to human, bovine and rat liver FABPs 
was, however, not affected by modification of the sulfhydryl 
group [83,139,H6). Considering the striking conservation of cysteine 
in human and rat liver FABPs [ііл (at position 69) this amino acid 
may be involved in the binding of other hydrophobic ligands or 
in some other function specific for hepatic FABPs. For the non­
specific lipid transfer protein a role for cysteine has been 
suggested in transient interactions of this protein with intra­
cellular membranes [НП . 
2.7. TISSUE DISTRIBUTION AND CONTENT OF FABPs. 
When FABPs from different tissues of the rat were isolated 
and characterized, it soon became clear that, although closely 
related, they are different proteins. They have distinct physico-
chemical characteristics and ligand specificity. Until now at 
least four distinct FABP types have been identified: hepatic, 
cardiac, intestinal and renal, and preliminary evidence is avail­
able for the existence of a distinct muscular FABP [82,κβ]. The 
names are derived from the tissue of their first detection, and 
do not imply a confinement solely to these tissues. Murine adipo­
cytes contain a specific lipid-binding protein (murine adipocyte 
P2 or p422), that binds both oleic acid and retinole acid [H9]. 
Tissue distribution of cardiac and hepatic FABPs of rat, man 
and pig has been investigated with specific antibodies in immuno­
diffusion experiments [U6,150,151], ELISA procedures [H8,i52,i53], and 
by Western blotting мгз.нв.ізз]. The heart and liver FABP types are 
clearly distinguishable with specific antibodies [86,96,us,iso, 153,ISM . 
Intestinal FABP is immunochemically distinct from liver FABP 
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tisú. Immunoreactivity with antibodies to rat liver FABP is 
restricted to liver, small intestinal mucosa and adipose tissue 
[87,89,151,153,155,156], while anti-heart FABP antibodies react with a 
variety of rat tissues [102,123,151-153,156]. Cardiac FABP is found in 
heart as well as in several skeletal muscles, and reactivity was 
also found with kidney, aorta, brain, testis, ovary, lung and 
adipose tissue. The tissue distribution of cardiac and hepatic 
FABPs is similar in man and pig cue]. In slow-twitch muscles the 
content of heart FABP is significantly higher than in the fast-
twitch type [123,152,153,157]. Low-molecular-mass proteins reactive 
with antibodies against intestinal FABP are present in intestine 
and stomach [151]. Concomitant expression of two distinct FABP type 
has until now been described for two tissues. Intestinal mucosa 
contains the liver and intestinal FABP types [Нб], and in rat 
kidney recently heart FABP and a kidney-specific FABP type have 
been identified [102]. The kidney FABP type is predominantly 
present in the cortex, whereas heart FABP is found in both cortex 
and medulla. 
Indications for the presence of more FABP types than the 
heart, liver, intestinal and kidney types can be derived from the 
variable Kd values of dealbuminized cytosolic proteins of various 
rat tissues [158], and especially from the differences between the 
fatty acid-binding capacity and the content of heart and liver 
types in these tissues [152] (Fig. 2.3). Many investigators deter­
mined the FABP content of various tissues with antibodies against 
liver FABP [76,нб, 159,160]. The comparison of the FABP content of 
various rat tissues, determined with anti-liver FABP, with the 
cytosolic oleic acid-binding capacity clearly demonstrates the 
inability to determine FABP in many tissues with anti-liver FABP 
antibodies. Similarly, antiserum directed against heart FABP does 
not detect FABP in liver whereas the FABP content of e.g. kidney 
adrenal and brain is grossly underestimated (Fig. 2.3). 
The relationship of liver FABP to its homologues from brain 
and lung cytosol still remains unclear. Rat brain cytosol was 
reported not to [94], or only slightly [issi react with anti-liver 
FABP. Bass et al. [I6I) could not detect any reactivity with cyto­
sol, whereas only one of the two FABPs they isolated from rat 
brain reacted with anti-liver FABP. With lung immunereactivities 
were reported with antibodies to liver FABP [i62], or to the 
cardiac type [i5i,i53]. FABP from adipose tissue is immunochemically 
similar to liver FABP [89], but cytosolic proteins from adipose 
tissue react also with antibodies to heart FABP [150,152]. Rat mam­
mary gland contains a FABP, that shows an immunochemical identity 
to heart FABP [ібЗ]. FABPs form 4-6% of cytosolic proteins in rat 
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Fig. 2.3. Conparison of the fatty acid-binding capacity and the irmunoreact ivi ties with 
anti-rat heart and liver FABP antibodies of cytosols from various rat tissues. 
heart and 2-4% in rat liver, kidney, adrenal, skeletal muscles, 
mammary gland, brain and intestine І87,і50-і53,ібз-іб5]. Human liver 
contains approximately the same content of FABP as the corres­
ponding rat tissues, but rat heart contains more FABP than human 
heart cue]. 
The tissue distribution of heart and liver FABPs based on 
immunochemical observations agree well with that of mRNA of both 
types in these tissues. Rat heart FABP mRNA is present in relati­
vely high amounts in slow-twitch muscle (e.g. soleus), in inter­
mediate levels in fast-twitch skeletal muscle, and testes, in low 
levels in kidney, brain, aorta and adrenal [123,124,166] but not in 
liver, intestine, spleen and lung иг«. In male rats, liver FABP 
mRNA was demonstrated in high concentrations only in liver and 
intestine (0.7 and 2.1% of total mRNA, respectively) И67]. Intes­
tinal FABP mRNA is limited to small (1% of total mRNA) and large 
intestine in rat, man and monkey ио7,і50,ібл. No more than a trace 
of these mRNAs was present in the other investigated tissues. 
2.8. CELLULAR AND SUBCELLULAR DISTRIBUTION OF FABP. 
In livers of man, rat and mice, FABP is only detectable in 
hepatocytes ti59,i68-i70]. No other cell type present in liver reacts 
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with antibodies to hepatic FABP. In the hepatic acinus of the 
male rat, there is a declining portal-to-central gradient of 
liver FABP, whereas in the female it shows a more uniform pattern 
cui]. In fetal human liver FABP is detectable already after 7 
weeks of gestation in a uniform distribution throughout the fetal 
liver. Its distribution changes into a primarily periportal 
localization in adult human liver [170,17Z]. The intestinal and 
hepatic FABP types both decrease in concentration from the proxi­
mal to the distal part of the intestine in suckling and adult 
rats and both FABP types are located predominantly in the top of 
the villi [H6,168,173,174]. This decline is not found in weanling 
animals [ітзі. 
By inununocytochemical staining [I69,i73,i75i, and immunochemical 
quantitation of subcellular fractions 1152,1531, FABPs are only 
detectable in the cytosol of heart, liver, and intestine. In fed 
rats, reactivity with anti-liver FABP is mainly located around 
glycogen areas, where smooth endoplasmatic reticulum and mito­
chondria are located [169,175]. After 2 days fasting this pattern 
changed into a diffuse distribution throughout the hepatocyte 
[175]. No evidence was found for the association of FABP with mito­
chondria [152,153,169], smooth endoplasmic reticulum [169,175] or 
lysosomes [169]. A small fraction of intestinal FABP (16%) was 
found in association with intracellular membranes [H6j. For rat 
heart a gradient-like distribution of FABP (with 15% present in 
mitochondria) was suggested, based on immuno-electron micro­
scopical observations [165]. Using immunogold labelling and 
immunodiffusion, binding of FABP to bovine liver and heart mito­
chondria, nuclei, and microsomes was shown [176-178]. Bovine liver 
FABP was demonstrated only in association with the outer mito­
chondrial membrane [179], but cardiac FABP was also found in the 
matrix of the myocardial mitochondria [178]. Using a highly 
sensitive double-antibody immunoassay, the FABP concentrations 
of subcellular fractions of bovine myocard were determined. FABP 
accounted for 0.02 and 0.003% of total protein of mitochondrial 
matrix and nuclei, respectively, whereas cytosolic FABP accounted 
f o r 0.32% Of c y t o s o l i c [178]. 
The subcellular distribution of FABP differs clearly from 
those of non-specific lipid transport protein (sterol-carrier 
protein2) and phosphatidylcholine transfer protein пво-Ш]. Only 
60-70% of these proteins is located in cytosol of liver. In the 
adrenal gland the cytosolic portion of sterol-carrier protein2 
Í S O n l y 19% [183] . 
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2.9. BINDING CHARACTERISTICS OF FABPs. 
Up to 85% of the fatty acids endogenously bound to rat liver 
FABP are unsaturated, with a high percentage (50-75%) of poly­
unsaturated species [25,в7,нз,і84,ів5]. For bovine heart FABP similar 
data were reported [186]. The different isoforms of rat liver FABP 
have distinct profiles of endogenously bound fatty acids t25,90]. 
The molar ratio of endogenously bound fatty acids varied between 
0.4 and 1.3 mol/mol FABP C25,90,i64,i84]. 
The affinity for long-chain fatty acids estimated from the 
coelution of a mixture of (labelled) fatty acid and cytosolic 
protein from a gel filtration column was in the jumolar range стз-
75,187]. However, because of the non-equilibrium conditions of the 
coelution method, accurate determination of Kd values necessi­
tates another approach. Assays employing an equilibrium between 
bound and free fatty acids allow Scatchard plot analysis of bin­
ding data. Equilibrium dialysis, fluorescence and radiochemical 
binding assays have been used to determine the dissociation 
constants of FABPs for a variety of ligands (Appendix I) . Kd 
values for long-chain fatty acids are in the range of 0.1-1 μΜ 
for all FABP types. The Kd values for their CoA and carnitine 
esters are in the same order of magnitude [25,76,84,188]. 
Both heart and liver FABPs show a preference for the longer, 
unsaturated fatty acid species c74,75,аз,84,87,95,189]. Human and rat 
liver FABP and human heart FABP have a preference for long-chain 
saturated fatty acids of 16-19 carbon atoms, but mono- and poly­
unsaturated fatty acids up to 22 carbon atoms are quite well 
bound [83,84,189]. Bromo-substitution did not affect binding, in 
contrast to a 2-hydroxyl group [83]. The fluorescent fatty acids 
11-(dansylamino)undecanoic acid, 16-anthroyloxy-palmitic acid and 
1-pyrene-dodecanoic acid, all show Kd values comparable to those 
of oleic acid [83]. The Kd values are somewhat higher with the 
former 2 acids for the FABPs from heart than from liver [вз]. For 
oleic acid the reverse is the case. 
Binding is generally considered to occur non-covalently, at 
an equimolar ratio [25,84,β5,ΐ64,ιβ9,ΐ90], but some controversy has 
arisen, concerning the stoichiometry of fatty acid binding to 
FABP. Haunerland et al. [95] first reported binding of 2 mol 
oleate per mol FABP from bovine liver. The binding of both fatty 
acid molecules would occur at a single binding site, whereby the 
molecules are in parallel orientation [HO]. The marked difference 
in Kd values (Appendix I) indicate that binding of the first 
ligand alters the affinity of the binding site for the second 
molecule ti39]. Offner et al. [86,i09] observed binding of oleic and 
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palmitic acid to rat heart and liver FABP and human heart FABP 
at a 2 mol/mol ratio, using liposomes as fatty acid donors. 
Kidney FABP showed only one binding site, under similar con­
ditions ног]. In our laboratory this assay produced values of 
maximally 0.7 mol oleic acid/mol human heart FABP [84]. Transfer 
assays of oleic acid from mitochondria to liver or heart FABPs, 
and Lipidex binding assays, showed a comparable binding stoichio-
metry, that did not exceed 1 mol fatty acid per mol FABP из]. 
In NMR studies on [13C]oleic acid binding to rat liver and 
intestinal FABPs, Cistola et al. could not demonstrate a stoi-
chiometry exceeding 1 mol/mol скз.нм. Palmitic acid, however, was 
bound up to 2-3 mol/mol by liver FABP, but maximally in an equi-
molar ratio by the intestinal type. The measurements of the 
higher binding ratios were allowed by the preservation of the 
equilibrium condition with the employed technique, since it did 
not require separation of bound and free fatty acids. The mate­
rials applied for separation of bound and free ligand in other 
assays may compete with FABP for ligand binding, thus leading to 
an underestimation of the binding capacity of FABP [U3]. An in­
crease of the amount of Lipidex does, however, not affect the 
binding of fatty acid to FABP [i9i]. Apparently the stoichiometry 
of fatty acid binding to FABP is greatly dependent on the assay 
conditions applied. Especially the solubility and the associa­
tive behaviour of the fatty acid may be important. The binding 
ratio of palmitic acid to hepatic FABP was shown to depend on the 
physical state of the unbound fatty acid, thus on temperature, 
and on the pH of the assay mixture nw. 
Rat liver and intestinal FABP genes have been inserted and 
brought to expression in E.coli ti25,i26]. The bacterially derived 
FABPs were used to study ligand binding and secondary and ter­
tiary structures. The liver FABP type could bind up to 2 mol 
long-chain fatty acid per mol with a Kd value of 1.7-3.2 μΜ, and 
a higher affinity for unsaturated fatty acids M26j. Site directed 
mutagenesis of the carboxyl-terminal part of rat liver FABP 
markedly reduced fatty acid binding [125]. Binding properties of 
E.coli-derived intestinal FABP were similar to those of the 
native intestinal FABP. It bound one mol fatty acid per mol 
protein, but the apparent Kd values were also clearly increased 
[126]. Intestinal FABP has an approximately equal affinity for 
oleic, palmitic and arachidonic acid (Kd 2.9-3.7 μΜ) . Analysis 
of its tertiary structure showed that intestinal FABP non-
covalently binds one mol of fatty acid per mol protein изо], which 
was confirmed by "c-NMR studies им]. 
Pig heart FABP was reported to sel f-associate into several 
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forms of higher molecular weight [192]. This concentration-
dependent self-aggregation was suggested to be an important 
regulatory step in the control of energy production through the 
^-oxidative pathway in heart И65]. The self-aggregated FABP forms 
of heart may play different roles in cardiac energy metabolism. 
In this model, only two forms act in the translocation of acyl-
carnitine to mitochondria [193]. Self-aggregation has not been 
reported for any other FABP type. Other investigators found no 
evidence for a concentration-dependent self-association of heart 
FABP from cattle [96], rat t86) or man [io9]. 
The ligand specificity of liver FABP is clearly distinct 
from that of the other FABP types. Liver FABPs appear to function 
as a general carrier of hydrophobic ligands, whereas the other 
FABP types apparently function more specifically as carriers for 
long-chain fatty acids and their CoA and carnitine esters. Human 
heart FABP only binds fatty acids, and long-chain acyl-carnitine 
and -CoA esters ικ:. Liver FABP has been reported to bind (in 
vitro) retinyl-palmitate us«], heme [25,156,189,Ж], prostaglandins 
[190], hematin, l-anilino-8-naphthalene sulfonate (ANS), biliru­
bin, and bromosulfophthalein ti95], with affinities comparable to 
those for long-chain fatty acids (Appendix I). Binding of lyso-
phosphatidylcholine im:, steroids [76] and bile acids И95] to liver 
FABP has also been demonstrated, but with somewhat lower affi­
nity. No binding of retinoids laz:, clofibric acid [вз.тз, prosta­
glandins, long-chain alcohols [83,189], methyl-palmitate, CoA, 
malonyl-CoA ti89] or cholesterol [189,W] could be detected to rat 
and human liver FABP in studies of competitive displacement of 
ll-(dansylamino)undecanoic acid or ANS. Palmitoyl-carnitine and 
palmitoyl-glycerol are only bound with very low affinity [83]. 
Liver FABP showed a higher affinity for monohydroxy-bile acids 
than for trihydroxy-bile acids in competition to ANS [195]. Various 
inhibitors of carnitine-palmitoyl transferase have a high affi­
nity for FABP [83] . 
To date binding of ligands other than fatty acids has only 
been reported for hepatic FABP, not for any of the other FABP 
types. Binding characteristics are similar for the isolated iso-
forms of liver FABP [25,83]. Recently, it was described that the 
murine adipocyte P2 (p422) protein is able to bind both oleic 
and retinole acid from liposomes [H9], but its Kd value for oleic 
acid was much lower (3 μΜ). 
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2.10. FUNCTIONAL PROPERTIES OF FABPs. 
Although the involvement of FABPs in intracellular fatty 
acid transport and utilization is generally accepted, the massive 
amount of research into these proteins has only provided much 
circumstantial evidence for their physiological role(s). No 
conclusive evidence is available. 
Two major functions have been assigned to the FABPs. First, 
the facilitation of transport, which may include release of fatty 
acids and/or movement through the aqueous phase, and secondly, 
modulation of enzyme and/or metabolic activities by storage of 
substrates, sequestration of substrates and/or effectors and 
protection against inhibitors. The function may be related to the 
ligand bound to the protein: fatty acid, acyl-CoA, acylcarnitine 
or other hydrophobic ligands. 
The major role assigned to FABPs is facilitation of intra­
cellular transport or specific trafficking of fatty acids and 
acyl-derivatives, thereby providing a possibility of targeting 
of these compounds towards oxidation or esterification. Tipping 
and Ketterer [197] concluded on basis of theoretical considerat­
ions, that FABP could enhance the rate of intracellular trans­
port of its ligand by an order of magnitude. Cooper et al. [53] 
presented evidence that the metabolism of palmitic acid in liver 
is diffusion-limited, and that almost all fatty acids in the 
cytosol are bound to FABP. From the concomitant increase of Z-
protein (FABP) content and palmitic acid uptake by livers iso­
lated from Clofibrate treated rats, Renaud et al. [198] concluded 
that this protein is involved in fatty acid uptake. Experiments 
with inhibitors of fatty acid binding to FABP, as flavaspidic 
acid or a-bromopalmitic acid, with jejunal preparations, 
hepatocytes and perfused liver did not give equivocal results 
[184,199-201] . 
The ability of FABPs to release fatty acids from membranes 
was demonstrated by many investigators [вз.івв.гог-гмі. Liver FABP 
is, however, less effective than albumin in preventing fatty acid 
accumulation in membranes [нзі. Evidence for in vitro fatty acid 
transfer between membranes by FABP could be obtained for membrane 
systems separated by a polycarbonate filter ггог.гоз], and for two 
separated monolayers сгогі. FABPs are able to deliver long-chain 
fatty acids to the mitochondrial /?-oxidation system for oxidat­
ion [26,88,165,202], or to microsomes for acyl-CoA synthesis [вз.гозі. 
At a 1:1 ratio of fatty acid to protein, FABP-bound palmitate 
proved to be a better substrate for the mitochondria than albu­
min-bound fatty acid [26]. 
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Maximal rates of palmitoylcarnitine oxidation in rat heart 
mitochondria varied according to a FABP concentration-dependent 
function [193]. A model for a FABP-dependent flux of acylcarnitine 
between the cytoplasm and the inner mitochondrial membrane was 
postulated on basis of electronspin resonance studies of 16-
doxylstearoylcarnitine distribution and oxidation [193]. The 
occurrence of two specific self-aggregated FABP species as acyl­
carnitine translocators would contribute to the regulation of 
/3-oxidation and energy production in the heart [193]. 
Evidence for the physiologically important function of FABPs 
in modulation of metabolism has been derived from their influence 
on the in vitro activity of a number of enzymes. Rat liver FABP 
is able to preclude or reverse the inhibition by fatty acids or 
their acyl-CoA esters of mitochondrial ATP/ADP translocase tzosi, 
microsomal 4-methyl sterol oxidase [98,206] and acyl-CoA:cholesterol 
acyltransferase [206] and of cytosolic acetyl-CoA carboxylase [207], 
and both the mitochondrial [Ш] and microsomal acyl-CoA synthases 
(Η3,ΐ62,ΐ8β,ΐ99,20β]. When liposomes were used as fatty acid donor, 
instead of salt or detergent suspensions, liver FABP markedly 
decreased the activity of microsomal acyl-CoA synthase [209]. Wu-
Rideout et al. сгов] described an inhibitory effect of liver FABP 
on mitochondrial long-chain acyl-CoA synthase. Heart FABP does 
not stimulate microsomal acyl-CoA synthase activity naai. Hepatic 
and intestinal FABPs stimulate the activity of several microsomal 
enzymes involved in the synthesis of triacylglycerols and phos­
pholipids, such as acyl-CoA: glycerol-3 phosphate acyltransferase 
[179,184,210], diacylglycerol acyltransferase [211,2121 and phosphatidate 
phosphohydrolase [213]. Lung FABP stimulates 2-4-fold the activity 
of pulmonary microsomal glycerophosphate acyltransferase t2H]. 
Human liver FABP stimulates glucose-6-phosphate dehydrogenase 
[215]. The effects of FABPs on the activities of a number of 
enzymes may depend on the system in which the fatty acids or 
acyl-CoA esters are presented. They may either reflect a speci­
fic influence of these proteins on the release of fatty acids 
from membranes, or a site-directed transfer of fatty acids or 
acyl-CoA esters to the active site of the enzyme. An aspecific 
solubilizing effect may be involved in their influence on several 
enzymes, but the (partial) impossibility observed in some cases 
[184,199,211,214], to duplicate the observed effects with albumin re­
flects a more direct involvement of FABP. Furthermore, McCormack 
and Brecher showed that fatty acids must first desorb from lipo­
somal membranes, before FABP can have an effect on acyl-CoA for­
mation by acyl-CoA synthase [203]. FABPs apparently penetrate a 
phospholipid bilayer only to a minor extent [202]. Bordewick et 
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al. ti79] presented evidence for a direct interaction of (bovine) 
liver FABP with microsomal membranes in the stimulation of acyl-
transferases. 
The relative cytosolic abundance of FABPs [e.g. в7,нв,і50-і53,ібі,ібЗ-
165] suggests a role for these proteins in temporary intracellular 
storage of fatty acids. Binding of fatty acids and their CoA- and 
carnitine-esters by FABPs enables the maintenance of a low 
concentration of the unbound form of these substances within the 
cell over a large concentration range, which is important because 
of the damaging effects of high concentrations of these compounds 
on membranes сгіб], and the marked influence of acyl-CoA esters on 
many enzyme activities. 
A protective role may be of special importance during 
ischemia in heart, when high concentrations of free fatty acids 
arise [21Л. Recent observations on ischemia in perfused rat hearts 
showed, however, a marked release of FABP from the heart together 
with only minor amounts of fatty acids слв]. This seems to plead 
against a protective role of FABP in heart, but fatty acids may 
be stripped from FABP during membrane passage. 
The intracellular storage pool of FABP-bound fatty acids can 
readily deliver substrate for energy production or biosynthetic 
processes. Binding to FABP may regulate the intracellular concen­
trations of fatty acids and acyl-CoA and acyl-carnitine esters, 
and thus influence the overall rate of intracellular lipid meta­
bolism. Inversely, the amount of fatty acid stored intracellular-
ly by binding to FABP may be determined by the rates of fatty 
acid uptake and utilization. 
Some recent studies have indicated a role for FABPs or 
related proteins in (indirect) regulation of growth and differ­
entiation. The level of liver FABP is positively associated with 
the growth activity of rat hepatocytes [219]. Ligands of this 
protein may be involved in normal mitosis and carcinogen-induced 
cell proliferation of hepatocytes [219]. A polypeptide growth 
inhibitor purified from bovine mammary gland (MDGI), which shows 
extensive homology with rat heart FABP, inhibits proliferation 
of Ehrlich ascites and mammary carcinoma cells cm]. Cellular 
retinol- and retinole acid-binding proteins may mediate transport 
of these ligands to their nuclear receptor [220], and in this way 
influence their action on epithelial differentiation and tumori-
genesis (ггп. The adipocyte differentiation is accompanied by the 
transcriptional activation of the gene of the adipocyte lipid-
binding Р
г
 (p422) protein [222]. 
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2.11. INFLUENCE OF PHYSIOLOGICAL CONDITIONS AND DRUG TREATMENT 
ON FABPs. 
Most support for the physiological role(s) of FABPs has been 
gathered from studies of the relation of the FABP content or the 
fatty acid-binding activity of cytosolic proteins with physio­
logical conditions and drug treatments that involve changes in 
lipid metabolism (Appendix II) . The different tissues show a 
distinct response of the FABP concentration to physiological 
changes. The concentration of liver FABP can markedly change, 
whereas that of heart FABP is relatively stable. Although less 
information is available, intestinal FABP appears to be closer 
to the hepatic type in its response to variations. Both the FABP 
contents of heart and liver, but not of intestine, are higher in 
females [B7,i50,15ϊ,ΐ5β,i7i,223,224]. The sex influence in liver corresponds 
to the effects of steroid hormones іггъ:. 
Starvation ti53,ise,225-227], (hypolipidemic) drugs and peroxisome 
proliferators tiso, 153,ise,227-230] only have a marked effect on the FABP 
content of liver. Clofibrate also has an increasing effect on the 
fatty acid-binding capacity of kidney cytosol [159] and on the 
hepatic FABP type in rat intestine nso]. The capacity of the ß-
oxidation system in several rat tissues ггзп is strongly correla­
ted with the cytosolic fatty acid-binding capacity in control 
and clof ibrate-treated animals [232]. Brain forms an exception in 
this respect. Increase of the fat content or addition of fat to 
the diet clearly affects the FABP content of liver мбо.гзз.гз*] and 
heart [165]. A high carbohydrate diet also increases the liver 
FABP content [233]. In intestine, a high-fat diet produces a rela­
tively larger induction of the intestinal FABP type [223]. Chronic 
alcohol consumption by rats induced a dramatic increase of 
hepatic FABP content [235], but this was not always the case [236]. 
Choline-deficient diet increased the FABP concentration of rat 
liver threefold [23П. The diurnal rhythm had only a minor in­
fluence on the levels of liver and heart FABP uso,153,158,227,229]. 
During prenatal and postnatal development the FABP content 
of heart and liver increase [87,152,153,223,238-2401, as do the /3-oxida-
tive capacities of these tissues [23i]. Interestingly, the cyto­
solic fatty acid-binding capacity of both tissues is already at 
the adult level in newborn animals [158]. Based on bromosulfo-
phthalein binding, the liver FABP content is already at the adult 
level at the late fetal stage in guinea pigs [24i] and monkeys [242]. 
FABP-immunoreactive hepatocytes were found in the human liver as 
early as the seventh week of gestation ητο], and remained present 
in a frequency of approximately 80% throughout the gestational 
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period c243]. This percentage is lower in adult liver. In the human 
intestine, immunoreactive FABP was demonstrated at the 23rd week 
of gestation. Changes of the α-fetoprotein content could not ex­
plain the differences between fatty acid-binding capacity and 
FABP content [153]. The two FABPs in kidney show a distinctive 
developmental pattern [102]. Whereas the heart type is detectable 
at comparable levels in neonatal and adult kidney, the concen­
tration of the kidney FABP type markedly increases during post­
natal development 11021. 
The FABP concentration varies markedly among various types 
of skeletal muscle [123,152,153,1571. The FABP content is higher in 
slow-twitch than in fast-twitch muscles. Chronic electrosti­
mulation of rat tibialis anterior (a fast-twitch muscle), that 
had previously been shown to cause a rise in oxidative metabolism 
[2W], induced a rise of the FABP content to a level comparable to 
that of slow-twitch muscle and close to that of heart [245]. 
Myoglobin and mitochondrial enzyme activities showed much smaller 
increments [245]. 
2.12. STABILITY AND TURNOVER. 
Most investigations concerning stability and turnover rates 
of FABPs have been carried out with the hepatic and intestinal 
types. FABPs are very stable proteins, with a high resistance to 
enzymic digestion [вз,9о,ііо,і4б], and radiation пзі]. The binding of 
fatty acids to liver wi and heart FABP mo] appears to even 
increase this resistance. The liver FABP produced in E.coli had 
a comparable stability, but a mutant liver FABP, produced by 
site-directed mutagenesis of the FABP gene introduced in E.coli, 
had a clearance rate that was 10-fold higher than that of the 
wild-type FABP [125]. The mutant protein had a modified carboxy-
terminal sequence, resulting in an altered secondary structure 
with a decreased hydrophobicity and a markedly reduced binding 
of oleic acid. 
During isolation of bovine FABPs Spener and coworkers apply 
temperatures up to 50°С and a pH of 4.0, without significantly 
affecting the activity of the proteins [95,96]. Ion-exchange chro­
matography and delipidation at an early stage of purification, 
however, lead to loss of binding activity [96]. 
Bass et al. [227] determined the rates of degradation of FABP 
and total cytosolic protein after pulse-labelling with NaHuC03, 
and calculated half-lives of 3.1 and 2.9 days for FABP and total 
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protein. Apparently the degradation rate of liver FABP is compa­
rable to that of an average cytosolic protein. Based on the 
observed half-life, FABP concentrations change only relatively 
slowly, compared to the rate of fluctuations of fatty acid meta­
bolism. This is in agreement with the slight diurnal rhythm of 
the protein ciso, 153,158,227,2291. The isoforms of rat liver FABP have a 
similar degradation rate in vivo [22л, although their endogenous 
ligands differ C25,90]. 
The half-life of [35S]methionine-labelled FABP in cultured 
neonatal rat cardiomyocytes was 2.5 days [239]. The ability of 
hepatocytes to modulate the concentration of a protein which 
appeared to be identical to liver FABP [219] within the relatively 
short time period spanned by mitosis [246] is not compatible with 
a half-life of 2-3 days. The half-life of 2 h reported for the 
sterol-carrier protein and hepatic FABP [24Л markedly contrasts 
the findings reported by Bass et al. t227j. However, despite their 
substantial similarity, FABP and sterol-carrier protein are now 
considered to be different proteins [248,249]. 
The higher levels of liver FABP in female rats, as well as 
the increased content of this protein in liver of male animals 
at Clofibrate treatment are not related to differences in the 
turnover rate of the protein. They appear to be correlated with 
an increase of the specific FABP mRNA content of the liver nsoi. 
The liver and intestinal FABP types exhibit different regu­
latory responses in intestinal mucosa [150]. Although the mRNA 
concentration of the liver FABP type is approximately 50% higher 
in the intestine of female rats than of males, there is no sex-
related difference in the steady-state level of this protein, due 
to a 1.35-fold higher turnover rate in female jejunum nso]. No 
sex-related differences are observed for the intestinal FABP type 
or its mRNA. 
A differential regulatory response is also present in the 
effect of Clofibrate treatment on both types of FABP in the 
intestinal mucosa of male rats. Whereas the liver type is induced 
up to 2-fold by Clofibrate, the intestinal FABP type is only 25% 
higher. Clofibrate treatment doubled the concentration of liver 
FABP mRNA in the intestine, but had no effect on the intestinal 
FABP mRNA [150]. The influence of sex-difference and of Clofibrate 
indicate that the concentrations of both proteins are modulated 
via changes in their rates of synthesis [25,150]. 
Postnatal development of mRNA levels for the different FABP 
types appears to be quite different in various rat tissues. In 
small intestinal epithelium both mRNAs for liver and intestinal 
types of FABP are first detectable between the 19th and the 21st 
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day of gestation тл. They undergo a coordinated three to four­
fold increase during the first postnatal day. Thereafter the 
levels of intestinal FABP mRNA remain constant, while liver FABP 
mRNA increases further in intestine. Both mRNAs increase in this 
tissue during growth from 120 to 400 gram bodyweight. Liver FABP 
mRNA is expressed in a declining gradient from duodenum to colon. 
Furthermore, hepatic mRNA expression in the intestinal wall shows 
a second gradient, from the crypts to the villus tips CIMI . 
Liver FABP mRNA concentration increases about 2-fold in 
liver within the first 24 h after birth, but it does not change 
further until 35 days ибл. During growth from 120 to 400 g, the 
FABP mRNA concentration doubles again. Sheridan and Wilton found 
a linear increase of FABP specific mRNA in rat liver during post­
natal development [250]. The FABP mRNA concentration in human liver 
undergoes much smaller changes during the fetal and neonatal 
period [251]. Hepatic FABP mRNA expression decreases gradually from 
the periphery to the central veins of the liver lobes, and is 
restricted to hepatocytes ri68]. 
Distinct patterns of developmental change in heart FABP mRNA 
concentration are observed in heart, placenta, brain and testes 
of the rat иги . This specific mRNA sequence was already detect­
able in myocardium at day 19 of gestation. Its level rises 
rapidly during the first 48 h after birth, to reach the maximal, 
adult, value at approximately 14 days. Brain and testes also show 
a postnatal increase of cardiac FABP mRNA, but later than heart. 
Maximal values are reached at 24 and 70 days, respectively, in 
these tissues. Changes in the heart FABP mRNA concentration in 
kidney form a contrasting pattern to that observed in heart and 
brain [124]. The renal concentration of heart FABP mRNA is maximal 
during the fetal period, then falls rapidly during the first two 
days after birth, peaks again around day 8, and finally declines 
to a very low adult level. The significance of this aberrant 
developmental pattern is still unclear. Possibly, a quantitative 
switch between the two FABP types expressed in the kidney [іогі may 
relate to this phenomenon. In rat placenta the heart FABP mRNA 
concentration rapidly increases during the late gestational 
period [124]. 
2.13. FABP AND PATHOLOGY. 
Structural mutants or FABP deficiencies due to genetic 
aberrations, have not been observed in man or animals up to now. 
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Some pathological or experimental conditions show changes in the 
content or appearance of FABPs (Table 2.7). In diabetes a decline 
of liver FABP content was observed, together with the appearance 
of a FABP form with a molecular mass of 400 kDa [225]. The appear­
ance of a high-molecular form was also observed under diabetic 
conditions in human and rabbit placenta [252]. Hypertension, 
induced by DOCA-NaCl treatment or infusion of angiotensin-II 
resulted in the disappearance of the kidney FABP type from kidney 
cortex, whereas the heart FABP type remained unchanged in cortex 
and medulla [102]. The same models of experimental hypertension 
induced a marked decrease of the heart FABP type and its mRNA 
in rat aorta, but not in heart, skeletal muscle or kidney оъп. 
Surprisingly, spontaneously hypertensive rats showed an increase 
of FABP in the medulla, but not in the cortex [253]. 
FABP content and intracellular fatty acid metabolism may be 
closely related. In Morris hepatoma a nutritional regulation of 
fatty acid synthesis was absent, together with a decrease of the 
FABP content to 20% of that in liver [254]. The FABP level appears 
to be associated with normal mitosis and carcinogen-induced pro­
liferation of hepatocytes [219]. This suggests that liver FABP may 
not only carry ligands that promote hepatocyte division, but also 
Table 2.7. 
FABP and pathology. 
Reported changes Refs. 
Diabetes 
rat liver 
rabbit placenta 
hunan placenta 
Hypertension 
spontaneous 
rat kidney 
induced by DOCA-NaCl 
or angiotensin 11 
rat kidney 
rat aorta 
Morns hepatoma 
rat 
Hepatitis, cirrhosis, 
Gilbert's syndrome, 
Dubin-Johnson syndrome 
hunan liver 
serin 
Obesity (Zucker rat) 
rat liver 
1 schemia/Ca-paradox 
perfused rat heart release of FABP 
decreased FABP content, appearance of high-molecular form 
appearance of different form 
appearance of different form 
increased FABP content In medulla, not f η cortex 
disappearance kidney FABP from cortex, no effect on heart FABP type 
marked reduction of heart FABP type 
low FABP content 
decreased FABP content 
elevated FABP levels 
increased FABP content 
225 
252 
252 
253 
102 
166 
254 
159 
262 
218,255 
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certain chemically activated carcinogens in their passage from 
cytoplasm to chromatin [219]. The covalent binding of metabolites 
of carcinogens to this protein was already detected before its 
fatty acid-binding capacity was known [76]. Liver FABP content is 
markedly decreased in patients with various liver diseases, 
whereas their serum FABP concentration is higher than in normal 
subjects [159]. A release of heart FABP in the perfusate was found 
in experimental ischemia and Ca-paradox in perfused rat hearts 
[217,255] . 
2.14. CHROMOSOMAL LOCALIZATION OF FABP GENES. 
Localization of the genes encoding for FABPs, and other 
hydrophobic ligand-binding proteins, may provide new insights 
into their physiological roles and regulation. Useful information 
may be derived from the comparison of inbred strains with known 
mutations or deletions, in situ hybridization to metaphase chro­
mosomes and somatic cell hybrid clones. Table 2.8 summarizes the 
available data concerning chromosomal localization of the genes 
encoding heart, liver and intestinal FABP, cellular retinol-
binding proteins, adipocyte P2 (p422) protein, and albumin in man 
and mouse. No data are available for rat. The mouse genes for 
liver, intestinal [107] and heart [124] FABPs are located on diffe­
rent chromosomes, as are the human intestinal and liver FABP 
genes [io7,256]. Human heart FABP-encoding DNA sequences have not 
yet been assigned to a specific chromosome, but interestingly a 
cDNA probe to its mouse counterpart hybridized with sequences on 
at least three chromosomes [124]. These may represent pseudogenes, 
Table 2.8 
Chromosomal localization of genes encoding FABP and other proteins 
with high affinity for hydrophobic ligands. 
Protein 
Liver FABP 
Intestinal FABP 
Heart FABP 
Albumin 
CRBP 
CRBP-II (intestine) 
Adipocyte Р
г
 <p«2) 
Chromosome 
Man 
2 (p12 - q12) 
4 (q2e - q31) 
4 (qll - q22) 
(req on) 
Mouse 
4, 8 and 10 or 15 
or actively transcribed genes that encode other, closely related, 
proteins that are not yet identified [124]. These proteins may be 
other FABP types, closely related to heart FABP, such as the FABP 
from skeletal muscle that is also detected by antibodies to heart 
FABP [123,152,153]. 
Although a number of hydrophobic ligand-binding proteins are 
closely related, and probably originate from a common ancestor 
gene поя, the genes encoding for these proteins are located 
dispersed throughout the genome in both mouse and man. Only the 
CRBP and CRBP-II genes are closely linked on the same chromosome. 
The genes for human intestinal FABP [256] and albumin [257] are both 
located on the long arm of chromosome 4. In the mouse albumin is 
encoded by a gene on chromosome 5, that is closely linked to the 
gene for alpha-fetoprotein, a protein that is also involved in 
fatty acid transport [258]. 
2.15. CONCLUSIONS. 
The existence of various types of FABPs, and the relative 
abundance of these proteins in many tissues are indications of 
an important function for these proteins in cellular metabolism. 
The distinct tissue distribution and ligand specificities, and 
the differential response of the various FABP types to metabolic 
changes induced by various conditions show an adaptation of each 
type of this protein to a specific environment. These properties 
of the FABPs may relate to tissue-specific differences in target­
ing of hydrophobic ligands (fatty acid, acyl-CoA, acylcarnitine, 
or other) to specific subcellular systems, interaction with and 
protection of cellular membranes or enzyme systems, or modulation 
of lipid metabolism. Furthermore, FABPs may be indirectly invol­
ved in regulation of growth, differentiation and transmembrane 
signalling. 
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Chapter 3. 
MATERIALS AND GENERAL PROCEDURES. 
3.1. MATERIALS. 
The list below sums up all specific reagents and materials 
that were used in this study, including the suppliers. 
[l-^Cjarachidonic acid, [l-uC]myristic acid, [l-uC]oleic acid, 
[l-uC]palmitic acid, [l-uC]palmitoyl-coenzyme A, and [1-UC] 
stearic acid: Amersham International pic, Amersham, UK. 
[l-14C]Palmitoyl-carnitine: New England Nuclear Research Products 
Dreieichenhain, FRG. 
(specific activities of the radioactive compounds were 2.15-2.22 
GBq/mmol, approximately 120-135 dpm/pmol). 
Lipidex 1000: Canberra Packard, Downers Grove, IL, USA. 
Protein A-Sepharose CL-4B, Sepharose CL-4B, Sephacryl S-200, 
Pharmalyte ampholines: Pharmacia Biotechnology International, 
Uppsala, Sweden. 
DEAE-cellulose (DE-32): Whatman International Ltd., Maidstone, 
Kent, UK. 
IgG fractions of sheep-anti rat serum albumin, goat-anti rat 
serum albumin, and rabbit-anti swine serum albumin : Cappel 
Laboratories, West Chester, PA, USA. 
Horseradish peroxidase-conjugated sheep-anti rabbit IgG, peroxi­
dase conjugated swine-anti rabbit IgG, rabbit-anti human serum 
albumin (IgG fraction): Dakopatts a/s, Glostrup, Denmark. 
Horseradish peroxidase conjugated goat-anti rabbit IgG: Nordic 
Immunology, Tilburg, The Netherlands. 
Nitrocellulose sheets (BA-85, pore size 0.45 μιη): Schleicher and 
Schuell, Dassel, FRG. 
Flat-bottom polystyrene Microtiter ELISA plates: Greiner, 
Nürtingen, FRG. 
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0-phenylene-diamine, Tween-20, bovine serum albumin: Sigma 
Chemical Co., St.Louis, MO, USA. 
4-chloro-l-naphthol: Aldrich Chemie Benelux NV, Brussels, 
Belgium. 
Triton X-100: Serva, Heidelberg, FRG. 
Tresyl-chloride (2,2,2-trifluoroethanesulfonyl chloride): Fluka 
AG, Buchs, Switzerland. 
Алшіопух-LO: Millmaster Onyx International, Fairfield, NJ, USA. 
Clofibrate (Atromid S): ICI, Rotterdam, The Netherlands. 
Cholesterol, bilirubin, fatty acids: Merck, Darmstadt, FRG. 
All-trans retinol and retinoic acid: Eastman Kodak Co., Roches­
ter, NY, USA. 
Prostaglandins E,, A,, F,,, and 15-Methyl-prostaglandin F2e: The 
Upjohn Company, Don Mills, Ontario, Canada. 
Egg phosphatidylcholine: Lipid Products, South Nuffield, Surrey, 
UK. 
Unless otherwise stated, all other chemicals were of the highest 
available purity grade, purchased from Merck, Darmstadt, FRG, 
Boehringer, Mannheim, FRG or Sigma Chemical Co., St.Louis, MO, 
USA. 
3.2. ORIGIN OF TISSUES. 
Rat tissues. 
Rat tissues (heart, liver, skeletal muscles, intestine, 
kidney, adrenals, brain) were obtained from random-bred male 
albino Wistar rats, weighing 200 ± 20 g, unless otherwise stated. 
Water and food (a pelleted diet containing 22% protein, 4.8% fat 
and 67% carbohydrates, RMH-TM, from Hope Farms BV, Woerden, The 
Netherlands) were provided at libitum. The animals were main­
tained on a cycle of alternating 12 hour light and darkness 
periods. Animals were killed by cervical dislocation around the 
midpoint of the light period. 
Pig tissues. 
Most tissues (heart, liver, muscle, kidney) were collected 
at the slaughterhouse, placenta immediately after delivery at 
the farm. They were used immediately, or in some cases stored 
at -70°C until use. 
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Human tissues. 
Human tissue samples (heart, liver, muscle, kidney, intes­
tine, brain, and retina) were obtained either from biopsies taken 
from patients undergoing surgery, or from autopsies within 20 h 
after death. Placenta was obtained shortly after delivery. The 
materials were used immediately, or stored at -70°c until use. 
3.3. PREPARATION OF HOMOGENATES AND CYTOSOLS, 
AND SUBCELLULAR FRACTIONATION. 
Rat hearts and livers were perfused in situ with cold homo-
genization buffer (10 mM K-phosphate/ 154 mM KCl, pH 7.4), and 
excised. After removal of fat, all tissues were immediately cool­
ed in ice-cold homogenization buffer, and rinsed with the same 
buffer. The materials were then minced and whole homogenates, 40% 
(v/v) for liver, 25% for heart, kidney and brain and 10% for all 
other tissues, were prepared in ice-cold homogenization buffer, 
either by hand-homogenisation in a Potter-Elvehjem homogenizer, 
or, for large samples, in a Waring Blendor followed by a Polytron 
homogenizer. The homogenates were centrifuged 10 min at 600 χ g. 
The resulting supernatant was then centrifuged for 90 min at 
105,000 χ g to yield a cytosolic protein preparation. Floating 
fat was aspirated and finally the clear supernatants were stored 
at -20oC. 
Subcellular fractionation. 
Livers and hearts from male albino Wistar rats (200 ± 20 g) 
were cooled to 00C in SET buffer (250 mM sucrose/ 2 mM EDTA/ 10 
mM Tris-HCl, pH 7.4) immediately after excision. All subsequent 
steps were performed at 0°C. To isolate mitochondria, tissues 
were homogenized in 20 vol. SET buffer and centrifuged at 600 χ 
g for 10 min. Pellets were resuspended in 0.5 vol. SET buffer and 
spun down again (10 min, 600 χ g). The 600 χ g supernatants were 
combined and centrifuged for 10 min at 10,000 χ g. The 10,000 χ 
g supernatant was used for preparation of microsomal and cyto­
solic fractions (90 min 105,000 χ g pellet and supernatant). The 
mitochondrial fraction (10,000 χ g pellet) was resuspended in 0.5 
vol. SET buffer and divided into 3 parts. One portion was kept 
as intact mitochondria, one part was extracted with 0.05% Na-
deoxycholate (pH 7.0) and subsequently centrifuged for 10 min 
at 20,000 χ g. The third part was extracted with a solution of 
125 mM KCl/ 1 mM EDTA/ 10 mM K-phosphate (pH 6.0) and centrifuged 
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for 10 min at 20,000 χ g. The obtained pellet was then extracted 
with Na-deoxycholate as described above. The obtained fractions 
and mitochondrial extracts were used for immunological quanti­
tation of FABPs. 
3.4. BIOCHEMICAL METHODS. 
Dealbuminization of cytosolic proteins. 
Prior to determination of the fatty acid-binding capacity, 
residual albumin was removed from cytosolic protein samples by 
affinity chromatography. Sepharose CL-4B was activated with 
tresyl-chloride according to the method of Nilsson and Mosbach 
t263]. The IgG fraction of antiserum to albumin of man, rat or pig 
was coupled to the activated gel at pH 7.5, essentially as des­
cribed for trypsin [263]. Coupling yield was approximately 14-15 
mg IgG/ml Sepharose. Columns of 10 ml Sepharose-anti-albumin 
were routinely used to remove residual albumin from cytosolic 
protein preparations of all tissues (2-4 mg protein). The 
dealbuminized protein samples were concentrated by ultrafiltra­
tion, using a Diaflo YM-2 membrane. 
Dealbuminization was verified by quantitation of the albumin 
content prior to and after the procedure by an enzyme-linked 
immunosorbent assay (ELISA), that was performed essentially as 
described by Hudson and Hay [264]. 
Preparation of Lipidex 1000. 
The methanol in which Lipidex 1000 is supplied was removed 
by extensive washing with water on a Buchnel funnel, followed by 
10 vol. 10 mM Tris-HCl (pH 8.0). The material was stored in a 1:1 
suspension in the same buffer in glass vials at 4°C. 
Delipidation. 
Endogenous fatty acids were removed from protein samples by 
delipidation on a Lipidex 1000 column (0.8 χ 6 cm) at 37"C, as 
described by Glatz et al. [164], to obtain accurate values of fatty 
acid-binding activity. 
Preparation of fatty acid-buffer solutions. 
Aqueous solutions of fatty acids were obtained by mixing 
40 nmol fatty acid from an ethanolic stock solution (450 μΜ) 
with 6.4 ml 10 mM Tris-HCl (pH 8.5). The aqueous solutions were 
used immediately afterwards. 
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Fatty acid-binding assay. 
Protein samples were delipidated with Lipidex 1000 at 37°C, 
and cytosolic protein samples were first dealbuminized on an 
anti-albumin-Sepharose 4B column, as described above. [1- UC]-
labelled fatty acid (0.1-3.0 μΜ; 130 dpm/pmol), delipidated 
protein and buffer (10 mM Tris-HCl, pH 8.0) were mixed in 1.5 ml 
polyethylene vials in a final volume of 0.4 ml. After incubation 
for 10 min at 37°С the mixtures were cooled on ice and 0.1 ml 
ice-cold Lipidex 1000 suspension in 10 mM Tris-HCl (pH Θ.0) (1:1, 
v/v) was added to separate protein-bound and free fatty acids 
им]. The amount of protein-bound fatty acid was calculated from 
the radioactivity in supernatant samples, obtained after a 30 min 
incubation at O'C. Fatty acid-binding parameters were obtained 
from Scatchard plot analysis of the binding data [265]. 
3.5. IMMUNOCHEMICAL TECHNIQUES. 
Preparation of antisera. 
New Zealand White rabbits were injected intracutaneously on 
the back at multiple sites with an emulsion of 1 ml 10 mM Tris-
HCl (pH 8.0) containing 100 дд FABP and 1 ml Freunds complete 
adjuvant. At 3-week intervals rabbits were boostered with the 
same amount of antigen, mixed with Freunds incomplete adjuvant. 
Blood samples for antibody titer determinations were collected 
every 3 weeks. Final exsanguination was performed by cardiac 
punction. Sera were isolated and stored at -20°C. IgG-fractions 
of the antisera were prepared with protein-Α Sepharose as des­
cribed by Goudswaard et al. [266]. 
Determination of antibody titers. 
Aliquots of 50 μΐ pure FABPs in 50 mM sodium-carbonate (pH 
9.6) were coated onto the wells of a microtiter plate overnight 
at 20°C. The wells were washed 5 times with PBS-Tween (5.4 mM Na-
phosphate/ 1.3 mM K-phosphate/ 150 mM NaCl (pH 7.4), 0.05% Tween-
20) and once with distilled water. Successive 2-fold dilutions 
of the antiserum (100 μΐ in PBS-Tween) were added and the plates 
were incubated for 1 h at 20°C. The wells were washed as des­
cribed above and 100 μΐ of lOOOx diluted peroxidase conjugated 
swine-anti rabbit IgG in PBS-Tween was added. After 1 h incubat­
ion (at 20°C) the wells were ./ashed again. The bound peroxidase 
was assessed with 100 μΐ of a freshly prepared solution of 2.2 
mM o-phenylene diamine/ 0.012% H202 in 100 mM citrate/ 200 mM K-
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phosphate (pH 5.0). After incubation in the dark for 30 min at 
20*С the reaction was stopped by addition of 50 μΐ 12.5% H2S04. 
The product of the peroxidase reaction was determined at 492 nm 
with a Titertek Multiscan. 
Antibody titers were defined as the reciprocal values of the 
serum dilution required to obtain 50% maximal reaction, deter­
mined from a semi-log plot of absorbance versus serum dilution. 
Maximum was obtained from wells incubated with 10-25x diluted 
antiserum, minimum from wells without serum. 
ELISA for the quantitative measurement of FABPs. 
Standard curves (in triplicate) of 0-7 ng FABP and aliquots 
containing 1.25 or 0.625 ¡ig cytosolic protein/ml in 50 mM sodium-
carbonate (pH 9.6) were coated on 96-well ELISA plates, overnight 
at гО'С (80 μΐ/ well) . Samples were coated 8-fold in both concen­
trations. IgG-fractions of the antisera were appropriately 
diluted in PBS-Tween to produce linear standard curves. The rest 
of the procedure was carried out as described above for titer 
determinations. The amount of immune-reactive protein in the 
samples was determined from standard curves, calculated by linear 
regression analysis. 
3.6. ELECTROPHORESIS, ISOELECTRIC FOCUSING, AND WESTERN BLOTTING. 
Polyacrylamide slabgel electrophoresis. 
Polyacrylamide slab gel electrophoresis at pH 8.8 (4-20% 
acrylamide gradient in 0.1% SDS) was performed according to the 
method of Laemmli аьп, using a GE-2/4 Gel LS Electrophoresis 
Apparatus (Pharmacia Biotechnology International, Uppsala, 
Sweden). Slots were loaded with 1-50 ßg of protein. Gels were 
fixed with methanol/ acetic acid/ water (5:1:4; by vol.) and 
silver-stained according to the method of Morrisey [268]. 
Ultrathin-layer isoelectric focusing. 
Native ultrathin-layer isoelectric focusing was performed 
on 5% Polyacrylamide gels (100 χ 200 mm, 0.3 mm thick). Gels, 
containing 2% Pharmalyte ampholines (pH 3-10 or 4-6.5), were 
prepared on silanized glass plates. Phosphoric acid (1 M) was 
used as anode solution and 1 M NaOH as cathode solution. Protein 
samples (1-10 μg) were subjected to focusing at 2500 V in a 
Desaga Mediphor Electrophoresis Apparatus. Gels were fixed 
overnight in trichloroacetic acid/ water (12:88; by vol.), con-
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taining 5% sulphosalicylic acid, and then washed twice for 20 min 
with ethanol/ acetic acid/ water (20:8:72; by vol.) and stained 
with 1.25% Coomassie brilliant blue R-250 in the same solution 
for 1 h at 70°C. Gels were destained with ethanol/ acetic acid/ 
water (20:8:72; by vol.) for 1 h at 70°C and subsequently at 
room temperature until the background was clear. A calibration 
protein mixture (Pharmacia) was included for determination of pi 
values. 
Western blotting. 
Buffers for immunoblotting: 
Transfer buffer: 25 mM Tris/ 192 mM glycine (pH 8.8)/ 
20% (v/v) methanol. 
Blocking solution: 10 mM Tris-HCl/ 350 mM NaCl (pH 7.6)/ 
3% (w/v) bovine serum albumin. 
Incubation buffer: 10 mM Tris-HCl/ 150 mM NaCl (pH 7.6)/ 
0.3% bovine serum albumin (w/v)/ 1% Triton 
X-100 (v/v)/ 0.5% Na-deoxycholate (w/v)/ 
0.1% sodium dodecyl sulfate (w/v). 
PBS (phosphate buffered saline): 
5.4 mM Na-phosphate/ 1.3 mM K-phosphate/ 
150 mM NaCl (pH 7.4). 
PBS-Triton: 5.4 mM Na-phosphate/ 1.3 mM K-phosphate/ 
150 mM NaCl (pH 7.4) , 0.5% Triton X-100 (v/v) 
Substrate solution: 4-chloro-l-naphthol (0.5 mg/ml)/ 0.012% H202 
Blotting of proteins from SDS-polyacrylamide slabgels to 
nitrocellulose paper and immunodetection of antigens was carried 
out essentially as described by Towbin et al. [269]. Proteins were 
transferred electrophoretically to nitrocellulose in transfer 
buffer, using a 12 V car-battery charger as power supply. 
Blotting was performed overnight at approximately 80 mA at 20°C. 
Immediately after blotting the nitrocellulose sheets were dried. 
For immunostaining the blots were first saturated by incubation 
for 1 h in blocking solution. Blots were then incubated for 2 h 
with antiserum diluted in incubation buffer. After washing twice 
with incubation buffer and once with PBS-Triton the nitrocellu-
lose filters were incubated with peroxidase-conjugated goat-anti 
rabbit IgG [250x diluted in PBS-Triton, containing 0.5% (w/v) 
bovine serum albumin] for 1 h. The blots were subsequently washed 
twice with incubation buffer and once with PBS. Antigens were 
detected by incubation of the bound peroxidase with substrate 
solution. 
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3.7. MISCELLANEOUS PROCEDURES. 
Radioactivity measurements. 
Radioactive samples were counted in a Tricarb 4000 series 
liquid scintillation counter (Packard Instruments), using Aqua-
luma plus liquid scintillation cocktail (Lumac/3M, Schaesberg, 
The Netherlands). 
Protein determinations. 
For protein quantification the method of Lowry et al. t270] 
was used, if necessary after precipitation of the protein with 
trichloroacetic acid ігтм. Bovine serum albumin was used as stan­
dard. In case of pure FABPs, protein concentration was calculated 
from quantitative amino acid analysis, since the Lowry procedure 
gave an overestimation, dependent on the type of FABP. 
Statistical comparison of data. 
Statistical significance of differences were calculated by 
Student's unpaired t-test. Values are given as mean ± SD. 
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Chapter 4. 
PURIFICATION, CHARACTERIZATION AND BINDING 
PROPERTIES OF FABPs FROM HUMAN, PIG AND RAT HEART.* 
4.1. INTRODUCTION. 
The first evidence for the presence of FABP in rat heart was 
based on coelution of protein samples with radiolabelled fatty 
acids on a gel filtration column [κ,πι. The protein was first 
isolated from rat and pig heart by Fournier and co-workers taaj«]. 
Rat heart FABP later has been isolated and characterized by 
several authors [85,86,154]. Unterberg et al. im recently published 
a paper on human heart FABP. These isolations were all based on 
the coelution method, except the purification of rat heart and 
liver FABP by Glatz et al. tesi, where a radiochemical binding 
assay was used to monitor the purification. This assay applies 
Lipidex 1000 at 0°C to separate free and protein-bound fatty 
acids after equilibration at 37°C ci«]. Affinity of the gel fil­
tration matrix and of other proteins present in the sample (e.g. 
albumin) for fatty acids may lead to competition for the 
available ligand in the coelution procedure. This problem is 
prevented when the binding assay is used to locate fatty acid-
binding activity in samples after each purification step. 
In rat heart, FABP may comprise up to 4 nmol/mg of cytosolic 
protein [151,158,164]. Fournier et al. юві and Glatz et al. [26] demon­
strated the ability of heart FABP to deliver fatty acids to the 
mitochondrial ß-oxidation system, supporting the view that FABP 
plays an important role in intracellular translocation of fatty 
acids. In heart, FABP may also act as an intracellular storage 
pool of fatty acids and protect the cell against the detrimental 
effects of long-chain fatty acids and acyl-CoA esters, as occur 
during ischemia and hypoxia. The precise function of FABP in 
* 
This chapter Has adapted from Pau lussen et a l . , 1988 [84 ] . 
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lipid metabolism however, remains to be established. A systematic 
investigation of the protein-ligand interaction and of the 
preferential ligand population may provide clues in this respect 
for the various types of FABP. 
Quantitative binding data of fatty acids to heart FABPs are 
only available for rat heart FABP, with oleic and palmitic acid 
and their CoA esters [85,86]. With bovine and human heart FABP, 
only some qualitative results were given for the binding of fatty 
acids [96,97,177], and some data with respect to fluorescent fatty 
acids [177,272]. The binding of other ligands, except for lyso-
phosphatidylcholine to heart FABP [196], has never been studied to 
our knowledge. 
The homology of heart FABPs can be studied by immunochemical 
analyses. An antiserum against bovine heart FABP showed cross-
reactivity with human heart FABP, and with cytosols of pig and 
rat heart [97]. Preparation of FABPs from various tissues and from 
various species, and more antisera may provide more insight in 
this respect. 
In this chapter the purification and physico-chemical 
characterization of FABPs from heart of man, pig and rat are 
described. Their affinity for fatty acids, CoA-esters and other 
hydrophobic ligands was studied. With purified FABPs specific 
antisera were raised, which were used to determine immunological 
cross-reactivity. The effect of the IgG fraction of anti-human 
heart FABP serum on fatty acid binding was investigated. 
4.2. METHODS. 
Purification of fatty acid-binding protein. 
All purification steps were performed at 4°C. An amount of 
500-600 mg cytosolic protein was concentrated to 8 ml by ultra­
filtration on a Diaflo YM-2 membrane (Amicon Corp., Lexington, 
USA). After precipitation of denaturated protein by centrifugat-
ion at 10,000 χ g for 10 min, the material was applied to a 
Sephacryl S-200 gel filtration column (2.6 χ 110 cm) equilibrated 
in 30 mM Tris-HCl (pH 8.0). During the chromatography procedures 
protein was located by measurement of the absorbance at 280 nm, 
and 5 ml fractions were collected at a 40 ml/h flow rate. Samples 
of the fractions were assayed for fatty acid-binding activity. 
The activity-containing fractions in the 10-20 kDa range were 
combined and dialysed overnight against 5 mM Tris-HCl (pH 8.4). 
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The dialysed protein solution was then loaded onto a DE-32 
cellulose anion-exchange column (2.5 χ 8 cm) equilibrated in the 
same buffer. Bound protein was eluted stepwise (flow 36 ml/h) 
with 15, 30 and 50 mM Tris-HCl (pH 8.0), followed by a gradient 
of 0-300 mM KCl in the latter buffer, and fractions of 9 ml were 
obtained. Finally, the columns were washed free of remaining 
proteins with 1 M KCl. 
Fatty acid-binding activity measurements. 
Determination of fatty acid-binding activity was performed 
as described in section 3.4. Column fractions were routinely 
tested at a concentration of 1 μΜ fatty acid. Specific binding 
activities at the subsequent stages of the purification procedure 
were measured with a range of 0.1-10 μΜ fatty acid, after delipi-
dation (and dealbuminization in case of cytosolic proteins). 
Competition assays in the presence of heme, retinol or 
retinole acid contained 0.06% Ammonyx-LO. This detergent was also 
included in the control incubations of these experiments. Concen­
trations of [UC]oleic acid and of competitive ligands used in 
these experiments are given in Tables 4.4 and 4.5. 
Binding of fatty acids from liposomes. 
Binding of fatty acids using liposomes as donors was deter­
mined as described by Brecher et al. ігты. Different amounts of 
multilamellar liposomes, containing egg phosphatidylcholine, 
cholesterol and [uC]oleic acid (20:7:1) were incubated in 10 mM 
Tris-HCl/100 mM NaCl (pH 7.4) for 60 min at 25°C with FABP or 
bovine serum albumin in a total volume of 150 μΐ. Liposomes were 
precipitated by centrifugation (3 min, 15,000 χ g) and the amount 
of protein-bound fatty acids was determined from the radio­
activity in the supernatant (specific activity of the [14C]oleic 
acid was 3300 dpm/nmol). Using [14C]oleic acid and [3H]cholesterol 
double-labelled liposomes, precipitation was shown to be almost 
complete (over 96%). 
Electrophoretic techniques. 
Slabgel electrophoresis. 
Polyacrylamide slabgel electrophoresis was performed at pH 
8.8 on a 4-2 0% acrylamide gradient in 0.1% SDS. Gels were fixed 
with methanol/acetic acid/water (5:1:4; by vol.) and silver-
stained according to the method of Morrisey [268]. 
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Isoelectric focusing. 
Native ultrathin-layer isoelectric focusing was performed 
on 5% Polyacrylamide gels (0.3 mm thick), containing 2% Pharma-
lyte ampholines (pH 3-10 or 4-6.5). Phosphoric acid (1 M) was 
used as anode solution and 1 M NaOH as cathode solution. After 
focusing of the protein samples (1-10 μg) at 2500 V, the gels 
were fixed overnight and stained with Coomassie brilliant blue 
R250. pi values were determined from a calibration protein mixture 
(Pharmacia) that was included. For more details see section 3.6. 
Amino acid analysis. 
Samples of FABPs were hydrolysed with 6 M HCl (containing 
0.05 % phenol) for 24 h at 105°C and analyzed on a Rank Hilger 
Chromaspek analyzer in Na-citrate buffer, using norleucine as 
internal standard. Tryptophan and tyrosine were determined 
spectrophotometrically as described by Edelhoch [274]. 
Immunochemical procedures. 
Preparation of antisera. 
New Zealand white rabbits were injected subcutaneously at 
multiple sites on the back with 100 μg FABP in 1 ml buffer D, 
mixed with 1 ml complete Freund's adjuvant. The rabbits were 
given subcutaneous booster injections (100 jug in 1 ml, mixed with 
1 ml incomplete Freund's adjuvant) at 3 week-intervals until 
sufficiently high titers were obtained. Titers were determined 
in an enzyme-linked immunosorbent assay (ELISA), that was per­
formed essentially as described by Hudson and Hay [2W]. A detailed 
description of the procedure is given in section 3.5. The IgG 
fraction of the antiserum was isolated with Protein A-Sepharose 
CL-4B, as described by Goudswaard et al. ігш. 
Inhibition of fatty acid binding by anti-FABP IgG. 
Inhibition of fatty acid binding to human heart FABP was 
studied as described for non-specific lipid transfer protein 
C150], with some modifications. Delipidated FABP (1.5 дд) was 
incubated in 300 μΐ 10 mM Tris-HCl (pH 8.0) in the presence of 
2.5 mg lysozyme and different IgG concentrations (from either 
pre-immune or anti-human heart FABP serum) for 30 min at 370C. 
Lysozyme was used as inert protein instead of albumin [1821, 
because of the fatty acid-binding properties of the latter. After 
1 h at 0oC, [uC]oleic acid binding was determined as described 
in section 3.4. 
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4.3. RESULTS. 
Purification of heart FABPs. 
FABP was purified from the cytosol of heart of man, pig and 
rat by gel filtration and subsequent anion-exchange chromato­
graphy. Fig. 4.1 shows the binding of [l-uC]oleic acid to 
proteins of 105,000 χ g supernatant of human heart muscle after 
gel filtration on Sephacryl S-200. The first peak showing fatty 
acid-binding activity corresponds to a molecular mass of more 
then 60 kDa and contains serum albumin. The second fatty acid 
binding peak, with a molecular mass of 10-20 kDa, represents 
FABP. Only this protein peak is reactive with a specific anti­
serum to human heart FABP. Gel filtration of pig and rat heart 
105,000 x g supernatant on Sephacryl S-200 gave comparable 
results. Application of the same method as described for rat 
heart FABP [85], using DEAE-Sephacel anion-exchange chromatography 
and a second gel filtration step on Sephadex G-50 yielded FABP 
preparations that always contained myoglobin and some other minor 
proteins. Variation of the pH of the buffer did not lead to 
better results. Pure FABPs were obtained with anion-exchange 
chromatography on DEAE-cellulose, starting at pH 8.4 with a low 
ionic strength buffer and eluting at pH 8.0 by an increase of the 
ionic strength (Fig. 4.2). The fractions of the Sephacryl S-200 
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Fig. 4.1. Gel filtration of В ml concentrated hunan heart 105,000 χ g supernatant, 
containing 582 mg protein, on Sephacryl S-200 (2.6 χ 100 cm). The соішгі uas eluted with 
30 πΜ Tris-HCl (pit 8.0) at 4 *C. The flow rate Has 40 nl/h and 5 ml fractions were 
collected. Fractions uere assayed for protein ( — ) , ( Cloleic acid binding (100 μΐ 
sanples) (0—0) and iimunologtcal reactivity with ant i-hunan heart FABP senjn (1 (ig 
protein) (»—·). 
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column containing FABP were dialysed against 5 mM Tris-HCl (pH 
8.4) and applied to the DEAE-cellulose anion-exchange column. 
Adsorbed proteins were eluted stepwise with increasing Tris 
concentration at pH 8.0. Myoglobin was present in the fraction 
eluted with 15 mM Tris-HCl (pH 8.0), due to its higher pi. Human 
heart FABP eluted as a single peak with 30 mM. The same procedure 
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Flg. 4.2. Amon-exchange chrenatography of the caifcined FABP-containing fractions of 
the Sephacryl 5-200 column on DEAE-cellulose (DE-32). The FABP-contaimng fractions mre 
dialysed overnight against S nM Tns-HCl (pH 8.4) and loaded onto a DE-32 соlum (2.S 
χ 8 en) equilibrated in the same buffer. Fractions of 9 ml were collected at a 36 nl/h 
flow rate. Panel a: hunan heart; panel b: pig heart and panel c: rat heart. Bound 
protein waa eluted stepwise with 15, 30 and SO nM Tris-HCl (pH 8.0) ( ). Pig heart 
FABP was eluted with a linear KCl gradient ( ) in 50 nH Tris-HCl (pHB.O). Protein 
was monitored at 280 nm ( ) and 300 μι sanplee were assayed for I Cloleic acid 
binding (0—0). 
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Table 4.1. 
Purification of FABP from heart. 
Man 
Pig 
Rat 
Purification step 
105,000 χ g SLpernatant 
Sephacryl S-200 
DEAE-cellulose 
105,000 χ g supernatant 
Sephacryl S-200 
DEAE-cellulose 
105,000 χ g supernatant 
Sephacryl S-200 
DEAE-cellulose 
Protein 
(mg)' 
582 
44.8 
I.1d 
460 
54.6. 
4.6d 
536 
64.4 
3.4" 
Specific binding 
activlt/" 
(nmol/ng) 
1.7e 
5.0 
30.7 
1.1e 
3.7 
12.1 
1.8e 
3.7 
27.3 
Yield 
(Χ) 
100 
22.6 
9.6 
100 
39.9 
11.0 
100 
24.7 
9.6 
Purification 
(-fold) 
1.0 
2.9 
18.1 
1.0 
3.4 
11.0 
1.0 
2.1 
15.2 
' Determined by the method of Lowry et al. [270]. 
Measured with 1 μΜ [1- Cloleic acid at 37'C, with delfpidated protein sanples. 
e
 Determined after dealtxjninization. 
Determined from quantitative amino acid analysis. 
was applied for the purification of FABPs from pig and rat heart. 
Rat heart FABP eluted with 50 mM Tris and pig heart FABP was 
released from the column at nearly 200 mM KCl in the latter 
buffer. Representative results of the purification procedures are 
summarized in Table 4.1. The yield of the FABPs was about 10%. 
characterization of heart FABPs. 
Protein samples from different stages of the purification 
procedures were subjected to Polyacrylamide gel electrophoresis 
in SDS. The purified FABPs obtained after DEAE-cellulose anion-
exchange chromatography contain single protein bands with an 
estimated molecular mass of 15,000 Da for rat and pig heart FABP 
and 15,500 Da for human heart FABP (Fig. 4.3). 
Isoelectric focusing of these proteins on ultrathin-layer 
Polyacrylamide gels revealed one band with an isoelectric point 
of 5.2, 4.9 and 5.0 for human, pig and rat heart FABP, respecti­
vely. These isoelectric points agree with the behaviour of the 
proteins on the DEAE-cellulose anion-exchanger. The discrepancy 
with the previously reported values of 7.0 [85] and 5.5-5.8 [86] for 
rat heart FABP may be due to the presence of urea during those 
isoelectric focusing studies. Delipidation had no effect on the 
observed isoelectric points, as was also observed for bovine 
heart FABP [96]. 
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The purity of the FABP pre­
parations could also be concluded 
from the specific reaction with 
FABP that was observed on blots of 
cytosolic protein preparations 
iiwnunostained with antisera raised 
against these FABPs. 
The amino acid composition 
of the FABPs was derived from 
acid-hydrolysed samples. Trypto­
phan and tyrosine were determined 
spectrophotometrically. Tyrosine 
values obtained in this way cor­
responded with the values found by 
amino acid analysis. The overall 
amino acid composition of the 
heart FABPs of the three species 
shows many similarities, as the 
presence of tryptophan and the 
absence of cysteine (Table 4.2). 
Pig heart FABP however contains 
relatively more proline, alanine, 
glutamic acid (+ glutamine) and 
tryptophan, and less threonine and 
lysine than the human and rat pro­
teins. The amino acid composition 
of rat heart FABP closely corre­
lates with earlier reports [85, 
86,110], that of human heart FABP 
differs from previous data [97] by 
a higher glutamine (and glutamic 
acid) content, a lower number of 
lysines and the absence of cys­
teine. Data on the amino acid composition of pig heart FABP have 
not been published earlier. Bovine heart FABP mostly resembles 
human and rat heart FABP in its amino acid composition, but was 
shown to contain cysteine [961. 
As was reported before [85,86], the method of Lowry et al. 
[270] is not accurate for determination of the protein mass of the 
purified FABPs. Quantitative amino acid analysis showed that 
concentrations determined by the Lowry method were 1.2-1.4 times 
too high. 
94000-
68000- m 
43000-
30000-
20100-
14400-
1 2 3 4 5 6 7 
Fig. 4.3. SOS-polyacrylamide gel electro­
phoresis of FABP-containing protein sam­
ples at different stages of purification 
from hunan heart (lanes 2-4) and of pig 
and rat heart FABP. The gel was stained 
uith silver. Lanes 1 end 7: calibration 
proteins (with Mr): a-lactalbumin 
(14,400); soybean trypsin inhibitor 
(20,100); carbonic anhydrase (30,000); 
ova I bum η (43,000), bovine serun albunin 
(68,000) and phosphorylase-b (94,000). 
Lane 2: cytosolic protein (30 <ig); lane 3: 
combined FABP-containing fractions after 
Sephacryl S-200 gel filtration (15 дд); 
lane 4: hunan heart FABP (1.5 дд); lane 5: 
pig heart FABP (2 /ig); lane 6: rat heart 
FABP (2 дд). 
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Binding characteristics 
heart FABPs. 
of 
Table 
Amino 
4.2. 
acid compos 
binding proteins. 
Amino 
acid8 
Asx 
Thr 
Ser 
Glx 
Pro 
Gly 
Ala 
Cys 
Val 
Met 
lie 
Leu 
Туг 
Phe 
Trp 
His 
Lys 
Ara 
Man 
108 
127 
54 
102 
IB 
84 
57 
0 
63 
17 
33 
104 
li 
46 
9 
25 
107 
32 
10 
ition of heart 
Pig 
105 t 7 
54 i 2 
60 t 3 
130 t 3 
45 ± 1 
81 tlO 
85 t 6 
0 
62 î 6 
12 t 5 
27 ι 5 
95 t 7 
24 t 3 
44 ι 7 
34 i 1 
28 t 3 
76 t 3 
38 1 2 
fatty ac 
Rat 
119 t 2 
134 ι 9 
66 i 6 
102 t 6 
11 t 1 
93 i 9 
56 ι 3 
0 
79 t 5 
10 t 2 
36 t 4 
74 ι 4 
15 t 3 
44 i 4 
12 ι 1 
28 ι 5 
95 l 7 
27 t 7 
Values are means t S.D. of three preparations 
and given in residues/1000 amino acid residues. 
Binding parameters for 
different long-chain fatty 
acids and fatty acyl-esters 
were obtained from Scatchard 
plot analysis of binding iso­
therms at 31°C. Fixed amounts 
of purified, delipidated FABP 
were incubated with fatty acid 
concentrations of 0.1-3 μ,Μ. 
Binding characteristics were 
comparable for all heart FABPs 
investigated (Table 4.3). The 
highest binding capacities 
were observed for oleic and 
palmitic acid. Myristic acid, 
arachidonic acid, palmitoyl-
coenzyme A and palmitoyl-car-
nitine were bound to a lesser 
extent. Binding affinities for 
palmitoyl-coenzyme A and -carnitine were comparable to that for 
palmitic acid. No marked influence of pH was observed on binding 
of oleic or palmitic acid in the range of pH 6.5-9.0. 
Affinity of human heart FABP for different fatty acids and 
fatty acid derivatives was also assessed by measuring inhibition 
of the binding of [uC]oleic acid. Total ligand concentration was 
kept at 1 μΜ (Table 4.4). In a control experiment no ligand was 
added to determine the effect of a decrease of the oleic acid 
concentration. Human heart FABP exhibits the highest affinity for 
fatty acids of 18 carbon atoms and longer, preferring the 
unsaturated types. Palmitic and stearic acid take intermediate 
positions, whereas fatty acids of shorter chain-length and CoA 
and carnitine esters of palmitic acid do not compete well with 
oleic acid. 
The effect of other hydrophobic ligands on [UC]oleic acid 
binding was determined in a second series of competition studies 
(Table 4.5). Increasing concentrations of unlabelled ligands were 
added. Heme, bilirubin and prostaglandin E^ that were reported 
to bind to liver FABP 125,98,190,194,195], could not effectively inhibit 
oleic acid binding by heart FABP, neither could three other 
prostaglandins, cholesterol, retinol or retinole acid. 
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Table 4.3. 
Binding parameters for long-chain fatty acids and acyl-esters. 
Pig Rat 
Bmax Apparent Kd Bmax Apparent Kd 
Fatty acid (nmol/mg) (μΜ) (nmol/mg) (μΜ) 
Myristic acid 5.62 I 1.18 0.88 t 0.41 12.98 t 0.41 1.81 * 0.16 
Palmitic acid 26.71 t 3.40 0.60 t 0.24 23.40 t 3.00 1.26 t 0.40 
Oleic acid 30.00 t 2.44 0.20 t 0.05 22.68 t 2.16 0.43 t 0.09 
Arachidonic acid 18.04 t 2.13 0.17 t 0.04 14.38 l 3.41 0.24 t 0.03 
Palmitoyl-coenzyme A 19.43 t 2.37 0.50 ι 0.13 N.D. 
Palmitoyl-carnitine 12.98 t 0.98 0.42 i 0.34 N.O. 
N.D. = not determined. 
Data are derived from Scatchard plot analysis of binding isotherms at 37'C. Per assay 1.5-2.5 дд delipidated protein (based on quantitative 
amino acid analysis) was used. Values are means i SD of 3-5 experiments. 
Bmax 
(nmol/mg) 
13.22 t 6.11 
22.15 t 5.95 
29.03 t 4.34 
18.05 t 3.39 
20.49 t 5.28 
11.22 t 3.13 
Apparent Kd 
(дд) 
0.95 i 0.22 
0.78 t 0.16 
0.38 t 0.11 
0.16 t 0.04 
0.51 t 0.04 
0.59 t 0.24 
Table ІЛ. 
Effect of fatty acids and derivatives on [ Cloleic acid binding to hunan heart FABP 
[UC]oleic acid 
Competitor 
(ДМ) o.a 
0.2 
0.5 
0.5 
0.2 
o.a 
None 93 ι 4 78 ± 9 57 t 6 
Oleic acid (control) 
Laurie acid 
Myristic acid 
Palmitic acid 
Stearic acid 
Linoleic acid 
Arachidonic acid 
E rueic acid 
Palmitoyl-CoA 
Pa Imi toyl-carni tine 
(018:1) 
(012:0) 
(CU:0) 
(C16:0) 
(018:0) 
(018:2) 
(020:4) 
(022:1) 
72 ± 
84 1 
93 ι 
88 ι 
81 t 
78 t 
84 t 
89 t 
86 i 
70 t 
11 
7 
14 
12 
6 
7 
10 
9 
12 
8 
42 ι 6 
73 t 6 
79 ± 15 
68 t 7 
64 t 9 
48 t 7 
47 t 3 
54 ι 16 
71 t 6 
58 t U 
17 ι 4 
40 1 7 
41 1 10 
29 1 7 
30 1 9 
23 t 5 
26 t 14 
24 t 8 
49 s 9 
52 ι 7 
Incubation vials contained 5 дд/ліі de h pi dated FABP and a total fatty acid concentration of 1 ДН. 
Values are given as percentage of the binding at 1 μΗ [ C]oLeic acid and represent means t SD of 
at least 3 experiments. 
Addition of Mg + had no effect on the binding to human heart FABP 
of either oleic and palmitic acid or competition of prosta­
glandins with oleic acid, in contrast to observations with rat 
liver FABP [190]. Flavaspidic acid, an inhibitor of fatty acid 
binding to hepatic FABP И99], also decreased oleic acid binding 
to heart FABP, but to a lesser extent. 
Binding of fatty acid by FABP from multilamellar liposomes. 
When incubated with [uC]oleic acid-containing liposomes, 
human heart FABP takes up fatty acids from the membranes. The 
maximal fatty acid binding was slightly dependent on protein 
concentration, but did not exceed 0.7 mol/mol FABP (Fig. 4.4), 
indicating the presence of only one fatty acid-binding site per 
FABP molecule. Calculation of binding parameters from the data 
obtained with fatty acid concentrations up to 5 μΜ using 
Scatchard plot analysis gave Kd values similar to those obtained 
with the Lipidex binding assay (0.5-1.0 μΜ) . Incubation of bovine 
serum albumin with these liposomes resulted in a 5 mol/mol bind­
ing ratio (insert Fig. 4.4). 
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ОІоіс acid (MN'*) 
,14r Fig. 4.4. Binding of [ Cloleic acid by hunan heart FABP from liposomes. Different 
concentrations of protein were incubated with increasing amounts of [ Cloleic acid 
containing phosphatidylcholine liposomes for 1 h at 2SeC. Liposomes were spun down and 
binding of oleic acid to FABP was determined from the amount of radioactivity present 
in the supernatant. FABP concentrations: (0—0) 5.6 μΜ; <•—•) 11.3 μΜ; (I—·) 22.5 
μΗ. Insert: binding of oleic acid by 5 μΜ bovine serun albumin. 
Immunological relationship of FABPs. 
The heart FABPs of the three species were examined for 
cross-reactivity with specific anti-FABP sera. On immunoblots 
of cytosolic proteins the antisera only reacted with FABP. The 
immunological cross-reactivity was determined in ELISA as the 
serum dilution at which half maximal binding occurred and expres­
sed as a percentage of the reaction of an antigen with its speci­
fic antiserum. Antiserum to human heart FABP reacted with human 
and pig heart FABP; the antiserum directed against pig heart FABP 
showed a similar cross-reactivity (Table 4.6) . Both antisera gave 
a weak cross-reaction with rat heart FABP. Anti-rat heart FABP 
serum only reacted strongly with rat heart FABP. None of the 
antisera reacted with liver FABP of man, pig or rat, purified 
as described tesi. Antiserum to rat liver FABP did not react with 
heart FABP of the three species either. 
Inhibition of oleic acid binding to FABP by specific antibodies. 
Binding of [ C]oleic acid to human heart FABP could be 
inhibited by preincubation of the protein with the IgG fraction 
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Table 4.5. 
H,. Effect of various possible ligands on [1- Cloleic acid binding to hunan heart FABP 
Competitor 
Oleic acid 
Heme 
Bilirubin 
Prostaglandin E, 
Prostaglandin A1 
Prostaglandin F1(I 
15-Hethyl-prostaglandin F 2 a 
Cholesterol 
Retinol 
Retinole acid 
0.2 
B-Flavaspidic acid 98 ± β 
Concentration of 
1.0 
75 i 
Μ ι 
as t 
97 1 
104 t 
ее t 
99 ι 
96 t 
97 t 
99 t 
10 
Concentration 
0.5 
77* 10 
2.С 
58 1 
96 ι 
88 t 
98 t 
95 ι 
94 t 
93 ι 
103 i 
96 ι 
96 i 
competitor 
I 
12 
14 
of competitor 
1.0 
67 ± 11 
(μΜ) 
• (UM) 
4.0 
40 ι 4 
91 i 6 
76 ι 6 
98 t 2 
86 i 11 
86 t 10 
97 t 4 
106 i 4 
85 i 5 
86 ι 4 
5.0 
59 i 6 
14 Incubation vials contained 5 дд/ml delipidated FABP and 1 μΗ [ Cloleic acid. Increasing 
concentrations of unlabelled ligand uere added. Values are expressed as percentage of the 
binding of 1 дМ [ CJoleic acid and represent means 1 S.D. of at least 3 experiments. 
of the antiserum to human heart FABP (Fig. 4.5). IgG isolated 
from the pre-immune serum of the same rabbit did not affect oleic 
acid binding. 
4.4. DISCUSSION. 
Pure and myoglobin-free FABPs could be isolated from the 
cytosol of heart of man, pig and rat by gel filtration on Seph-
acryl S-200, followed by anion-exchange chromatography on DEAE-
cellulose. The recovery of FABP of about 10% is comparable to 
that obtained with rat liver FABP tasi. The heart FABPs are of 
comparable size, human heart FABP having a somewhat higher mole­
cular mass. The isoelectric points observed correspond with 
values reported before [88,97,192] and are in the same range as that 
of bovine heart FABP [96]. All liver FABPs have a somewhat smaller 
molecular mass (95,іоз,іо5], and a higher isoelectric point [87,92,95]. 
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The amino acid composition of the heart FABPs shows marked 
differences from that of rat [85,86,103], bovine [95] and human liver 
FABP [92,105]. In contrast to liver, tryptophan is present in heart 
FABPs [96,iio] and cysteine is absent, except for bovine heart FABP 
196]. In agreement with their lower pi values the number of lysine 
residues is lower in heart FABPs compared to liver FABPs [85-87, 
95,195]. The observed differences agree well with the marked diffe­
rences of the primary structure of rat heart and liver FABP моб, 
110,117,123]. 
All 3 heart FABPs exhibited comparable binding characteris­
tics. Binding affinity increased with longer acyl chains. Kd 
values observed with rat heart FABP for palmitic and oleic acid 
are comparable to those obtained with samples of heart cytosolic 
protein [158,1W]. Palmitic acid binding capacity of rat heart FABP 
was somewhat lower than observed previously [85]. Based on the 
Lipidex binding assay, 0.3-0.5 mol oleic or palmitic acid is 
bound per mol protein. This relatively low stoichiometry may be 
caused by loss of binding activity of the protein during the 
purification, since no contamination with other proteins could 
be detected on SDS-polyacrylamide gel electrophoresis, using 
highly sensitive silver-staining nor on immunoblots or in iso­
electric focusing gels. These and our previous data [26,85,1M] 
substantiate the binding of up to one mol fatty acid per mol 
FABP. This value is in contrast with the binding ratio of 2 
mol/mol observed by Offner et al. [86] for both rat heart and 
liver FABP using liposomes as fatty acid donors. We could 
however, not obtain ratios exceeding 0.7 with the same liposome 
assay. The apparent Kd values for oleic and palmitic acid of rat 
liver FABP were much higher in the liposome system [273] than we 
Table 4.6. 
limunological cross-reactivity of heart fatty acid-binding proteins. 
FABP 
from 
Man 
Pig 
Rat 
Antiserun anti· 
100 
72 
16 
hunan 
t 4 
i ¡, 
anti 
77 
100 
Η 
-pig 
i 8 
t 1 
anti-rat 
9 ± 1 
4 t 1 
100 
Serun dilutions at which half maximal binding was obtained in an 
ELISA were taken as measure for the immunological cross-reactivity 
of the three heart FABPs. Per well 0.25 дд FABP was used. Values are 
means i S.D. of at least 3 experiments, and given as percentage of 
the binding of the specific antiserim to the antigen. 
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IgG 'Tigi 
Fig. 4.5. Inhibition of fatty acid binding by the IgG fraction of antiserum against 
hunan heart FABP. Delipidated human heart FABP (1.5 Hi) was preincubated at З/'Х with 
increasing amounts of IgG directed against human heart FABP (0—0) or from preimnune 
senjn (·—I) in the presence of 2.5 mg lysozyme (as inert protein). After keeping the 
mixtures on ice for 1 h, fatty acid binding was assayed at 1 (iM [ Cloleic acid. Binding 
is given as percentage of the control (which contained only lysozyme and FABP). 
and others found in the Lipidex binding assay [25,85,1M]. With human 
heart FABP we observed comparable values with both assays. Recent 
NMR-studies showed a 1:1 stoichiometry in fatty acid binding to 
rat liver FABP in a vesicle system of 4 mol oleic acid and 20 mol 
phosphatidylcholine per mol FABP снз]. Oleic acid partitioning 
favoured membrane binding with increasing oleic acid content. 
Rudel et al. [177] established a 1:1 stoichiometry of 16-(9'-
anthroyloxy)palmitic acid to bovine heart FABP by fluorimetrie 
titration in agreement with electrophoretic data CIBÒ] . Fournier 
et al. [192] reported a binding ratio of 0.2 mol/mol for 12-doxyl-
stearic acid. 
The preference for binding of long (unsaturated) fatty acids 
was confirmed by their competition with [UC]oleic acid binding 
to human heart FABP. Although many other hydrophobic ligands are 
bound by liver FABP [25,98,i90,m-i96), heme, bilirubin, prostaglan-
dins, cholesterol and retinoids were unable to compete with oleic 
acid as a ligand for human heart FABP. The competition assay does 
not exclude a separate binding site for hydrophobic ligands other 
than that for fatty acids, as was observed for lysophosphati-
dylcholine binding to rat liver FABP [196]. The latter compound 
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was however not bound by rat heart FABP ti96]. The binding of 16-
(9 '-anthroyloxy) palmitic acid by bovine heart FABP [272] and of 
dansyl-amino-undecanoic acid by rat heart FABP [2M] was weak 
compared to the analogous liver proteins. These observations also 
indicate structural differences of the fatty acid-binding sites 
of heart and liver FABP. 
The binding of acyl-CoA esters by heart FABPs was also 
observed by other investigators [96,97], but no data were given. 
Recently, Burrier et al. [ΐββι reported that rat liver but not rat 
heart FABP bound oleoyl-CoA. Rat liver FABP binds CoA esters of 
palmitic and oleic acid with lower affinity than their correspon­
ding fatty acids tzsi, in contrast to the comparable affinity of 
heart FABP for palmitic acid and palmitoyl-CoA shown here. Pal-
mitoyl-CoA however, less effectively displaced oleic acid than 
palmitic acid from human heart FABP, similarly as from rat liver 
FABP [25]. With regard to the possible protective role of this 
protein in heart, e.g. during ischemia [275,276], the binding of 
long-chain acyl-CoA and -carnitine esters to FABP may be of 
importance. 
The high degree of immunological cross-reactivity between 
human and pig heart FABP and their antisera contrasts their low 
reactivity with antiserum to rat heart FABP and with rat heart 
FABP, respectively. The antiserum against bovine heart FABP 
reacted with cytosol and FABP from human and bovine heart and 
with rat and pig heart cytosol [97]. The absence of a reaction of 
anti-heart FABP sera with liver FABP was already observed 
separately for rat [86] and cattle [96]. 
In conclusion, FABPs from rat, human, bovine and pig heart 
appear to form a closely related group that is clearly different 
from liver FABP. All species-specific forms have a molecular mass 
of about 15 kDa and an isoelectric point around pH 5. Liver FABP 
appears to be a more general carrier for hydrophobic ligands, 
whereas heart FABP is more specifically involved in binding of 
fatty acids and acyl-derivatives. The fatty acid-binding capacity 
of rat heart cytosol is not markedly influenced by sex, star­
vation or Clofibrate treatment in contrast to that of liver [158]. 
All these observations suggest different roles of liver and heart 
FABP types in cellular metabolism. Their specific tissue distri­
bution [82,151,153,277] is another important indication in this 
respect. 
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4.5. SUMMARY. 
Fatty acid-binding proteins were isolated from cytosol of 
hearts of man, pig and rat by gel filtration and anion-exchange 
chromatography. The heart FABPs had a Mr of about 15 (pig, rat) 
and 15.5 kDa (man); pi values were 5.2, 4.9 and 5.0 for human, 
pig and rat heart, respectively. In contrast to liver FABPs, 
tryptophan was present in the heart FABPs. Binding characteris-
tics for long-chain fatty acids determined with the radiochemical 
binding assay were comparable for all 3 proteins. Heart FABPs 
also bind palmitoyl-CoA and -carnitine with an affinity compa-
rable to that for palmitic acid. Other ligands investigated -
heme, bilirubin, cholesterol, retinoids and prostaglandins -
could not compete with oleic acid for binding by human heart 
FABP. Binding parameters of FABP for oleic acid from multilamel-
lar liposomes were comparable to those from the Lipidex binding 
assay. Immunological interspecies cross-reactivity with antisera 
against the heart FABPs was much higher between man and pig than 
between rat and man or pig. None of the antisera reacted with 
liver FABPs. The IgG fraction of anti-human heart FABP serum 
inhibited fatty acid binding to human heart FABP. 
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Chapter 5. 
FATTY ACID-BINDING CAPACITY 
OF CYTOSOLIC PROTEINS OF VARIOUS RAT TISSUES. 
Effect of postnatal development, starvation, sex, 
Clofibrate feeding and light cycle.* 
5.1. INTRODUCTION. 
To quantitate the amount of fatty acid-binding protein 
present in tissue cytosols, and to investigate the influence of 
various parameters on the FABP concentration, a variety of proce-
dures has been applied (Table 2.2). Quantitation of this protein 
from the amount of radioactivity present in the FABP-containing 
fractions after coelution of a protein sample with labelled fatty 
acids, which was used in many studies [74,87,89,278], is hampered by 
the high affinity of ligands for most gel types HOI,226], and by 
the existence of a non-equilibrium between protein and ligand. 
The same disadvantages apply to the electrophoretic quantitation 
of FABP in the presence of labelled ligand. 
Immunochemical determination of FABP [87,K6,i60] depends on 
the availability of appropriate, highly specific, antibodies, 
and can only provide quantitative data without further informa-
tion on functional properties. Already in 1974 Ockner and Manning 
ruó) found indications that most hepatic FABP was not identical 
with the intestinal protein. Until now at least four distinct 
structurally different low-molecular-weight FABPs have been iden-
tified: hepatic, intestinal, cardiac and renal FABP [85,87,іоі-іоз,і50]. 
These types may have a different reactivity, depending on the 
applied antibody. The concomitant expression of two distinct FABP 
types in one tissue has been described for jejunum, where the 
hepatic and intestinal types are present MSOI , and for kidney, 
that contains heart FABP together with a kidney-specific type of 
the protein ti02]. The mRNAs of intestinal and liver FABPs are 
present in various adult rat tissues Мбл. To ensure reliable data 
This chapter was adapted from Paulussen et al., 1986 [158]. 
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on tissue FABP content based on immunochemical quantitation, the 
applied antibodies have to be well characterized regarding their 
mono-specificity for FABP in cytosolic protein preparations, and 
their reactivity towards different FABP types. 
Determination of FABP by gel filtration and subsequent 
affinity chromatography of cytosolic protein on oleoyl-amino-
hexylamino-Sepharose [228] applies denaturating conditions for the 
elution of the protein, and thus is not adequate for the study 
of fatty acid-binding characteristics and comparison of different 
ligands. 
For quantitation of FABPs by total binding capacity and 
investigation of fatty acid-binding characteristics, assays are 
available that involve binding of radioactive or fluorescent 
fatty acids. The radioactive fatty acids may be presented to the 
protein either free in aqueous solution, or incorporated in 
multilamellar liposomes. After establishment of the binding 
equilibrium, a separation of free and protein-bound ligand can 
be achieved with dextran-coated charcoal [279] or Lipidex 1000 
[1911, or by centrifugation in the case of liposomes [273]. With 
fluorescent labels, binding is determined from the enhancement 
of fluorescence that occurs upon binding of the fatty acid 
analogue, requiring no separation of bound and free ligand tаз,280]. 
This assay is most sensitive for liver FABPs, due to their high 
enhancement of fluorescence at binding of fluorescent fatty 
acids, but appears less suitable for heart FABP, where only a 
minor fluorescence enhancement occurs by binding to the protein 
[83]. Prior to the determination of its fatty acid-binding capa­
city, protein samples have to be delipidated to prevent competit­
ion of endogenously bound ligand, especially at low fatty acid 
concentrations и«]. Both for delipidation and as adsorbent for 
unbound fatty acids Lipidex 1000 is preferred, because it does 
not retain or denature protein, as takes place with charcoal ti9i]. 
Fatty acid-binding assays for FABP are, however, only useful for 
quantitative purposes in the absence of other proteins with fatty 
acid-binding activity, like e.g. albumin. 
The functional assay that was developed in our laboratory, 
in which unbound and protein-bound fatty acids are separated with 
the use of Lipidex 1000 [i9i], allows an accurate determination 
of the fatty acid-binding capacity of cytosolic protein prepa­
rations. With this method the FABP content of rat heart and liver 
were shown to be in the same order of magnitude [164]. The palmi-
tate-binding capacity showed a marked diurnal variation in both 
tissues [164]. Other investigators found only a slight diurnal 
variation of liver FABP measured by immunoassay [225]. 
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This chapter describes the determination of the fatty acid-
binding capacity of rat tissue cytosols as a measure for their 
FABP content. The influence of postnatal development, starvation, 
sex, Clofibrate feeding and light cycle was studied. In some 
experiments both oleic and palmitic acid were used as ligands. 
5.2. METHODS. 
Preparation of cytosols. 
Rat tissues were obtained from male albino Histar rats, 
weighing 180-220 gram, unless otherwise stated. Hearts and livers 
were perfused in situ with 10 mM K-phosphate/ 154 mM KCl (pH 
7.4). Tissues were excised and immediately cooled and rinsed in 
the same buffer. Cytosols were prepared as described in section 
3.3. Clofibrate treated rats received an oral dose of 50 mg 
clofibrate/day in 1 ml 60% glycerol (v/v) for 8-10 days. Rats 
were maintained on a cycle of alternating 12 h light and dark 
periods. The animals were killed by cervical dislocation around 
the midpoint of the light phase, unless indicated otherwise. 
Dealbuminization, delipidation and fatty acid-binding assay. 
Cytosolic protein samples (2-4 mg) were cleared of residual 
albumin by immuno-affinity chromatography. The affinity column 
(10 ml) was prepared by coupling of the IgG fraction of sheep 
anti-rat albumin to tresylchloride-activated Sepharose CL-4B, 
prepared as described by Nilsson and Mosbach [263]. After concen­
tration of the dealbuminized protein samples by ultrafiltration, 
using a Diaflo YM-2 membrane, and subsequent delipidation on a 
0.8 χ 6 cm Lipidex 1000 column at 37'C, the binding of [UC]-
labelled fatty acid at 37°С was determined by the Lipidex proce­
dure, as described in section 3.4. Amounts of 20-25 ßg protein 
were applied per assay. 
Other procedures. 
Sephacryl S-200 gel filtration was carried out as previously 
described in section 4.2. Protein was measured by the method of 
Lowry et al. moi, with bovine serum albumin as standard. Enzyme-
linked immunosorbent assay (ELISA) of albumin was essentially as 
described by Hudson and Hay CZMJ . The product of the peroxidase 
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reaction was determined with a Titertek scanner at 492 nm. 
Fatty acid-binding parameters were derived from Scatchard 
plot analysis [265] of the binding isotherms at 37"C, using 6-10 
fatty acid concentrations. Maximal binding (B^) is expressed 
in nmol fatty acid/mg cytosolic protein, apparent binding affi­
nity (Kd) in μΜ fatty acid. Binding constants were compared by 
the Student's unpaired t-test. 
5.3. RESULTS. 
All samples analyzed for fatty acid binding were passed 
through a Sepharose-anti-albumin column to remove residual 
albumin and delipidated, to obtain accurate values of fatty acid-
binding activity. The albumin concentration, calculated from an 
ELISA using specific anti-rat serum albumin antibodies, decreased 
from 0.1-0.3 nmol/mg cytosolic protein (depending on the effi­
ciency of perfusion) to less than 0.02 nmol/mg protein after 
dealbuminization. Cytosolic protein preparations that have not 
been delipidated show a nonlinear relationship between the amount 
of protein and fatty acid bound, resulting in underestimation of 
the fatty acid binding, especially at lower fatty acid concentra­
tions. With delipidated proteins the relation is linear, as was 
0 30 
О 20 
0 30 
Bound (nmol/mg protein) 
Fig· 5-1- Scatchard plot analysis of the binding of oleic and palmitic acid by liver 
cytosol of a clofι brate-fed rat. Results of a representative experiment are showi. 
Dealbunimzed, delipidated cytosolic protein samples (25 Mg) were incubated Kith 0.1-
3.0 μΜ [1- С] labelled fatty acid. After equilibration, free and protein-bound fatty 
acids were separated by use of Lipidex 1000 at 0*C. The concentration of free fatty 
acids Has calculated from the Initial concentration and the amount of protein-bound 
fatty acid. 
Panel A: oleic acid binding; Г--0.998 <n=9); № 0 . 9 2 llM; Bmax-4.81 nmol/mg cytosolic 
protein. 
Panel B: palmitic acid binding; r*-0.995 (n=8); Kd=0.71 μΜ; Bmax=3.86 nmol/mg cytosolic 
protein. 
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Table II. 
DiBtributton of cytosolic fatty ас id-binding 
activity in rat tissues. 
Tissue 
Heart 
Liver 
Kidney 
Adrenal 
Brain 
M.quadriceps 
Diaotirasm 
(5) 
(Г) 
M 
(5) 
(i) 
(4) 
(4) 
Oleic acid 
Bmax 
(яіюі/uq) 
4.38 t 0.43 
2.21 ι 0.30 
1.92 * 0.28 
3.35 t 0.58 
1.87 t 0.23 
1.61 i 0.41 
2.02 t 0.12 
bindinq 
Apparent Kd 
(ilM) 
0.63 t 0.20 
0.37 t 0.13 
1.31 t 0.48 
0.71 t 0.25 
1.49 10.19 
0.76 i 0.31 
0.52 t 0,0? 
also shown previously ti64]. 
Binding parameters were de­
termined with Scatchard plot 
analysis of fatty acid bind­
ing isotherms at 37'C. After 
delipidation we always ob­
served linear Scatchard 
plots (correlation coeffi­
cient (r) - -0.992 ± 0.011, 
mean ± SD, n=194), indicat­
ing a reproducible, (nearly) 
complete delipidation. Fig. 
5.1 shows representative 
Scatchard plots for palmitic 
and oleic acid binding, in 
this case by liver cytosol 
of a clofibrate-fed rat. 
Table 5.1 shows that 
the maximal fatty acid bind­
ing capacity is of the same 
order of magnitude in the 
cytosol of kidney, adrenal, 
brain, quadriceps muscle and diaphragm as in heart and liver. 
Sephacryl S-2 00 gel filtration (not shown) demonstrated that the 
fatty acid-binding activity was (nearly) completely located in 
the protein fraction of Mr 10,000-15,000, as was observed for 
liver and heart is». These proteins have a high affinity for 
Data of oleic acid binding of dcalbuninized, delipi-
dated cytosolic protein preparations of male, adult, 
fed rats are derived from Scatchard analysis of 
binding isotherms at 37*C Per assay 20-25 дд 
protein was applied. Values represent means i SD of 
the nurtoer of separate preparations indicated within 
parentheses. 
Table 5.2. 
Postnatal development of cytosolic fatty acid-binding capacity. 
Age 
(davs) 
Liver 
Oleic acid bindina 
Bmax Apparent Kd 
(птоі/гн) (UM) 
Heart 
Oleic acid bindinq 
Bmax Apparent Kd 
(nmol/mg) (uH) 
0 
10 
21 
40 
70 
2.32 t 0.34 
2.84 t 0.27 
2.44 1 0.58 
2.57 ι 0.49 
2.21 t 0 30 
0.57 t 0.23 (4) 
0.33 t 0.12 (4) 
0.52 1 0.13 (4) 
0.84 ι 0.22 (6) 
°·37 ι 0-13 (7) 
3.42 t 0.83 
3.60 t 0.59 
3.67 ι 0.81 
3.95 t 0.58 
4.38 t 0.43 
0.52 t 0.16 (4) 
0.33 1 0.08 (4) 
0.27 1 0.06 (4) 
0.47 ι 0.06 (5) 
0.63 ι 0.20 (5) 
Data of oleic acid binding were obtained as described in Table 5.1. Values represent means ι SD of 
the nunber of separate preparations given within parentheses. Male, fed rats were taken from different 
litters. With 0- and 10-day-old rats, tissues of several animals from the same litter were combined. 
No significant age-related differences were found in heart and liver. 
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oleic and palmitic acid in all these tissues. 
The effect of postnatal development on the cytosolic fatty 
acid-binding capacity of heart and liver was determined in rats 
of 0 (i.e. within 12 h of birth), 10, 21, 40 and 70 days of age 
(Table 5.2). In both tissues the fatty acid-binding activity is 
already present at birth, and does not change markedly during 
postnatal development. 
The fatty acid-binding constants for oleic acid were measu-
red after 66 h of starvation in 40- and 70-day-old animals (Table 
5.3). Starvation increases maximal oleic acid-binding capacity 
of liver, but no changes are observed in heart. The oleic acid-
binding capacity of both heart and liver cytosol is higher in 
female than in male rats (Table 5.4). No differences are observed 
with palmitic acid. The binding affinities for oleate and palmi-
tate acid are comparable in male and female animals. In males the 
binding capacity for oleate in liver is higher than for palmi-
tate, whereas heart shows a slightly higher binding capacity for 
palmitate. In female rats the binding capacity in liver does not 
differ for oleate and palmitate, but the binding capacity in 
heart is 2-fold higher with oleate. 
The maximal binding capacities for both oleate and palmitate 
were also determined at the midpoint of the dark phase of the 
light cycle (Table 5.5). When compared to mid-light values, only 
the oleate-binding capacity of liver is higher. The palmitate-
binding capacity of liver cytosolic protein is slightly, but 
significantly, lower. In heart both the binding capacity for 
oleate and palmitate are decreased at the midpoint of the dark 
phase. 
The effects of feeding of the hypolipidemic drug Clofibrate 
Table 5.Ï. 
The effect of starvation on cytosolic fatty acid-binding capacity of heart and liver. 
Age Condition 
(davs) 
40 fed 
starved 
70 fed 
starved 
Liver 
Oleic acid bindinq 
Bmax Apparent Kd 
(nmol/mq) (IIM) 
2.57 t 0.49 
4.36 t 0.76a 
Ζ.21 t 0.30 
3.25 ι 0 64 a 
0.84 t 0.22 (6) 
0.78 t 0.30 (4) 
0.37 i 0.13 (7) 
1.06 t 0.18 (4) 
Heart 
Oleic acid binding 
Bmax Apparent Kd 
(nmol/mq) (uM) 
3.95 t 0.58 
3.09 ι 0.39 
4.38 ι 0.43 
4.39 i 1.32 
0.47 1 0.06 (5) 
0.68 t 0.17 (4) 
0.63 t 0.20 (5) 
0.82 t 0.16 (4) 
Significance of Bmax values: different from fed P<0.01. Data of oleic acid binding were obtained 
as described in Table 5.1. Starvation period was 66 h. Values are means t SO of the nunber of separate 
preparations of male rat tissues given within parentheses. 
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on the fatty acid-binding capacities of heart, liver, kidney, and 
quadriceps muscle are summarized in Table 5.6. Clofibrate feeding 
does not affect the oleate-binding capacity in quadriceps muscle. 
Oleate-binding capacity of liver is, however, 2-fold increased, 
whereas a decrease in binding capacity is found for oleate in 
heart, and for palmitate in liver. In kidney, a 1.5-fold rise in 
maximal oleate binding is induced by Clofibrate feeding. 
The apparent Kd values for oleate and palmitate found with 
liver and heart cytosolic proteins are within the same range, and 
comparable to previous data obtained with palmitate nw. There 
is no explicit difference in the Kd values for oleic and palmitic 
acid in the various series of experiments. The values are in the 
same order of magnitude as observed with purified FABP prepara­
tions from liver and heart [25,85,248]. The Kd values for oleate in 
adrenal, skeletal muscle and diaphragm (Table 5.1) are comparable 
to the Kd values in heart and liver. Brain and kidney cytosols 
display somewhat higher dissociation constants for oleate. 
5.4. DISCUSSION. 
Gel filtration and the binding assay established the 
presence of one or more FABPs in the molecular weight range of 
10,000-15,000 Da in all rat tissues investigated. With the 
applied binding assay the total activity of all FABPs in the 
cytosol was determined. Some FABPs may be associated with mem-
Table S.A. 
Effect of sex and fatty acid on fatty acid-binding capacity 
of cytosols from heart and liver of fed rats. 
Sex 
male 
female 
Fatty acid 
oleic acid 
palmitic acid 
oleic acid 
Dalmitic acid 
Liver 
Fatty acid 
Вшах 
(nmol/mq) 
2.21 t 0.30 
i.OS t 0.38е 
3.W t 0.71b 
3.88 t 0.24 
binding 
Apparent Kd 
(iiM) 
0.37 ι 0.13 
1.00 t 0.24 
0.75 * 0.14 
0.54 ι 0.13 
(7) 
(8) 
(4) 
(4) 
Heart 
Fattv acid 
Bmax 
(rmol/mg) 
4.38 t 0.43 
3.40 t О.З^ 
5.94 t 0.79d 
2 98 t 0.57е 
bindinq 
Apparent Kd 
(ЦМ) 
0.63 t 0.20 
0.83 1 0.11 
0.82 t 0.21 
0.46 ι 0.12 
(5) 
(4) 
(5) 
(«J 
Statistical significance of Bmax values: a P<0.0001 (liver, male; oleic ve palmitic acid); P<0.01 
(liver, oleic acid: male vs female); c P<0.05 (heart, male; oleic vs palmitic acid); P<0.01 (heart, 
oleic acid; male vs female); e P<0.001 (heart, female; oleic vs palmitic acid). 
Binding parameters were obtained as described in Table 5.1. Values are means t SO of the nuiiber of 
preparations given within parentheses. 
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branes or cell organelles [98,нб], although this is not observed 
with immunocytochemistry сіби. The binding capacity for oleate 
ranged from 1.6-4.4 nmol/mg cytosolic protein in the investigated 
rat tissues. This indicates a proportion of 2-6% of cytosolic 
proteins, calculated on basis of the molecular mass of FABP (14-
15 kDa), which is higher than found for sterol carrier protein 
in these tissues in the light phase ігвіз. The binding capacity 
values of liver and heart cytosol of male, fed rats for palmitate 
in the light phase agree with earlier data published by Glatz et 
al. [164]. The values for liver also correspond to the data found 
with immunochemical analysis іел and affinity chromatography 
[228,282]. For brain an amount of 0.4% of cytosolic protein was 
reported [М,Ш], which is much lower than the 2.6% determined in 
this study. The binding capacity of rat brain cytosol is high in 
comparison to the low fatty acid-oxidation capacity of that 
tissue [23П. The apparent Kd values for oleate in brain and kidney 
suggest the presence of other fatty acid-binding proteins in 
these tissues than those found in heart and liver. 
During postnatal development up to 70 days we did not 
observe changes in the oleate-binding capacity in heart and liver 
cytosol of male rats. Foliot et al. am reported a 2-fold in­
crease in rat liver during postnatal development to adult values 
at 30 days, based on bromosulfophthalein binding, whereas Ockner 
et al. [87,223] found a 1.4-fold higher level with 60-day-old than 
with 30-day-old animals, using immunochemical quantitation of 
FABP. Levels of liver FABP mRNA increased in the first day after 
birth, but remained constant during the next 34 days of life ИОЛ . 
Table 5.5. 
The influence of the lieht cycle on the fetty acid-binding activity in cytosol of rat heart and liver. 
Fatty 
acid 
oleic acid 
palmitic acid 
Phase 
ttfhen 
killed 
light 
dark 
light 
dark 
Liver 
Fattv acid binding 
Вшах 
<nmol/mq) 
2.21 ι 0.30 
Ï.12 1 0.45a 
4.08 ι 0.38 
3.17 ± 1 0в Ь 
Apparent Kd 
(UN) 
0.37 i 0.13 
0.73 ι 0.17 
1.00 i 0.24 
0 85 ± 0 36 
(7) 
(9) 
(8) 
(β) 
Heart 
Fattv acid binding 
В max 
(nmol/mq) 
4.38 1 0.43 
2.59 t 0.40е 
3.40 t 0.39 
1.55 , 0 24 е 
Apparent Kd 
(UN) 
0.63 i 0.20 
0.44 t 0.13 
0.83 ι 0.11 
0.53 t 0.19 
(5) 
(9) 
(5) 
<»} 
Statistical significance, different from light phase: ° P<0.001; P<0.05. Fatty acid-binding para­
meters were obtained as described in Table 5.1. Values represent means ι SO of the nunber of separate 
experimenta ind'cated within parentheses. Rats (mates) were maintained on a cycle of alternating 12 
h light and dark periods. Animals were killed arowid the midpoint of the light or dark phase of the 
light cycle. 
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Total palmitate-oxidation capacity (per g wet weight) of rat 
liver was maximal at 21 days, that in rat heart at an age of 70 
days [231]. 
Other investigators found 1.2-1.5-times higher levels of 
FABP in liver cytosol of female than of male animals with the 
comigration technique ігта.гагі and immunochemical quantification 
[87,150]. We observed a comparable difference in oleate-binding 
capacity of liver and heart cytosol of female rats. However, on 
comparison of palmitate binding data no sex-related differences 
were found. Bass et al. [ISO] observed that in intestine sex has 
no influence on the content of FABPs of either the liver or the 
intestinal type. 
Fatty acid-binding capacity of heart cytosolic protein was 
not affected by 66 h starvation of 40- and 70-day-old rats. In 
liver cytosol oleate-binding capacity was increased 1.4- and 1.7-
fold, respectively. With the immunochemical іггл and comigration 
method игя a moderate decrease (16 and 35%, respectively) was 
observed in the concentration of FABP of liver cytosol after 48 
h starvation. The fatty acid-oxidation capacity and the citrate 
synthase activity per g liver increased by 43 and 52%, respecti­
vely, after 66-h starvation of 40-day-old rats [283]. Since liver 
weight decreased by 37%, the capacity of fatty acid oxidation 
remains 
Table 5.6. 
The effect of Clofibrate feeding on the fatty acid-binding capacity 
of cytosols from various rat tissues. 
Tissue Fatty Condition Fatty acid binding 
acid Bmax Apparent Kd 
(nmol/mq) luM) 
Liver 
Heart 
Kidney 
Skeletal muscle 
oleic acid 
palmitic acid 
oleic acid 
oleic acid 
oleic acid 
fed 
clofibrate-fed 
fed 
clofibrate-fed 
fed 
clofibrate-fed 
fed 
clofibrate-fed 
fed 
clofibrate-fed 
2.21 ι 0.30 
4.71 i 0.58a 
4.0β i 0.38 
3.33 1 0.43e 
4.38 t 0.43 
3.29 ι 0.31e 
1.92 t 0.28 
3.17 ι 0.60b 
1.61 t 0.41 
1.34 t 0.07 
0.37t 0.13 
0.861 0.16 
1.00i 0.24 
0.72 1 0.11 
0.63 ι 0.20 
0.39 1 0.11 
1.31 ι 0.48 
1.78 10.41 
0.76 10.31 
0.73 10.01 
( 7 ) 
( 4 ) 
( 8 ) 
( 4 ) 
( 5 ) 
( 6 ) 
( 4 ) 
( 4 ) 
( 4 ) 
(«) 
Statistical significance, Вшаж values different from fed animals: * P<0.001; P<0.01,· c P<0.05. 
Data of fatty acid binding were obtained as described in Table 5.1. Hale rats received an oral dose 
of 50 mg Clofibrate in a 1 ml 60X (v/v) glycerol solution, for 8-10 days. Values represent means t 
SO of the nuitoer of separate preparations given within parentheses. 
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nearly constant in whole liver. Although cytosolic protein may 
decrease more at starvation than liver weight [22л, the relati­
vely higher concentration of FABP may annul this decrease. 
When the fatty acid-binding activity was determined at the 
mid-point of the dark phase of the light cycle, only the oleate-
binding capacity of liver cytosol was moderately higher. No 
diurnal variation of liver FABP was observed with immunochemical 
analysis by Bass et al. [22η, in contrast to the (2-10-fold) 
diurnal change of sterol carrier protein observed in various 
tissues [геи. The decrease of palmitate binding by liver and heart 
cytosolic protein at mid-dark are at variance with earlier obser­
vations и«]. This discrepancy may be caused by an incomplete 
removal of residual albumin in that study. In this study we 
applied anti-albumin antibodies that were covalently linked to 
Sepharose, instead of non-covalently Protein-A-bound, to ensure 
complete dealbuminization, and we also investigated more series 
of animals. The palmitate-oxidation capacity was increased at the 
mid-dark period in liver, and to a minor extent also in heart, 
but changes are related to fluctuations of other mitochondrial 
activities ммз as with starvation сгаз]. The concomitant and 
comparable changes in FABP and fatty acid-oxidation capacity of 
rat liver due to starvation or to the light-dark cycle are 
therefore related to changes in liver composition, and indicate 
a protection of this protein and of mitochondrial enzymes against 
starvation-induced proteolysis. 
Administration of the hypolipidemic drug Clofibrate 
increased the FABP content of liver approximately 2-fold [25,150,224, 
227.228,2β4,285]. We found a similar increase of the binding capacity 
for oleate, but a minor decrease for palmitate. Clofibrate treat­
ment resulted in a 2-fold increment of liver FABP in intestine, 
and a 25% increase in intestinal FABP nso]. No literature data 
are available on the effect of Clofibrate feeding on the fatty 
acid-binding capacity of kidney, heart and muscle. The observed 
effects of Clofibrate feeding on fatty acid binding in liver, 
kidney, heart and muscle (Table 5.6) and in intestine nso] indi­
cate that the levels of the different types of FABP are regulated 
by separate mechanisms. The effects of Clofibrate feeding 
correspond with those on the total palmitate-oxidation capacity 
[231]. Clofibrate treatment caused a 2.8, 2.1 and 1.2-fold rise 
in the palmitate-oxidation capacity in liver, heart and kidney, 
respectively, and had no effect on oxidation in skeletal muscle. 
A 45% increase of oleate binding by liver cytosol was obtained 
in rats fed diets containing 19% (w/w) fat (Veerkamp, Zevenbergen 
and Paulussen, unpublished data) . The fatty acid-oxidation capa-
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city in liver rose with about 30% in these rats. Clofibrate, 
starvation and high-fat diets also induce an increase of pal-
mitoyl-CoA hydrolase [284,287]. The increase of acyl-CoA concen-
tration observed under these conditions [286,zun may relate to 
these phenomena. 
The binding capacity differs for palmitate and oleate in 
male liver, and in female heart and liver. The effects of the 
diurnal cycle and of Clofibrate feeding on the binding capacity 
of liver cytosol of male rats also differ for oleate and palmi-
tate. This suggests that different proteins may be involved in 
the fatty acid binding, or that different regulatory or inductory 
mechanisms exist for different fatty acids. Other factor(s) 
present in the cytosol may influence the binding of the fatty 
acids to FABPs, since with purified FABP preparations from liver 
no difference in oleate and palmitate binding was observed [25,85]. 
In conclusion, various conditions appear to influence the 
fatty acid-binding capacity in the cytosol of rat tissues. Inter-
pretation of data is complicated by different results dependent 
on the applied fatty acid and sex. The fatty acid-binding capa-
city, as measure for the cytosolic FABP content shows no clear 
relationship with the capacity of fatty acid oxidation, taken in 
consideration the observations with brain and postnatal develop-
ment. The nutritional state and the diurnal cycle influence the 
capacity of cytosolic fatty acid binding and fatty acid oxidation 
per g liver to a comparable extent, but have no effect for whole 
liver. Clofibrate treatment apparently induces both FABP and 
fatty acid oxidation in rat liver and kidney. 
5.5 SUMMARY. 
Fatty acid-binding capacity of dealbuminized, delipidated 
cytosolic proteins from rat tissues was studied with a radio-
chemical binding assay. Oleate-binding capacity ranges from 1.6-
4.4 nmol/mg cytosolic protein in liver, heart, kidney, adrenal, 
brain, skeletal muscle and diaphragm. Differences in binding 
affinity indicate the presence of different fatty acid-binding 
proteins in these tissues. No change in fatty acid-binding capa-
city of heart and liver cytosol was observed during postnatal 
development up to 70 days. Starvation did not affect the fatty 
acid-binding capacity of heart, but increased the oleate-binding 
capacity in liver cytosol. Sex-related differences of binding by 
heart and liver cytosolic proteins were found with oleate, but 
not with palmitate. Fatty acid-binding capacity of heart and 
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liver cytosol did not show a marked diurnal variation. Clofibrate 
treatment had different effects on the oleate-binding capacity 
of cytosolic proteins: an increase in liver and kidney, no change 
in skeletal muscle and a decrease in heart. The results are 
discussed in relation to data on fatty acid oxidation. 
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Chapter б. 
IMMUNOCHEMICAL QUANTITATION 
OF FATTY ACID-BINDING PROTEINS. 
I. Tissue and intracellular d istr ibut ion, postnatal 
development, and Influence of physiological 
condit ions on rat heart and liver FABP.* 
6.1. INTRODUCTION. 
A number of structurally different types of FABPs exist in 
heart, liver, intestinal mucosa and skeletal muscle [25,27,79,82]. 
These different FABP forms are not confined to these four tis­
sues, but show a rather complex tissue distribution, suggesting 
a structural relation between FABP type and intracellular fatty 
acid metabolism of different tissues. 
Not only the FABP type, but also the FABP content of the 
cytosol differs among tissues. Several methods have been descri­
bed for the quantitation of these proteins. The comigration of 
(radio)labelled ligands with FABP on a gel filtration column, 
which was first applied for the isolation of this protein, has 
also been used for its quantitation [iw,223,225,233]. The major dis­
advantages of this procedure are competition of other fatty acid-
binding proteins in the cytosol with FABP and affinity of the 
gel matrix itself for fatty acids, and thus the non-equilibrium 
conditions of the assay. In our laboratory, a radiochemical 
binding assay was developed им to determine the FABP content 
of cytosolic protein samples as the fatty acid-binding capacity 
(after removal of albumin by affinity chromatography on anti-
albumin antibodies conjugated to Sepharose). 
Binding of fatty acids labelled with a fluorescent probe was 
also used to quantify the amount of FABP in protein samples сгао]. 
Kawashima et al. сггв] applied affinity chromatography on oleoyl-
aminohexylamino-Sepharose of the low molecular weight fraction 
obtained by gel filtration, but this method requires denaturating 
conditions to elute FABP, which makes quantitation of its amount 
* 
This chapter was adapted from Paulussen et al., 1989 [153]. 
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less accurate. Several authors reported data on FABP concentrat­
ions derived from immunodiffusion or Immunoelectrophoresis assays 
[87,146,150,151,160,165]. More accurate radioimmunoassays for quantitation 
of liver FABP were reported by others [ібо,284]. Many earlier 
investigations [e.g. 159,160,284] did not, however, take into account 
the existence of a greater variety of FABP forms in their assay 
of FABP content of other tissues than is present in liver. More 
recently, Crisman et al. [152] developed a quantitative enzyme-
linked immunosorbent assay (ELISA) for measurement of heart FABP. 
Wilkinson and Wilton [229] labelled FABP with antiserum and 1 2 5I-
labelled protein-Α on immunoblots to establish the amount of FABP 
in their samples. 
This chapter deals with the development of an ELISA for the 
quantitation of rat liver and heart FABP forms in cytosolic 
protein preparations of various rat tissues with IgG fractions 
of specific antisera. The assay was used to determine the 
subcellular distribution of FABP in heart and liver and the 
influence of a number of physiological conditions and of post­
natal development on the FABP content of heart and liver. To 
provide a better evaluation of the FABP contents of tissue 
samples, we compared the immunochemical data with our data on the 
fatty acid-binding capacity [158, chapter 5]. The a-fetoprotein content 
of heart and liver cytosol was determined during postnatal 
development, to provide a possible explanation for differences 
observed between FABP content and fatty acid-binding capacity. 
Also, the FABP content of liver was compared among 7 strains of 
inbred rats, and assayed after administration of a number of 
agents that are known to affect lipid metabolism. 
6.2. METHODS. 
Preparation of cytosols. 
Unless otherwise stated, cytosols were prepared from male, 
fed albino Wistar rats (weighing 200 ± 20 g) as described in 
section 3.3., and were stored at -го-С. 
Comparison of inbred strains and effects of agents affecting 
lipid metabolism. 
Liver cytosols used for the estimation of FABP content in 
a series of fully inbred strains of rats and after treatment with 
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agents affecting lipid metabolism were obtained from the experi­
ments described by Geelen et al. rzeei. In the experiment involving 
agents that affect lipid metabolism, all animals, including 
controls, received a diet supplemented with 5% olive oil. Supple­
mented diets were fed during 21 days, starting with 8-week-old 
Wistar rats. A molecular mass of 13,500 Da was used in calcu­
lations for sterol carrier protein-2 [289]. 
Subcellular fractionation. 
Homogenates of livers and hearts from male albino Wistar 
rats (200 ± 20 g) were prepared and fractionated into mitochon­
dria, microsomes, and cytosol as described in section 3.3. Two 
fractions of the mitochondria were extracted with 0.05% Na-
deoxycholate (pH 7.0) and KCl (125 mM KCl/ 1 mM EDTA/ 10 mM K-
phosphate, pH 6.0). Finally, the KCl extracted mitochondria were 
extracted with deoxycholate as well. The obtained fractions and 
mitochondrial extracts were used for immunological quantitation 
of FABPs. The extraction procedures are described in section 3.3. 
Preparation of antigens. 
Rat heart FABP was purified from 105,000 χ g supernatants 
by gel filtration on Sephacryl S-200 and DEAE-cellulose anion-
exchange chromatography as described in chapter 4. Rat liver FABP 
was purified according to Glatz et al. tesi, with some minor 
modifications. 
Preparation of antisera. 
Antisera were obtained from New Zealand White rabbits, that 
were immunized by intracutaneous injections of 100 ßg FABP at 3-
week intervals. Final exsanguination was performed by cardiac 
punction. Sera were isolated and stored at -20°C. A detailed des-
cription of the immunization procedure is given in section 3.5. 
IgG-fractions of the antisera were prepared with protein-A 
Sepharose as described by Goudswaard et al. [266]. 
ELISA procedures. 
Titer determinations. 
Blood samples were taken every 3 weeks for titer deter-
minations. Antibody titers were determined in ELISA with pure 
FABPs attached to the solid-phase, using successive 2-fold 
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dilutions of the sera. Peroxidase-conjugated swine anti-rabbit 
IgG was used for detection of the bound antibodies, with ortho-
phenylene diamine as substrate. The product of the peroxidase 
reaction was determined at 492 nm with a Titertek Multiscan. 
Details of the procedure are given in section 3.5. Titers were 
determined from titration curves, constructed of a semi-log plot 
of absorbance at 492 nm versus serum dilution, and were defined 
as the reciprocal values of the serum dilution required to obtain 
50% maximal reaction. 
ELISA for quantitation of FABPs. 
Measurements of cytosolic FABP content were carried out with 
a quantitative ELISA, performed as described in section 3.5. In 
short, calibration curves (0-7 ng FABP) and samples (50 and 100 
ng cytosolic protein) were used for overnight coating at 20°C. 
IgG-fractions of the antisera were appropriately diluted in PBS-
Tween (5.4 mM Na-phosphate/ 1.3 mM K-phosphate/ 150 mM NaCl, pH 
7.4/ 0.05% Tween-20), to produce linear standard curves. The 
microtitre plates were treated as described before (section 3.5) . 
The amount of immune-reactive protein in the samples was deter­
mined from calibration curves calculated from linear regression 
analysis. Molecular masses used in all calculations were 14,992 
Da for heart FABP nm] and 14,273 Da for liver FABP [90]. 
Quantitation of α-fetoprotein. 
α-Fetoprotein content of cytosols was determined in ELISA, 
similarly to the measurements of FABP. Antiserum to rat α-feto­
protein and α-fetoprotein standard were kindly donated by Dr. J. 
Uriel (Laboratoire de Chimie des Protéines, Institut de Recher-
ches Scientifiques sur le Cancer, CNRS, Villejuif, France). A 
molecular mass of 70,000 Da for α-fetoprotein [290] was used in 
calculations. 
Electrophoresis and Western blotting. 
Cytosolic protein samples (50 μg) were separated by Poly­
acrylamide slabgel electrophoresis in 0.1% SDS at pH 8.8 with 
7.5-20% acrylamide gradient gels (0.7 mm thick). Immediately 
afterwards, the proteins were transferred electrophoretically to 
nitrocellulose paper. After blotting the nitrocellulose sheets 
were dried. Immunostaining was carried out after blocking of all 
remaining binding sites on the nitrocellulose with bovine serum 
albumin. Antigens were detected with the double antibody tech­
nique, using peroxidase-conjugated swine-anti rabbit IgG as 
78 
second antibody and 4-chloro-l-naphthol as precipitating 
substrate [269]. Details are described in section 3.6. 
6.3. RESULTS. 
FABPs were isolated from cytosolic protein preparations of 
rat heart and liver by gel filtration and anion-exchange chroma­
tography. Purity of the isolated FABP preparations was confirmed 
by SDS-polyacrylamide gel electrophoresis and ultrathin-layer 
isoelectric focusing. Protein-Α purified IgG fractions of anti-
sera to rat heart and liver FABP raised in rabbits were used for 
immunochemical investigations of FABP content and distribution 
of heart and liver FABP types. 
The liver and heart forms of FABP have a clearly different 
tissue distribution within the rat. On Western blots, liver FABP 
is predominantly detected in liver and intestine (Fig. 6.1A). Rat 
A В 
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Fig. 6.1. Iimunostained Western blots of rat tissue cytosols. Panel A: after incubation 
with anti-rat liver FABP; panel B: incubated with anti-rat heart FABP. Cytosols: heart 
(lane 1); liver (2); m.quadriceps (3); m soleus (4); m.extensor digitorun longus (5); 
diaphragm (6); kidney (7); adrenal (8); intestine (9); spleen (10); adipose tissue (11); 
lung (12) and brain (lane 13). Slots were loaded with 50 дд of cytosolic protein. 
Blotting and staining was performed as described in section 3.6. 
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liver cytosol also appears 
to contain minor amounts 
of an immune-reactive pro­
tein of approximately 30 
kDa. This band was not 
present in the pure FABP 
preparation that was used 
for immunization, but it 
is found in liver FABP 
preparations that were 
repeatedly thawed and re-
frozen. Sheridan et al. 
C238] observed a similar 
phenomenon. Cytosols of 
lung and some types of 
muscle only showed reac­
tivity with proteins of 
molecular mass higher than 
FABP. Blotting analysis 
with antiserum raised 
against another liver FABP 
preparation showed that 
the reactivity in the 3 0 
kDa range was no artifact. 
The significance of these proteins is not clear. 
On Western blots of tissue cytosols, reactions with anti­
bodies against heart FABP were only observed in heart, m. soleus, 
m.extensor digitorum longus, diaphragm, kidney, and weakly in m. 
quadriceps (Fig. 6.IB), all in the 15 kDa region. Reactivity with 
proteins of other molecular weight was not seen. 
The FABP content of rat tissue cytosols was determined as 
the amount of anti-FABP-reactive protein with a quantitative 
enzyme-linked immunosorbent assay (ELISA). The antigens were 
directly adsorbed to a polystyrene surface, allowing the use of 
very small amounts of cytosolic protein (i.e. 50-100 ng). Incu­
bation with whole rabbit antisera gave insufficient reproducibi­
lity. This problem was overcome by using IgG-fractions of the 
antisera. IgG solutions were diluted to produce linear calibra­
tion curves, as demonstrated for rat heart FABP in Fig. 6.2. The 
assay has a sensitivity limit of 5 ng/ml. Recovery of pure FABP 
added to cytosolic protein samples was 92 ± 13 % (mean ± SD of 
3 determinations). The antisera against heart FABP cross-react 
only very weakly with liver FABP in ELISA (less than 1%), as do 
anti-liver FABP antibodies with heart FABP (2%). 
Fig. 6.2. Calibration curve of ELISA for the 
quantitative determination of rat heart FABP. 
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Table 6.1. 
Tissue distribution of heart and liver type FABP. 
Protein reactive with 
ant i-heart FABP anti-liver FABP 
Heart 57.1 1 5.7 (7) 1.9 t 0.7 (4) 
Liver 6.0 i 4.3 (6) 34.3 t 6.9 (6) 
H.quadriceps 23.1 i 3.9 (7) 
H.soleus 43.5 ι 10.2 (6) 
H.extensor digitorm longus 21.0 t 8.4 (6) 
Diaphragm 36.9 ± 7.2 (6) 
Kidney 11.5 t 2.6 (7) 0.4 t 0.2 (4) 
Adrenal 4.4 ι 0.5 (3) 2.2 i 0.5 (3) 
Intestine 3.3 t 2.3 (3) 6.4 t 2.0 (5) 
Spleen B.7 ι 0.4 (3) 1.0 t 0.2 (3) 
Adipose tissue 6.2 t 0.9 (3) 6.9 t 2.2 (3) 
Lung 20.2 t 3.5 (3) 
Brain 12.3 t 7.1 (4) 2.4 t 0.4 (3) 
Protein reactive uith anti-heart and anti-liver FABP [gG was measured in cytosol 
of tissues of male, adult, fed rats by a quantitative inmunoassay. Data were ob­
tained from multiple determinations at 2 concentrations of cytosolic protein for 
each sample. Values are expressed as FABP content in дд/лід protein and are given 
as means t SD of the nunber of separate preparations indicated within parentheses. 
The tissue distribution of heart and liver FABP is summa­
rized in Table 6.1. The amount of anti-liver FABP reactive 
protein in lung and skeletal muscles was omitted, because this 
only represents reactions with non-FABP proteins as observed on 
immunoblots. In ELISA, as on the Western blots, liver FABP is 
found in liver and intestine, and furthermore in adipose tissue 
cytosol. The content of liver FABP in rat intestine is smaller 
than found in jejunum tisoj. This is probably due to the use of a 
more distal part of the intestine in this study, since FABP 
concentration is highest at the proximal end ti46]. With brain 
cytosol, only a minor reactivity was observed with antibodies to 
rat liver FABP. 
The ELISA results show that heart FABP has a much wider 
distribution than the liver type. It was detected in high quanti­
ties in heart, diaphragm and m.soleus, and in lower concentra­
tions in the other skeletal muscles and lung. Smaller amounts 
were found in kidney, brain and spleen. Blood plasma and high 
speed supernatants of lysed erythrocytes did not react with 
either antiserum. 
Cellular FABP distribution was assessed by measurement of 
the FABP content of mitochondrial, microsomal and cytosolic frac­
tions after cell fractionation. Mitochondria were also extracted 
81 
σι 
E 
ö 
ε 
с 
с 
0) 
с 
о 
υ 
α 
< 
iL 
Heart 
έ è ю 
/ / •/ 
 ¿/ • / / •/  
-/ •/ •/ 
ι I 1 
i 
•/ 
•/ 
•/ jy 
10 2 1 
Liver 
A 
«l 
70 О 10 
Age (days) 
4 0 /Ό 
E 
σι 
с 
Ό 
С 
£1 
I 
Ό 
Oleic acid birdng 
Fig. 6.3. Postnatal development of FABP content (inmunoassay) and oleic 
acid-binding capacity (Lipidex assay) of rat heart and liver cytosol. 
with either KCl solution or deoxycholate to differentiate between 
FABP associated with the mitochondrial outer membrane and FABP 
located within the mitochondria. In both heart and liver, FABP 
was located solely in the cytosol (96 ± 2 and 99 ± 1% (n=3) , 
respectively). A slight amount of FABP was found in the micro­
somal fraction (3.2 and 0.8%), probably due to some residual 
cytosol, since this fraction was not washed. The mitochondria and 
mitochondrial extracts did not contain detectable FABP. 
The FABP content shows a 
marked increase during post­
natal development (Fig. 6.3), 
reaching adult values around 
day 21 in heart and between 40 
and 70 days in liver, respec­
tively. These data are contra­
ry to the constant fatty acid-
binding capacity observed du­
ring postnatal development in 
both heart and liver cytosol 
(Fig. 6.3., binding data from 
Ref 158) . The FABP content of 
livers of prenatal animals 
shows a rise from less than 
0.1 at 18 days of gestation to 
about 0.3 nmol/mg protein at 
term (22 days of gestation). 
Table 6.2. 
Postnatal development of α-Fetoprotein 
content of rat heart and liver cytosol 
Age 
(days) 
0 
10 
21 
40 
70 
a-Fetoprotein content 
Heart 
0.10 t 0 . 0 3 a 
0.08 t 0 . 0 1 a 
0.01 t 0.00 
0.00 t 0.00 
0.01 t 0.00 
Liver 
0.12 t 0 . 0 1 a 
0.06 t 0 . 0 1 a 
0.03 t 0.01 
0.02 t 0.01 
0.02 1 0.01 
Statistical significance of values 
versus 70 day-old animals: a P<0.001. 
Values were determined for male, fed 
rats by quantitative inmunoassay- All 
values are given in nmol/mg cytosolic 
protein, as means ι SD of 4-7 samples. 
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The fatty acid binding capacity (after dealbuminization) of the 
cytosols of developing animals can not entirely be assigned to 
FABP, as for adult tissues. The difference may be due to another 
soluble protein that decreases in concentration during develop­
ment, reciprocally to the increase in FABP concentration. This 
protein may be α-fetoprotein, which is synthesized by the fetal 
liver and is known to bind unsaturated fatty acids with high 
affinity [290,291]. To assess the possible involvement of α-feto­
protein in the fatty acid-binding capacity, the α-fetoprotein 
content of liver and heart cytosol was determined by immuno­
chemical quantitation (Table 6.2). The data show a postnatal 
decline of α-fetoprotein content of both tissue cytosols that is 
reciprocal to the increase of the FABP content. Rat α-fetoprotein 
has one high affinity binding site and 12 or 13 binding sites 
with lower affinity for arachidonic acid t290]. At the fatty acid 
concentrations used with the Lipidex assay these binding sites 
will not all be occupied. In addition to the 2.5 mol endogenously 
bound fatty acid per mol protein, α-fetoprotein bound only about 
2 mol exogenous fatty acid/mol when incubated with 9 fatty acids 
Table 6.3. 
Effect of various physiological parameters on FABP content 
and fatty acid-binding capacity of rat heart and liver cytosol. 
Tissue 
Heart 
Liver 
Statisti 
Animal 
Control 
Female 
Starved (6¿h) 
Clofibrate-
Dark phase 
Control 
Female 
•fed 
Starved (6£h) 
Clofibrate-
Dark phase 
fed 
cal significance 
FABP 
content 
3.81 ι 
4.87 1 
2.84 t 
3.12 t 
2.87 t 
2.40 t 
3.08 ι 
2.46 ι 
3.32 t 
2 77 t 
of differences 
0.38 
0.51a 
0.87 
0.76 
0.52b 
0.48 
0.44 
0.25 
0.36a'c 
0.39 
vs control: 
Oleic acid-
bindinq capaci tv 
4.38 
5.94 
4.02 
3.29 
2.59 
2.21 
3.44 
3.25 
4.71 
3.12 
• P<0.01; b 
i. 
P 
0.43 
0.79a 
1.37 
0.31Ь 
0.40Ь 
0.30 
0.71a 
0.64 
0.58Ь 
0.45Ь 
<0.001. 
Statistical significance of differences between FABP content and oleic 
acid-binding capacity: c P<0.01. FABP content vas measured imunologically 
in cytosolic protein sanples. Oleic acid-binding capacity was derived from 
Scatchard plot analysis of binding isotherms at 37*C of dealbumnized, 
dclipidated cytosol ι с protein preparations [158]. All values (expressed in 
nmol/mg cytosol 1С protein) are means 1 SO of 4-9 samples. Control animals 
were male, adult, fed rats and were sacrificed in the light phase. 
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at a concentration of 1.1-1.4 
mol each/mol α-fetoprotein 
[292]. Even when all 14 binding 
sites would be occupied, the 
rather low absolute values of 
o-fetoprotein content may only 
account for a part of the dif­
ference between FABP content 
and fatty acid-binding capaci­
ties of postnatal rat heart 
and liver. 
The immunologically de­
termined FABP content and the 
fatty acid-binding capacity 
determined with [14C] oleic 
acid [158] show a good agreement 
under all physiological condi­
tions for adult animals (Table 
6.3), except in liver of clo-
fibrate-fed animals. The FABP 
content of both heart and liver cytosol is higher in female than 
in male animals. Clofibrate treatment for 8-10 days does not 
affect the FABP content of heart, but induces a 38% increase in 
liver. The FABP content of rat liver is not influenced by star­
vation, or by the diurnal cycle. In heart, a slight decrease of 
FABP content is observed at mid-dark phase, and after a 66 h 
starvation period. 
When seven inbred strains of rats were examined for their 
hepatic FABP content (Table 6.4), statistically significant 
inter-strain differences were found. The Wistar rats were a few 
weeks younger than the other animals, but FABP content does not 
increase at older age in Wistar rats [23a,239,Fij. 6.3]. 
Much more drastic effects were found on liver FABP content 
than on SCP2 content in rats maintained for 3 weeks on diets sup­
plemented with agents that are known to modify lipid metabolism 
(Table 6.5). Except for Clofibrate, all agents cause a marked 
decrease of hepatic FABP content. In contrast to the marked 
decrease now observed after 3 weeks of cholestyramine feeding, 
we previously found a rise of liver FABP content upon addition 
of cholestyramine for 5-7 days ti64,293j. Addition of Clofibrate to 
the diet gave a comparable increase of liver FABP as Clofibrate 
administered by oral cánula (Table 6.3). Others observed a some-
what stronger effect of Clofibrate on liver FABP content t25,i5o, 
228,2M], but this may relate to a higher Clofibrate dose. 
rabie 6.4. 
Differences in liver FABP content 
among 7 inbred strains of rats. 
Strain 
Uistar 
UE К 
BN 
Brat 
SHR 
SD 
S3 
Body Height 
(α) 
200 t 20 
286 t 10 
383 ι 33 
318 t 38 
326 t 26 
417 t 43 
300 ι 9 
FABP content 
Cnmol/mq] 
2.40 t 0.48 
4.44 i 0.40a 
3.46 t 0.238 
3.52 t 0.40b 
3.21 t 0.30b 
2.77 t 0.07 
2.99 t 0.77 
Statistical significance versus rats 
of Wistar strain β P<0.001; b P<0.01. 
Values are given as means t SO for 5 
or 6 (male) animals, with exception of 
the S3 group, which consisted of 3 
animals. Uistar rats were 10-11 weeks 
old, all other animals were aged 15-16 
weeks. 
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Table 6 . 5 . 
Influence of various agents on the FABP and SCP, content of l i v e r . 
Treatment FABP content SCP, content 
(nnol/mq protein) (mcl/m protein) 
Control 2.30 ι 0.24 0.036 t 0.002 
Cholesterol (2%) 0 . « ± 0 . 2 9 a 0.035 i 0.002 
Cholestyramine (2X) 0.51 t 0 . 1 1 a 0.037 t 0.002 
Mevinolin (0.006X) 0 66 1 0 . 1 8 a 0.031 t 0.004 
C l of i b r at e (0.2X) 2.85 t 0.23 0.027 t 0.001 
Choi ate (0.5X) 0.94 t 0 . 1 7 a 0.028 ι 0.001 
S t a t i s t i c a l significance of data versus control: a P<0.0001. Cytosolic 
FABP content Mas measured by immunoassay. Data were obtained from 11-week-
old Uistar r a t s , which had received the indicated agent together with 5X 
o l i v e o i l for 21 days. Control animals were fed a diet containing only 5X 
o l i v e o i l . Values are given as means t SO of 5 animals. SCP, data are 
derived from Geelen et a l . [288] 
6.4. DISCUSSION. 
The absence of c r o s s - r e a c t i v i t y of FABPs from h e a r t and 
l i v e r with t h e i r respect ive a n t i s e r a in ELISA and on Western 
b l o t s e s tab l i shed the e a r l i e r proven exis tence of d i s c r e t e l i v e r 
and hear t FABP types . Most of our data on the d i s t r i b u t i o n of 
hear t and l i v e r FABP are comparable with the r e s u l t s obtained by 
others with ELISA [152] or immunodiffusion [151,155,157]. The contents 
of l i v e r FABP and h e a r t FABP in l i v e r and hear t agree qu i te well 
with the values determined immunochemically by o thers [87,150-152]. 
Comparison of our data on o l e i c acid-binding capaci ty [15B] and 
FABP content shows t h a t f a t t y acid-binding c a p a c i t i e s are marked­
ly higher in bra in and kidney. Adrenal cytosol conta ins almost 
no d e t e c t a b l e h e a r t or l i v e r FABP, but has a r e l a t i v e l y high 
o l e i c acid-binding capacity [issi. These observations imply the 
presence in these t i s s u e s of some other p r o t e i n ( s ) t h a t account 
for the high f a t t y acid-binding capaci ty . Bass e t a l . [ібі] des­
cribed the presence of two FABPs in bra in, the minor component 
of which reacted with antiserum t o l i v e r FABP. Whole bra in cyto­
sol did not r e a c t , however [ібп. Senjo e t a l . [94] did not find a 
c r o s s - r e a c t i v i t y of antiserum t o l i v e r FABP with FABP from r a t 
bra in . Fu j i i e t a l . [294] recent ly showed t h a t r a t kidney contains 
a type of FABP t h a t i s d i f fe rent from l i v e r FABP. FABPs of lung 
and adipose t i s s u e were reported t o be c lose ly r e l a t e d t o l i v e r 
FABP [89,162]. By c o n t r a s t , we found a react ion of a n t i b o d i e s t o 
hear t FABP with a p r o t e i n of about 15 kDa in lung c y t o s o l . Anti-
l i v e r FABP only reacted with p r o t e i n ( s ) of higher molecular mass 
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in lung cytosol. 
The observed presence of heart and liver FABP types in 
various tissues is compatible with the distribution of rat heart 
and liver FABP mRNA. Relatively high levels of heart FABP mRNA 
were found in slow twitch muscle (e.g. soleus), intermediate 
levels in fast twitch skeletal muscle, and low levels in kidney, 
brain and adrenal сігз.іг«]. Rat liver FABP mRNA is present in high 
concentrations in liver and intestine ti67]. At most, trace amounts 
were detected in other tissues investigated. 
At cell fractionation of heart as well as liver, FABP was 
solely found in the cytosol. Others made similar observations for 
liver FABP, on the basis of immunocytochemical studies M69], and 
for heart FABP with ELISA [152]. Ockner & Manning [HO] found 16% 
of rat intestinal FABP associated with various intracellular mem­
branes. For rat heart a gradient-like distribution of FABP (with 
15% present in mitochondria) was suggested, based on immuno-
electron microscopical observations [165]. The group of Spener 
[176,177] observed binding of FABP to bovine liver and heart 
mitochondria by gold-label electron microscopy and immunodiffus­
ion. The closely related cellular retinol-binding protein of rat 
liver is confined to the cytosol [295]. The subcellular distribu­
tion of FABP differs clearly from that of non-specific lipid 
transport protein or SCP2 and phosphatidylcholine transfer pro­
tein, 70 and 60% of which are located in the cytosol, respecti­
vely [180-182] . 
Our values on postnatal development agree with those of 
Ockner et al. [87,223], who described a comparable increase of rat 
liver FABP content between 30 and 60 days of age. Measurements 
of bromosulfophthalein binding [239] also indicated an increasing 
FABP content in liver, only the maximal value was reached between 
20 and 30 days of age. An approximately 10-fold increase of rat 
liver FABP content was observed with a fluorescence-enhancement 
method [238], although with lower absolute values. Developmental 
changes of FABP content of heart were also reported by Crisman 
et al. [152]. The increase of heart FABP content parallels the 
change in the palmitate oxidation capacity of heart from 0 to 70 
days after birth [231]. In rat liver, the palmitate oxidation capa­
city increases from birth up to 3 weeks and then decreases almost 
2-fold [231], while the FABP content rises further after 3 weeks. 
The reciprocal changes of FABP and a-fetoprotein contents 
in both liver and heart of postnatal rats may account to some 
extent for the constant fatty acid-binding capacities MSBI . The 
decrease of α-fetoprotein mRNA in liver after birth [296] is compa­
tible with the observed decrease of α-fetoprotein concentration. 
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Until now, no data were available on the presence of this protein 
in heart. Trojan and Uriel mn reported the presence of α-feto­
protein in the cytosol of a number of other tissues in newborn 
rats, and its disappearance during the first weeks after birth. 
It is interesting to note that agents known to modify lipid 
metabolism, as well as different physiological conditions, affect 
the hepatic FABP content. The agreement of FABP content and fatty 
acid-binding capacity in adult rats at most physiological 
conditions supports a 1:1 stoichiometry of fatty acid binding to 
FABP. On the other hand, this agreement may also indicate a regu­
lation of FABP concentration at the transcriptional and/or trans-
lational level, and not by a rapidly acting activation/ deacti­
vation mechanism. A similar conclusion was drawn from measure­
ments of FABP mRNA production [150,167], and turnover studies C227]. 
Discrete functions of heart and liver FABP types are clearly 
suggested by the structural differences of the proteins [25,27,79,85, 
90,iio,ii7]. Their different response to physiological variations, 
their tissue distribution and the clearcut difference in con­
comitant changes of FABP content and fatty acid oxidation capa­
city of heart and liver are other indications in this respect. 
In conclusion, assay of fatty acid-binding capacity may not 
always give an accurate measure of the FABP content of dealbumi-
nized cytosols, due to the presence of other proteins with fatty 
acid-binding ability. It should be emphasised that immunochemical 
data have to be based on two procedures, e.g. Western blotting 
and ELISA, to ensure the specificity of the immunoassay. Combi­
nation of data of fatty acid-binding capacity and of qualitative 
and quantitative FABP content may help to gain more insight into 
the number of different FABP types, and their tissue and func­
tional specificity. 
6.5. SUMMARY. 
Antisera against rat heart and liver FABP were applied in 
Western blotting analysis and ELISA, to assess their tissue and 
intracellular distribution, and the influence of development, 
physiological conditions and several agents on the FABP content 
of tissue cytosols. The data obtained are compared with the oleic 
acid-binding capacity. Heart FABP is found in high concentrations 
in heart, skeletal muscles, diaphragm and lung, and in lower 
concentrations in kidney, brain and spleen, whereas liver FABP 
is limited to liver and intestine. In heart and liver, FABP is 
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only present in the cytosol. The FABP content of both heart and 
liver shows a progressive increase during the first weeks of 
postnatal development, in contrast to their constant oleic acid-
binding capacity. The reciprocally declining α-fetoprotein 
content of both tissues may partially account for the comple­
mentary fraction of the fatty acid-binding capacity. The FABP 
content and the fatty acid-binding capacity of adult heart and 
liver were in good accordance under various physiological condi­
tions. Addition of Clofibrate to the diet induces an increase of 
liver FABP content, whereas feeding of cholesterol, cholestyr­
amine, mevinolin or cholate caused a marked decrease. The signi­
ficance of the combined determination of fatty acid-binding 
capacity and FABP content (by immunochemical quantitation and 
blotting analysis) is indicated. 
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Chapter 7. 
IMMUNOCHEMICAL QUANTITATION 
OF FATTY ACID-BINDING PROTEINS. 
II. Distribution of liver and heart FABP types 
in human and porcine tissues* 
7.1. INTRODUCTION. 
Long-chain fatty acids are an important energy source in 
many mammalian tissues, and take part in various biosynthetic 
processes. Due to their hydrophobic nature, carrier systems are 
essential for transport of these substances through the aqueous 
environments of the organism. Within the cell fatty acid-binding 
proteins (FABPs) are postulated to assume this carrier function 
[28]. FABPs are present in the cytosol of (nearly) all mammalian 
tissues, and have a molecular mass of 14-15 kDa and a high affi-
nity for long-chain fatty acids as common features. A number of 
different FABP types exist, each with its own ligand specificity 
and chemical structure. Until now five distinct FABP types have 
been identified: hepatic, cardiac, intestinal, adipose tissue and 
renal FABP [25,26,28,102]. The tissue distribution of the liver and 
heart FABP types was mainly studied in the rat by immunochemical 
[150-153] and immunohistochemical methods [i70,i73,243i and by dot-blot 
analysis of specific mRNAs [123,124,167]. These studies showed a 
rather complex distribution pattern, in which the presence of 
each type is not restricted to one tissue. In intestine and 
kidney, there even is a simultaneous expression of two FABP 
types. Studies of the amino acid and cDNA sequences of FABPs 
established a considerable homology between the FABPs from homo-
logous tissues of different species (for a recent review see 
[28]) . 
Comparison of the tissue distribution of corresponding FABP 
types in different species may help to get a better insight into 
the relation of the distinct types of this protein to the (tis-
* 
This chapter was adapted from Paulussen et a l . , 1989 [148]. 
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sue-related) differences in fatty acid metabolism. Data on the 
FABP content of human tissues amy also become useful reference 
values for investigations in pathological conditions. Therefore 
we studied the immunological cross-reactivity of liver and heart 
FABPs from man, pig and rat, and the tissue distribution of liver 
and heart FABP types in man and pig. 
7.2. METHODS. 
Origin of tissues and preparation of cytosols. 
Human tissue samples were either obtained from autopsies 
conducted within 20 h after death, or from biopsies taken at open 
surgery. Placentas were obtained shortly after delivery. Samples 
of pig tissues were collected fresh at the slaughterhouse, pla­
centa at the farm. The materials were either stored at -70°C or 
used immediately. Rat tissues were obtained from fed, male albino 
Wistar rats (200 ± 20 g). Cytosols were prepared as described in 
section 3.3. 
Human umbilical cord artery endothelial cells were cultured 
as described [298], and obtained from Dr. Van Hinsbergh (Gaubius 
Institute TNO, Leiden, The Netherlands). Cultured rat coronary 
microvascular endothelial cells were obtained from Dr. H. Piper 
(Dept. Physiology, University Dusseldorf, FRG). 
Isolation of FABPs. 
Heart FABPs were isolated from heart cytosols by gel fil­
tration on Sephacryl S-200 and DEAE-cellulose anion-exchange 
chromatography as described twj. Additionally, traces of myoglo­
bin were removed from the preparations by CM-cellulose chromato­
graphy in 20 mM K-phosphate/ 154 mM KCl (pH 6.0). Liver FABPs 
were obtained by the procedure described by Peeters et al. (83). 
FABPs from muscle were purified by gel filtration, anion- and 
cation-exchange chromatography [260]. FABP from rat kidney was 
isolated by gel filtration and DEAE-cellulose anion-exchange 
chromatography as described for rat heart FABP [84]. It was eluted 
with 50 mM Tris-HCl (pH 8.0), and further purified by filtration 
on Sephadex G-50. Its specific binding activity amounted to 25 
nmol/mg protein at 1 μΜ [l-HC]oleic acid. 
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Preparation of antisera. 
Antisera against FABPs were raised in New Zealand white 
rabbits. The immunization procedure and the determination of 
antibody titers are described in section 3.5. IgG-fractions of 
the antisera were prepared with protein-Α Sepharose as described 
by Goudswaard et al. [266]. 
Enzyme-linked immunosorbent assays. 
Cross-reactivities of FABPs with anti-FABP sera were deter­
mined from stepwise dilutions of the antiserum with 250 ng FABP 
coated per well. Cross-reactivity was determined as the recipro­
cal of the serum dilution required to obtain half maximal absor-
bance, and expressed as percentage of the value obtained with the 
specific antigen-antibody combination. 
The enzyme-linked immunosorbent assay for quantitative 
measurements of FABP concentrations were performed as described 
in section 3.5. Cytosolic protein (50 and 100 ng) was adsorbed 
to 96-well microtitre plates by overnight incubation at го-С. The 
cytosolic FABP was probed with anti-FABP IgG, and peroxidase-
conjugated swine-anti rabbit IgG was used as second antibody. The 
complex was visualised by incubation with o-phenylene diamine. 
The reaction was terminated by addition of 0.5 vol. H2S04 (12.5%, 
ν/ν) , and the product of the reaction was measured at 492 nm with 
a Titertek Multiscón. Results were determined by reference to a 
standard curve (0-7 ng FABP). Recovery of 2 ng FABP added to 100 
ng cytosolic protein was 105 ± 16% (n=ll). Molecular masses used 
in all calculations were 14,768 Da for human heart FABP [109J, and 
14,178 Da for human liver FABP [105]. Estimates of 14,800 and 
14,200 Da were used for pig heart and liver FABP, respectively. 
Electrophoresis and immunoblotting. 
Polyacrylamide slabgel electrophoresis was carried out 
according to Laemmli [267] with 7.5-20% acrylamide gradient gels 
(0.7 mm thick) in 0.1% SDS at pH 8.8. Gels were immediately used 
for blotting of the proteins to nitrocellulose paper, followed 
by immunostaining. The procedures are described in section 3.6. 
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7.3. RESULTS AND DISCUSSION. 
FABP preparations were isolated from tissue cytosols of 
human, porcine and rat origin by gel filtration and ion-exchange 
chromatography, and used to raise polyclonal antisera in rabbits. 
IgG fractions of the antisera were isolated, and their specifi-
city was confirmed on Western blots of cytosols. 
The cross-reactivities of the various FABPs were assessed 
with their antisera. Based on the reactivities of FABPs from rat 
tissues, the hepatic and cardiac types are clearly distinguish-
able. Similarly to rat, the FABPs from heart and liver of man and 
pig do not cross-react with their respective antisera (Table 
7.1) . The reactivity of the FABP preparation from rat kidney with 
anti-rat heart FABP (98 ± 19%), and the cross-reaction of rat 
heart FABP with antibodies against the FABP from rat kidney (58 
± 6%) indicate a strong homology of these two proteins. Recent-
ly, it was established that kidney contains two distinct FABPs, 
one of which is identical to the heart type [102]. 
The interspecies cross-reactivity of heart and liver FABPs 
from man, pig and rat with their antisera is shown in Table 7.1. 
Although obviously related, there are considerable species diffe-
rences with the heart and liver FABP types. The epitopes shared 
by the three hepatic FABPs apparently are the most immunogenic 
sites of pig liver FABP, resulting in a comparable reactivity of 
anti-pig liver FABP IgG towards all three liver FABPs. Anti-human 
Table 7.1. 
Cross-reactivity between FABPs from hunan, pig and rat heart and liver and their antisera. 
Antiserim against FABP fron 
human £ij¡ rat 
heart 
liver 
heart 
liver 
heart 
liver 
heart 
100 
i 
72 
2 
16 
12 
liver 
I 
100 
1 
Ï4 
4 
58 
heart 
77 
3 
100 
1 
H 
2 
liver 
2 
104 
2 
100 
<1 
81 
heart 
9 
2 
4 
<1 
100 
<1 
liver 
<1 
76 
<1 
63 
2 
100 
Antiserun dilutions at which half maximal binding was obtained in an ELISA were taken as 
measure for the iimunochemical cross-reactivity of the FABPs. Per well 0.25 дд FABP was used. 
Values are means of at Least 2 determinations, and given as percentage of the binding of the 
the specific antiserun to its specific antigen. 
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Table 7.2. 
Tissue distribution of h unaη heart and liver FABP types. 
Tissue Protein reactive with 
anti-heart FABP anti-liver FA8P 
Heart 20.8 t 1.5 (3) 3.3 t 1.3 (3) 
Liver 2.8 t 1.2 (3) 33.0 ± 5.7 (9) 
M.gastrocnemius 12.6 (1) 
M.gluteus 7.1 / 6.2 (2) 
M.quadriceps 10.6 I 2.2 (14) 1.1 t 1.4 (9) 
M.psoas 9.6 t 1.9 (5) 1.1 t 1.7 (7) 
Kidney - whole 6.1 t 1.3 (4) 2.6 t 0.6 (4) 
- cortex 7.1 t 3.0 (5) 3.« ι 0.9 (5) 
- medulla 5.8 1 2.8 (6) 3.1 ι 1.3 (6) 
Brain - cortex 5.5 t 2.1 (5) 3.3 i 0.3 (3) 
Placenta 2.8 / 5.2 (2) 3 7 / 4.3 (2) 
The FABP content of eytosols was determined in a quantitative ELISA as the amount 
of protein reactive with IgG-fractions of antisera against human heart and liver 
FABP. Data were obtained from multiple determinations of each sample at two cyto­
solic protein concentrations. Values are expressed in дд/mg protein and are means 
i 5D of the number of samples indicated within parentheses. 
liver FABP relatively is the most species-specific. Antisera 
against cardiac FABPs showed a larger cross-reactivity between 
man and pig than between rat and man or pig. 
To study the tissue distribution of the distinct FABP types, 
we determined the reactions of 1 μg cytosolic protein from a 
large series of tissues with serial dilutions of specific anti-
FABP sera, as a relative measure for the occurrence of different 
FABPs св2,277]. The values are, however, biased by the combination 
of variations in cross-reactivities of the FABP types towards the 
antisera, and differences in the FABP content between tissues. 
To get more accurate information on the presence of distinct 
FABPs and their concentrations in different tissues of man and 
pig, a quantitative ELISA procedure was applied, that was pre­
viously used for the assessment of FABP concentrations of rat 
tissue eytosols [153]. 
The concentrations of liver FABP in human and pig tissues 
(Tables 7.2 and 7.3) are comparable to those found in the rat 
tissues [153]. Some minor reactivities were found in other tissues, 
but hepatic FABPs are only found in significant amounts in liver 
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Heart 
Liver 
Skeletal muscle 
Κ ι drey 
Brain 
Spleen 
Lung 
Placenta 
15.7 ι 
8.4 ± 
0.3 (4) 
1-3 (3) 
1.5 (3) 
1.5 (5) 
0.7 (3) 
0.1 (3) 
1.2 (3) 
0.9 (6) 
Table 7.3. 
Tissue distribution of pig heart and liver FABP types. 
Tissue Protein reactive with 
anti-heart FABP anti- liver FABP 
5.7 ± 2.0 (3) 
59.9 ι 12.1 (3) 
2.7 ι 0.4 (3) 
2.8 t 1.6 C3) 
1.7 t 0.3 (3) 
1.8 t 0.1 (3) 
1.6 t 0.1 (3) 
1.8 t 0.3 (6) 
The FABP content of cytosols was determined in a quantitative ELISA, as described 
in Table 7.2. Values are expressed in мд/шд protein, and are means ι SO of the 
nunber of sanples indicated within parentheses. 
itself and in intestine. In a biopsy sample of the proximal part 
of human jejunum, the hepatic FABP content (29.1 дд/тд cytosolic 
protein) was comparable to that of liver. This observation agrees 
quite well with the relative hepatic FABP content of rat small 
intestine tisi]. The large intestine of rat contains less FABP 
[151,153]. Kamisaka et al. [159] found concentrations of 0.86, 0.28, 
0.18 and 0.13 mg immunereactive protein/g tissue with anti-liver 
FABP in human liver, kidney, heart and jejunum, respectively. Pig 
liver bound 71 pmol palmitoyl-CoA per mg protein [234]. This value 
is much lower than the FABP content (4.22 nmol/mg protein) we 
found. The FABP content of bovine liver cytosol [179] is comparable 
to our data on liver of man, pig and rat. 
Heart FABPs are found in high concentrations in heart and 
skeletal muscles, lower amounts are present in kidney, and brain 
(Tables 7.2 and 7.3). The concentrations are, however, generally 
higher for rat [153], than for man and pig. Rat heart contains 
about 55 мд/тд cytosolic protein 1152,153], but only 3.2 ßg FABP/mg 
protein was reported for bovine heart cytosol cm]. The finding 
of FABP in pig muscle is in contrast with its reported absence 
on basis of palmitoyl-CoA binding [234]. 
Concomitantly with the lower FABP concentration, the palmi-
tate oxidation capacity of human heart is also considerably lower 
than that of rat heart tZ3i]. The FABP concentrations of human 
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heart, m.quadriceps and m.gluteus correspond with the fatty acid 
oxidation capacity of these tissues. Fatty acid oxidation capa­
city C231] and FABP content И53,157,15в,2б0] of rat slow-twitch muscles 
are higher than of fast-twitch muscles. These differences in FABP 
content are in accordance with the distribution of cardiac FABP 
mRNA [123,124]. The average amount of protein of m.quadriceps cyto-
sol reactive with anti-heart FABP corresponds with the value 
determined with anti-muscle FABP [260]. These observations, and 
the high degree of similarity of human heart and muscle FABP 
[260], put some doubt to the existence of a muscle specific FABP 
type, as was suggested by some authors [299,зоо]. 
The comparable reaction of cytosol from human kidney cortex 
and medulla with anti-human heart FABP is consistent with the 
equal distribution of the heart FABP type in rat kidney мог]. The 
renal FABP type, that is predominantly located in the cortex мог], 
is not detected by this antibody. Both types could be isolated 
from human kidney cortex (Maatman and Veerkamp, to be published). 
The cytosol of human and porcine brain contains a comparable 
amount of protein reactive with antibodies against heart FABP 
as rat brain cytosol ti53]. Since fatty acids may deliver only a 
minor contribution to energy production in brain взі.зоіі, the 
presence of FABP in this tissue indicates a role for these 
proteins in other processes than ^-oxidation. 
The FABP contents of pig spleen and lung are lower than in 
these tissues of rat [153]. With anti-pig liver FABP antibodies, 
only a slight reactivity was found. Haq et al. [162], however, 
reported rat lung FABP to be immunologically related to the liver 
type. Bass et al. tisú found only a slight reaction of lung with 
antibodies against rat heart FABP, but could not detect any FABP 
in spleen immunologically. Heuckeroth et al. [124] did not observe 
heart FABP mRNA in spleen or lung, but others [167] found low 
concentrations of mRNA sequences homologous to rat liver and 
intestinal FABP cDNA in rat spleen and lung cytosol. 
In human placenta, the content of anti-FABP reactive protein 
was low. In pig placenta, the FABP content appears to be higher, 
and its structure closer related (possibly similar) to cardiac 
than to hepatic FABP. Based on fatty acid binding, FABP was 
previously found in placenta of rat ног] and rabbit воз], but not 
of man [303] and pig ізо«). Recently FABP was purified from human 
placenta oosi. Its characteristics were more comparable to the 
hepatic than to the cardiac type, but only heart FABP mRNA was 
found in rat placenta [117,124]. FABP may be important for the high 
utero-placental fatty acid transfer observed in some species, as 
man and rat сзоб]. In other species, this process appears to be 
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limited, e.g. in pig aan. However, fatty acid oxidation and 
synthesis take place in placenta of all species by the end of 
gestation нов]. 
With anti-heart FABP antibodies, FABP could be detected in 
cultured human endothelial cells in approximately one third of 
the concentration in heart (8.7 and 6.1 μg/Ing cytosolic protein, 
2 samples). Rat heart FABP type was found in cultured rat endo­
thelial cells in a comparable concentration. The presence of 
FABP in endothelial cells may have important implications for the 
understanding of the transport of fatty acids from the capillar­
ies to the tissue cells. Albumin is believed to play an important 
role in this process. Albumin-fatty acid complexes can pass the 
endothelial cells by transcytosis, a process that possibly invol­
ves specific albumin-binding proteins [29,30]. Albumin may also 
function as a fatty acid-carrier through the interstitial fluid 
»и. Scow and colleagues proposed a model in which fatty acids 
are transferred by lateral movement in membranes [32]. Neither 
view encompasses a role for intracellular FABP in endothelial 
cells. 
Placenta ШШШЁШ^^^^^Ш-^ р г ^ 
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Fig. 7.1. Relative content of heart and liver FABP types in himan, pig and rat tissues. 
The FABP concentrations of cytosols of various tissues uere determined as the amount 
of protein reactive with antibodies against heart (upper panel), or liver FABP (lower 
panel) from the same species. Values are expressed as percentages, relative to the FABP 
content of heart or liver. 
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Immunocytochemical studies showed that FABP was present in all 
compartments of rat heart, the capillary endothelium, the inter­
cellular spaces and the myocytes [165]. The presence of heart FABP 
and its mRNA in rat aortic tissue were established with poly­
clonal antibodies and a cDNA probe сібб]. The concentration of 
FABP in the interstitial fluid of rat heart, however, appeared 
to be very low a<m. Therefore its role is likely to be confined 
to the intracellular compartments of the various heart cells. 
The data presented in this and our previous study [153] demon­
strate a similar tissue distribution of the distinct FABP types 
in man, pig and rat. Although the absolute concentrations vary, 
a clear analogy among these three species appears when the heart 
and liver FABP contents of the various tissues are expressed 
relative to their concentration in heart or liver (Fig. 7.1). The 
apparent evolutionary preservation of the association of distinct 
FABP types with specific tissues, with their specific patterns 
of fatty acid utilization, supports the assignment of a major 
role for these FABPs. The different FABP types may perform 
distinct roles in intracellular fatty metabolism. 
7.4. SUMMARY. 
Antisera against heart and liver FABPs were used in ELISA 
to study the cross-reactivity between these FABP types of man, 
pig and rat, and to assess their tissue distribution in man and 
pig. No cross-reactivities were found of heart FABPs with anti-
liver FABP-sera and vice-versa. With the liver FABPs, marked 
species differences were found, but the three proteins are 
clearly related. Human and pig heart FABP are immunochemically 
closer related to each other than to this protein from rat heart. 
The tissue distribution of heart and liver FABP types is similar 
in man, pig and rat. Liver FABP is only found in liver and intes­
tine, and heart FABP is present in heart, skeletal muscle, kid­
ney, lung, brain and placenta. Cardiac FABP is also found in 
cultured human and rat endothelial cells. The FABP content of 
human and pig liver is comparable to that of rat liver, but the 
tissue concentrations of heart FABP are lower in man and pig 
than in rat. When the latter values are expressed relative to the 
FABP content in heart, analogous distribution patterns are 
observed in man, pig and rat. 
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Chapter 8. 
SURVEY AND SUMMARY. 
Fatty acid-binding protein(s) (FABPs) are believed to play 
a crucial role in the intracellular transport and storage of 
long-chain fatty acids and acyl-derivatives. The presence of 
FABPs in most mammalian tissues in relatively high concentrat-
ions, is a clear indication for an important role of these pro-
teins in intracellular fatty acid metabolism. In Chapter 2 the 
current state of knowledge on these proteins is presented. 
Chapter 3 gives the materials and general procedures applied 
during this study. The subsequent chapters of this thesis 
describe investigations that deal with the characteristics of 
FABPs from heart (Chapter 4), the influence of various condit-
ions on FABP content (Chapters 5 and 6), and the tissue distri-
bution of heart and liver FABP types in man, pig and rat (Chap-
ters 6 and 7). 
FABPs were isolated from heart cytosols of man, rat and pig 
by gel filtration and anion-exchange chromatography (Chapter 4). 
The heart FABPs can be clearly distinguished from their liver 
counterparts on basis of their physico-chemical characteristics 
(molecular mass, isoelectric point, amino acid composition, and 
their immunochemical properties), and their ligand specificity. 
Only long-chain fatty acids and their CoA- and carnitine-deriva-
tives bind to heart FABP, whereas liver FABPs bind a variety of 
low-molecular-weight hydrophobic ligands. 
The cytosolic fatty acid-binding capacity of rat tissues was 
estimated as a measure for their FABP content (Chapter 5). After 
removal of residual albumin by iiranuno-affinity chromatography, 
and delipidation, this capacity was determined by a radiochemical 
binding assay, using Lipidex 1000 to separate free and protein-
bound ligand. Based on the oleic acid-binding capacity, FABP is 
present in high concentrations in liver, heart, skeletal muscle, 
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brain, kidney, diaphragm and adrenal. The FABP content of these 
tissues amounts to 2-6% of total cytosolic protein. During post­
natal development, the fatty acid-binding capacity does not 
change appreciably in heart and liver cytosol. The oleic acid-
binding capacity is higher of cytosolic proteins of heart and 
liver from female than from male rats. The cytosolic fatty acid-
binding capacity is markedly influenced by starvation and 
Clofibrate treatment in liver, but not in heart. The diurnal 
rhythm has only a minor effect in heart and liver. 
Antisera against FABPs from human, porcine and rat tissues 
were used to study the degree of immunochemical cross-reactivity 
and tissue distribution of FABP types. An enzyme-linked immuno­
sorbent assay was developed for the quantitation of heart and 
liver FABPs in human, pig and rat tissue cytosols (Chapters 6 and 
7). 
The tissue distribution of heart and liver FABP types is 
similar in all three species. The presence of hepatic FABP is 
limited to liver and intestinal mucosa, only minor reactivities 
with the antibodies were observed in other tissues. Cardiac FABP 
has a much wider tissue distribution, and is found in heart, 
skeletal muscles, kidney, lung, brain and placenta. The observed 
tissue distribution of the heart and liver FABP types is in good 
agreement with the reported distribution of liver and heart FABP 
mRNAs. 
The cytosolic content of cardiac FABP decreases in the order 
heart > slow-twitch muscle > fast twitch muscle > other tissues. 
The FABP concentration of liver is comparable in man, pig and 
rat. The absolute concentrations of heart FABP type are lower 
in tissues of man and pig than of rat, but when the concentrat­
ions are expressed relative to the concentration in heart, a 
similar distribution pattern is obtained for all three species. 
The observed FABP concentrations of heart and muscles are in 
accordance with the palmitate oxidation capacities of the 
tissues. There is a good agreement between the FABP content 
(Chapter 6) and the cytosolic fatty acid-binding capacity of rat 
tissues (Chapter 5) for liver, heart and muscle, but not for 
brain, lung, kidney, diaphragm and adrenal. These differences 
indicate the existence of more tissue-specific FABP types than 
the liver and heart types. During postnatal development the FABP 
content of rat heart and liver markedly increased, but the oleic 
acid-binding capacity is already at adult level at birth. α-Feto­
protein is present in the cytosols in a concentration that 
decreases reciprocally to the raising FABP content, but this can 
only partially explain the observed difference. 
100 
The discrepancy between fatty acid-binding capacity and 
FABP content during postnatal development, and the differences 
in the cytosolic binding capacity and content of heart or liver 
FABP type of some tissues, imply an important warning against 
the use of a single parameter for quantitative measurements in 
these studies. The existence of (at least) five distinct FABP 
types, and the tissue-related differences in FABP content, oblige 
an intercomparison of several, independent, methods, to obtain 
reliable values on cytosolic FABP content. 
In conclusion, FABPs are a group of low-molecular-weight 
cytosolic proteins, that are present abundantly in mammalian 
tissues. Although still no conclusive evidence is available for 
the role of these proteins, the accumulated knowledge indicates 
distinct functions for the different FABP types. Liver FABP type 
acts as a rather general intracellular carrier for hydrophobic 
compounds, whereas the cardiac type is a more specialized binding 
protein. The presence of the heart FABP type only in tissues that 
rely on fatty acids as their major energy source, suggests that 
the main physiological function of this protein is the delivery 
of fatty acids to the /3-oxidation systems. The consistency of 
heart FABP content in response to various physiological condit-
ions is compatible with this view. The marked changes in the 
liver FABP content may be related to other functions of this 
protein that are distinct from the role of the cardiac FABP type. 
The apparently limited tissue distribution of other FABP types 
indicates a relation of these proteins to tissue-specific 
processes. 
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SAMENVATTING. 
Cytosolische vetzuurbindende eiwitten. 
Hogere organismen hebben een zeer complexe struktuur, met 
organen en weefsels met sterk gespecialiseerde functies. Voor een 
gericht transport van regulerende stoffen, bouwstenen, en energie 
leverende verbindingen naar de cellen in het lichaam waar deze 
stoffen nodig zijn is een effectief mechanisme nodig. Ook intra-
cellulair zijn gerichte transportprocessen van grote betekenis. 
In de laatste decennia zijn een aantal oplosbare eiwitten gevon-
den, die hierbij een belangrijke rol spelen. Zo zijn in het bloed 
een groot aantal eiwitten betrokken bij vervoer van hormonen en 
vitaminen. Het serumalbumine is een meer algemeen transporteiwit 
voor slecht water-oplosbare verbindingen, en speelt een belang-
rijke rol bij het transport van vrije vetzuren. Vetzuren worden 
ook getransporteerd in triacylglycerolen, fosfolipiden en 
cholesterolesters, die deel uitmaken van lipoproteinen en chylo-
micronen. 
In de cel vormt het cytoplasma een barrière voor vervoer van 
hydrofobe verbindingen tussen de plasmamembraan en de celorganel-
len waar die moleculen gemetaboliseerd worden. Om de passage door 
het cytoplasma mogelijk te maken bevat de cel een aantal speci-
fieke bindingseiwitten, met een hoge affiniteit voor verschil-
lende (groepen) verbindingen, als fosfolipiden, cholesterol, 
retinol. Tot deze groep intracellulaire transporteiwitten behoren 
de vetzuurbindende eiwitten (fatty acid-binding proteins, FABPs) . 
Deze groep eiwitten is betrokken bij het transport van vetzuren 
en mogelijk hun coenzym A- en carnitine-esters. FABPs werden 
ontdekt aan het einde van de jaren zestig. Sindsdien is veel 
bekend geworden over deze eiwitten. De aanwezigheid van FABPs in 
de meeste weefsels van zoogdieren, in relatief hoge concentra-
ties, is een sterke aanwijzing voor een belangrijke rol voor deze 
eiwitten bij het vetzuurmetabolisme. Het onderzoek dat in dit 
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proefschrift beschreven wordt, was erop gericht om meer kennis 
te verwerven over de struktuur en eigenschappen van de FABPs en 
hun functie in verschillende weefsels van de mens, het varken 
en de rat. 
In Hoofdstuk 2 wordt een overzicht gegeven van de huidige 
kennis van FABPs (de resultaten van de in de latere hoofdstukken 
beschreven onderzoeken zijn hierin reeds verwerkt). Uit de lite-
ratuur wordt duidelijk dat er verschillende typen FABP bestaan, 
die in verschillende weefsels gevonden worden. In de nier en in 
darmepitheel komen zelfs tegelijkertijd twee typen van het eiwit 
voor. Waarschijnlijk zijn de verschillende typen van het FABP 
aangepast aan de verschillen in het vetzuurmetabolisme van de 
weefsels. In dit hoofdstuk wordt een gedetailleerde beschrijving 
gegeven van de struktuur en de eigenschappen van de verschillende 
typen. 
Hoofdstuk 3 geeft de herkomst van de gebruikte materialen 
en een beschrijving van de toegepaste experimentele procedures. 
Hoofdstuk 4 behandelt de isolatie van FABPs uit hartweefsel van 
mens, varken en rat met behulp van gelfiltratie en anionen-
uitwisselings chromatografie en de karakterisering van deze 
eiwitten. De drie eiwitten verschillen wel in aminozuursamenstel-
ling, maar lijken toch sterk op elkaar. Op basis van fysisch-
chemische eigenschappen (molecuulgewicht, isoelektrisch punt, 
aminozuursamenstelling en immunochemische eigenschappen) en 
ligandspecificiteit kan het hart FABP type duidelijk onder-
scheiden worden van het lever type. Hart FABP bindt alleen vet-
zuren en vetzure esters, terwijl het lever FABP type ook andere 
hydrofobe liganden kan binden. 
In Hoofdstuk 5 worden effecten van fysiologische condities 
en van postnatale ontwikkeling en clofibraat toediening op het 
cytosolisch FABP gehalte van weefsels van de rat bestudeerd. Als 
maat voor het FABP gehalte werd de vetzuurbindingscapaciteit van 
cytosolisch eiwit bepaald met een radiochemische methode. Vooraf-
gaand aan de bepaling werd eventueel aanwezig serum albumine, dat 
ook vetzuren bindt, verwijderd door middel van immuno-affini-
teitschromatografie. Ook werden de endogeen gebonden vetzuren 
verwijderd. Met behulp van het hydrofobe chromatografie medium 
Lipidex 1000 werden vrije en eiwit-gebonden vetzuren gescheiden 
bij 0°C. Op basis van de oliezuurbindingscapaciteit werden FABPs 
gevonden in lever, hart, skeletspier, hersenen, nieren, bijnieren 
en diafragma van de rat. In deze organen bestaat 2-6% van het 
cytosolisch eiwit uit FABP. Het FABP gehalte van lever en hart 
van vrouwelijke ratten is hoger dan in mannelijke dieren. Tijdens 
de ontwikkeling van de geboorte tot volwassen dier blijkt de 
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vetzuurbindingscapaciteit van hart en lever niet duidelijk te 
veranderen. De cytosolische vetzuurbindingscapaciteit van lever 
wordt beïnvloed door onder andere vasten en het hypolipidemisch 
agens clofibraat, in tegenstelling tot de capaciteit in hart. Het 
dag-nacht ritme heeft slechts een beperkte invloed op de vetzuur-
bindingscapaciteit van beide weefsels. 
Tegen FABPs uit verscheidene weefsels van mens, varken en 
rat werden antilichamen opgewekt in konijnen, waarmee de inununo-
chemische kruisreactiviteit en de weefselverdeling van verschil-
lende FABP typen bestudeerd werd. Een enzym immunoassay werd ont-
wikkeld voor de kwantitatieve bepaling van het FABP gehalte van 
weefselcytosolen van mens, rat en varken (Hoofdstukken б en 7). 
De hart en lever FABP typen hebben een vergelijkbare weef­
selverdeling in de drie species. Lever FABP komt alleen voor in 
lever en in darmepitheel. Het hart type is aanwezig in hart, 
skeletspieren, nieren, longen, hersenen en placenta. Het hart 
FABP gehalte in oxidatieve spieren, die voor een belangrijk deel 
van vetzuren afhankelijk zijn voor de energievoorziening, is 
hoger dan in glycolytische spieren, waar vetzuren slechts een 
beperkte rol spelen voor energieproduktie. De hart FABP concen­
tratie daalt in de reeks hart > oxidatieve spieren > glyco­
lytische spieren > andere weefsels. De FABP concentratie in de 
lever is vergelijkbaar in mens, varken en rat. In hart zijn de 
gevonden concentraties voor mens en varken lager dan van de rat, 
maar uitgedrukt als percentage van de concentratie in hart ont­
staat een zelfde weefselverdelingspatroon voor alle drie species. 
De gevonden FABP concentraties in hart en spieren zijn in 
overeenstemming met de palmitinezuur oxidatiecapaciteit van deze 
weefsels. Het FABP gehalte (Hoofdstuk 6) en de cytosolische 
vetzuurbindingscapaciteit van ratteweefsels (Hoofdstuk 5) komen 
overeen voor lever, hart en spieren, maar niet voor hersenen, 
longen, diafragma, nieren en bijnieren. Deze verschillen duiden 
op het bestaan van meer weefselspecifieke FABP typen dan het 
lever en hart type. Het lagere FABP gehalte in het hart bij mens 
en varken komt overeen met de lagere vetzuuroxidatiecapaciteit 
van het hartweefsel van deze species vergeleken met de rat. 
Tijdens de postnatale ontwikkeling nemen het FABP gehalte en de 
vetzuuroxidatiecapaciteit duidelijk toe, terwijl de vetzuurbin­
dingscapaciteit bij de geboorte al op hetzelfde niveau ligt als 
in volwassen dieren. Alfa-foetoproteine, een foetaal eiwit dat 
betrokken is bij vetzuurtransport, werd gevonden in lever en hart 
in een concentratie die afneemt met de toename van het FABP 
gehalte. De hoeveelheid alfa-foetoproteine was echter zo laag, 
dat dit slechts gedeeltelijk het verschil tussen de vetzuurbin-
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dingscapaciteit en het FABP gehalte kon verklaren. 
De afwijking tussen de vetzuurbindingscapaciteit en de FABP 
concentratie tijdens postnatale ontwikkeling, en de verschillen 
in bindingscapaciteit en gevonden hoeveelheid hart of lever type 
FABP in verschillende weefsels, wijzen op een belangrijk risico 
van het gebruik van slechts één parameter voor kwantitatieve FABP 
bepalingen in dit soort studies. Het bestaan van (tenminste vijf) 
verschillende FABP typen en de verschillen in FABP concentratie 
per weefsel maken een vergelijking van verschillende, onafhanke-
lijke, bepalingsmethoden essentieel voor het verkrijgen van een 
betrouwbaar inzicht in de weefselverdeling en gehalten van deze 
eiwitten. 
Samenvattend, vetzuurbindende eiwitten vormen een groep 
laag-moleculaire cytosolische eiwitten, die in relatief hoge 
concentraties voorkomen in weefsels. Hoewel nog steeds geen 
direct bewijs beschikbaar is, zijn op basis van de verzamelde 
kennis duidelijk verschillende functies aanwijsbaar voor de 
verschillende typen van dit eiwit. Lever FABP is betrokken bij 
intracellulair transport van een groot aantal hydrofobe verbin-
dingen, terwijl hart FABP een meer specifiek vetzuurbindingseiwit 
is. De aanwezigheid van het hart type in weefsels die voor een 
belangrijk deel afhankelijk zijn van vetzuren voor hun energie-
voorziening duidt op vetzuurtransport naar /ï-oxidatie systemen 
als hoofdfunctie voor dit eiwit. De beperkte invloed van allerlei 
fysiologische condities op het hart FABP gehalte is in overeen-
stemming met die rol. De veel grotere variabiliteit van het lever 
FABP gehalte is waarschijnlijk gerelateerd aan andere functies 
van dit FABP type dan de rol bij energieproduktie. De andere FABP 
typen komen slechts in een beperkt aantal weefsels voor (het 
nier type alleen in de nieren, en darm FABP alleen in het darm-
epitheel), hetgeen een rol van deze eiwitten bij weefselspeci-
fieke processen suggereert. 
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APPENDICES. 
Appendix I. 
Ligand-binding affinities of FABPs 
Origin Ligand Kd value 
(дМ) 
Refs. 
liver palmitic acid 
palmitoyl-CoA 
stearic acid 
oleic acid 
oleoyl-CoA 
linoleic acid 
arachidomc acid 
erucic acid 
retinol 
retinyl palmtate 
heme 
hematm 
lysophosphatidylcholine 
prostaglandin-£1 
bromosulfopMhalein 
bi Iirubin 
11-Cdansylamino)-
undecanoic acid 
16-anthroyloxy-
palmitic acid 
1-pyrene-dodecanoic acid 
oestrone sulphate 
dehydroepiandrosterone 
0.6 
0.14 
0.7 
0.07 
1.2 • 
0.5 
0.6 , 
0.9 
21 
1 4 
0 15 
0.07 
15 
0.037 
0.69 
0 27 
0.24, 
0.72 
0 64 
30 
20 
1.0 
- 2.8 
- 1.5 
2.0 
0.92 
; 1 5 
; 1.10 
0.03 and 0.5 
25,76,85 
25,76,187 
25 
25,83,85,190,194,195,248 
25,188 
25 
25,85 
25 
194 
155 
25,194 
195 
196 
190 
195 
194,195 
83,189 
83 
83 
76 
76 
mynstic acid 0 95 
palmitic acid 0 78 
palmitoyl-CoA 0.51 
palmitoyl-carmtine 0.59 
oleic acid 0.38 
arachidomc acid 0.16 
ll-(dansylaimno)-
undecanoic acid 1.B4 
16-enthroyloxy-
palmitic acid 1 33 
1-pyrene-dodecanoic acid 0.22 
; 1 02 
84 
84,85 
84 
84 
83,84 
84 
83 
83 
83 
к ιdney palmitic acid 
oleic acid 
arachidomc acid 
1.0 
1 0 
0 9 
294 
294 
294 
Appendix I (continued). 
Origin Ligand Kd value Refs. 
luHi 
liver hematin 0.97 195 
195 
195 
0.62 83,199 
S3 
83 
83 
heart mynstic acid 0 88 84 
84 
84 
84 
84 
84 
PIG 
liver oleic acid 0.63 83 
83 
83 
83 
bromosulfophthaletn 
bi11 rubi η 
oleic acid 
ll-(dansylamino)-
undecanoic acid 
16-anthroyloxy-
palmitic acid 
1-pyrene-dodecanoic acid 
palmitic acid 
palmitoyl-CoA 
palmi toyl-carmtine 
oleic acid 
arachidonic acid 
97 
0.25 
0.78 
0 04 
0.38 
0 28 
0.65 
0 60 
0.50 
0 42 
0 20 
0 17 
11 (dansylammo)-
undecanoic acid 
16 anthroyloxy-
palmitic acid 
1 pyrene-dodecanoic acid 
mynstic acid 
palmitic acid 
oleic acid 
arachidonic acid 
12-doxylstearic acid 
63 
0 44 
0.25 
0.39 
1.81 
1.26 
0 43 
0 24 
0 85 
heart ynsti i .  84 
84 
83,84 
84 
192 
ll-(daneylemino)-
undecanoic acid 1 62 83 
16-anthroyloxy-
palmitic acid 0 69 83 
1-pyrene-dodecanoic acid 0 25 83 
CATTLE 
liver oleic acid 0.24 ; 2.15 139 
heart palmitic acid 0.90 186 
oleic acid 0.39 186 
arachidonic acid 0 30 186 
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Appendix II. 
Response of FABP content and fatty acid-binding capacity to physiological conditions end drugs 
Parameter 
Sex 
Steroid 
(female vs. male) 
hormones 
estrogens 
testosterone 
Postnatal age 
(0 vs. 70 days) 
Starvation 
Diet 
01 urna I 
Drugs 
high-fat 
high-carbohydrate 
rhythm 
(dark vs. 
light phase) 
Clofibrate 
eholestryramine 
mevinolm 
cholesterol 
chelate 
alcohol 
peroxisomal 
prol iferators 
Tissue 
liver 
heart η s, 
intestine 
liver 
liver 
liver 
heart 
liver 
heart 
intestine 
liver 
heart 
intestine 
adipose tissue 
marmary gland 
liver 
liver 
heart 
liver 
heart 
intestine 
muscle 
kidney 
liver 
liver 
liver 
liver 
liver 
liver 
liver 
(X) 
128 
./128 
n.s. 
153 
109 
16 
33 
η s. 
75 
201 
145 
FABP 
content 
132/144' 
127 
n.s. 
75 
138 
n.s. 
128 
22 
29 
41 
41 
318 
100 
120- >200 
Ref. 
153 
152,153 
150 
223 
223 
153 
153 
153 
153 
146 
165 
146 
163 
153 
153 
153 
153 
150 
153 
153 
153 
153 
235 
гзб,
3 
228-230,284 
. ь, 
(%) 
156 
136 
n.s. 
n.s. 
47 
n.s. 
148 
125 
120 
141 
59 
213 
75 
n.s 
165 
137 
217 
>200 
260 
Fatty acid-
ndinfl caoacitv 
Ref. 
158 
158 
158 
158 
158 
158 
233 
234 
233 
158 
158 
158 
158 
158 
158 
293 
235 
228 
229 
Values uere derived from data in nmol/mg protein, and expressed relative to those of control, adult, male 
fed animals (100X). 
n.s., no significant change 
1 in middle and distal part of intestine, respectively. 
(Mo significant effect in proximal section). 
2 Tiadenol, nafenopin, phthalic acid esters, acetylsalicylic acid. 
3 J.N. Veerkamp et al., unpublished results. 
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